SUBSTITUTED SPIRO-COMPOUNDS AND THE USE THEREOF FOR PRODUCING MEDICAMENTS

COMPOSES SPIRO SUBSTITUES, ET LEUR UTILISATION POUR PRODUIRE DES MEDICAMENTS

English Abstract

The present invention relates to substituted spiro compounds, to processes for
preparing them, to medicaments comprising these compounds and to the use of
these compounds for producing medicaments.

French Abstract

L'invention concerne des composés spiro substitués, leurs procédés de production, des médicaments les contenant, et l'utilisation de ces composés pour produire des médicaments.

Claims

CLAIMS:
1. A substituted spiro compound of general formula I,
<IMG>
wherein:
n is equal to 1;
I.)
R1 represents a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of cyclopropyl,
cyclobutyl,
cyclopentyl, cyclohexyl and cycloheptyl;
represents a phenyl radical, wherein the radical can in each case optionally
be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-
C2H5,
-NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, -C(=O)-OH, -C(=O)-O-CH3, -C(=O)-O-
C2H5,
-C(=O)-O-C(CH3)3, -O-C(=O)-CH3, -O-C(=O)-C2H5, -O-C(=O)-C(CH3)3, -N(CH3)2,
-N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=O)-O-CH3, -NH-C(=O)-O-C2H5, -NH-C(=O)-
102

O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-C(CH3)3, -C(=O)-NH2,
-C(=O)-NH-CH3, -C(=O)-NH-C2H5, -C(=O)-N-(CH3)2 and -C(=O)-N-(C2H5)2;
or represents a -C(=O)-NR11R12 group;
and
R2, R3, R4, R5, R6, R7 and R8, independently of one another, each represent a
hydrogen radical or
a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
II.)
R1 and R3 together represent a -(CH2)p group wherein p = 4;
and
R2, R4, R5, R6, R7 and R8, independently of one another, each represent a
hydrogen
radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
or
III.)
R1, R2, R7 and R8 each represent a hydrogen radical
and
R3, R4, R5 and R6, independently of one another, each
103

represent a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl, and n-heptyl;
and in each case
R9 represents a hydrogen radical;
R10 represents a radical selected from the group consisting of methyl, ethyl,
n-propyl,
Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl, n-heptyl, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-
butenyl,
3-butenyl, 2-methyl-1-propenyl, ethinyl, 1-propinyl, 2-propinyl, 1-butinyl, 2-
butinyl and
3-butinyl;
represents a phenyl or pyridinyl radical, wherein the radical can in each case
optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of
one another from the group consisting of F, CI, Br, I, -CN, -CF3, -SF5, -OH, -
O-CH3,
-O-C2H5, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -C(=O)-OH, -C(=O)-O-CH3, -
C(=O)-
O-C2H5, -C(=O)-O-C(CH3)3, -O-C(=O)-CH3, -O-C(=O)-C2H5, -O-C(=O)-C(CH3)3,
-N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=O)-O-CH3, -NH-C(=O)-O-C2H5,
-NH-C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-C(CH3)3,
-C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-NH-C2H5, -C(=O)-N-(CH3)2, -C(=O)-N-(C2H5)2,
-S(=O)2-CH3, -S(=O)2-C2H5, -S(=O)2 phenyl, -NH-S(=O)2-CH3, -NH-S(=O)2-C2H5,
-NH-S(=O)2 phenyl, -S(=O)2-NH-CH3, -S(=O)2-NH-C2H5, cyclohexyl, cyclopentyl,
pyridinyl, pyridazinyl, -(CH2)-benzo[b]furanyl, -O-phenyl, -O-benzyl, phenyl
and
benzyl,
on the condition that not one of the meta positions and the para position of
this
phenyl radical are substituted with substituents which are respectively bound
to the
phenyl radical via an identical atom selected from the group consisting of
oxygen,
sulphur and nitrogen;
104

or represents a -C(=O)-NR13R14 group;
R11 represents a radical selected from the group consisting of phenyl,
naphthyl,
indolyl, pyridinyl, (1,3)-benzodioxolyl and (1,4)-benzodioxanyl, wherein the
radical
can in each case optionally be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, CI, Br, I, -CN, -
CF3,
-SF5, -OH, -O-CH3, -O-C2H5, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
N(CH3)2,
-N(C2H5)2, -NH-CH3, -NH-C2H5, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-C(CH3)3, -C(=O)-
NH2, -C(=O)-NH-CH3, -C(=O)-NH-C2H5, -C(=O)-N-(CH3)2, -C(=O)-N-(C2H5)2, -S(=O)2-
CH3, -S(=O)2-C2H5, -NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH-CH3, -S(=O)2-
NH-C2H5, piperidinyl, 4-methylpiperidinyl and phenyl; wherein the phenyl
radical can
be substituted with 1, 2 or 3 substituents selected from the group consisting
of F, CI
and Br; and/or bound via a -(CH2) group or -(CH2)2 group;
R12 represents a hydrogen radical; or
R11 and R12 form together with the nitrogen atom connecting them as ring
member a
piperazinyl radical, wherein the radical can optionally be substituted with 1,
2, 3, 4 or
substituents selected independently of one another from the group consisting
of
oxo (=O), thioxo (=S), F, CI, Br, -OH, -O-CH3, -O-C2H5, -NH2, -NO2, -O-CF3, -S-
CF3,
-SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl,
tert-butyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, pyridinyl, pyridazinyl, pyrimidinyl,
[1,2,5]-thiadiazolyl, thiazolyl, phenyl and benzyl; wherein in each case the
cyclic
portion of the radicals pyrimidinyl, [1,2,5]-thiadiazolyl, thiazolyl,
pyridinyl, pyridazinyl,
phenyl and benzyl can be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, CI, Br, -OH, -
CF3,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
O-CH3,
-O-C2H5, -O-CF3 and -S-CF3;
R13 represents a radical selected from the group consisting of phenyl,
pyridinyl,
naphtyl, (1,4)-benzodioxanyl, quinolinyl and isoquinolinyl, wherein the
radical can in
each case optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
105

independently of one another from the group consisting of F, CI, Br, I, -CN, -
CF3,
-SF5, -OH, -O-CH3, -O-C2H5, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
C(=O)-OH,
-C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -O-C(=O)-CH3, -O-C(=O)-C2H5,
-O-C(=O)-C(CH3)3, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=O)-O-CH3,
-NH-C(=O)-O-C2H5, -NH-C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5,
-C(=O)-C(CH3)3, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-NH-C2H5, -C(=O)-N-(CH3)2,
-C(=O)-N-(C2H5)2, -S(=O)2-CH3, -S(=O)2-C2H5, -NH-S(=O)2-CH3, -NH-S(=O)2-C2H5,
-N[S(=O)2-CH3)]2, -N[S(=O)2-C2H5)]2, -S(=O)2-NH-CH3 and -S(=O)2-NH-C2H5 and/or
bound via a -(CH2) group or -(CH2)2 group;
R14 represents a hydrogen radical; or
R13 and R14 respectively form together with the nitrogen atom connecting them
as ring
member a radical selected from the group consisting of pyrrolidinyl,
piperidinyl,
(1,3,4,5)-tetrahydropyrido[4,3-b]indolyl, (3,4)-dihydro-1H-isoquinolinyl,
(1,3,4,9)-
tetrahydro-[b]-carbolinyl, imidazolidinyl, (1,3)-thiazolidinyl, piperazinyl,
morpholinyl,
azepanyl, diazepanyl and thiomorpholinyl, wherein the radical can in each case
optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of
one another from the group consisting of oxo (=O), thioxo (=S), F, CI, Br, -
OH,
-O-CH3, -O-C2H5, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl,
ethyl,
n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -N(CH3)2, -
N(C2H5)2,
-NH-CH3, pyridinyl, pyridazinyl, pyrimidinyl, [1,2,5]-thiadiazolyl, thiazolyl,
phenyl and
benzyl, wherein in each case the cyclic portion of the radicals pyrimidinyl,
[1,2,5]-thiadiazolyl, thiazolyl, pyridinyl, pyridazinyl, phenyl and benzyl can
be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of F, CI, Br, -OH, -CF3, methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, -O-CH3, -O-C2H5, -O-CF3 and -S-CF3;
or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a
mixture of
enantiomers thereof, a mixture of diastereomers thereof, a salt thereof or a
solvate
thereof.
106

2. A compound, enantiomer, diastereomer, racemate, mixture, salt or
solvate according to claim 1 wherein:
n is equal to 1,
I.)
R1 represents a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of cyclopropyl,
cyclobutyl,
cyclopentyl, cyclohexyl and cycloheptyl;
represents a phenyl radical
or represents a -C(=O)-NR11R12 group;
R2, R7 and R8 each represent a hydrogen radical;
and
R3, R4, R5, R6, independently of one another, each
represent a hydrogen radical or
a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
or
107

II.)
R1 and R3 together represent a -(CH2)4 group;
R2, R4, R7 and R8 each represent a hydrogen radical;
and
R5 and R6, independently of one another, each
represent a hydrogen radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1 ,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
or
III.)
R1, R2, R7 and R8 each represent a hydrogen radical
and
R3, R4, R5 and R6, independently of one another, each represent a methyl or
ethyl
radical;
and in each case
R9 represents a hydrogen radical;
represents a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
or represents a phenyl radical;
108

R10 represents a radical selected from the group consisting of methyl, ethyl,
n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a phenyl radical of general formula XX
<IMG>
wherein the line represents the bond of this phenyl radical to the spiro
compound of
general formula I;
and A, B and C each represent a substituent selected independently of one
another
from the group consisting of H, F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-
C2H5,
-NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, cyclohexyl, cyclopentyl, -C(=O)-OH, -
C(=O)-O-
CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -O-C(=O)-CH3, -O-C(=O)-C2H5, -O-C(=O)-
C(CH3)3, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=O)-O-CH3, -NH-C(=O)-O-
C2H5, -NH-C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-C(CH3)3,
-C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-NH-C2H5, -C(=O)-N-(CH3)2, -C(=O)-N-(C2H5)2,
-S(=O)2-CH3, -S(=O)2-C2H5, -S(=O)2 phenyl, -NH-S(=O)2-CH3, -NH-S(=O)2-C2H5,
-S(=O)2-NH-CH3, -S(=O)2-NH-C2H5 and -NH-S(=O)2 phenyl;
on the condition that not one of positions A and position B of this phenyl
radical are
substituted with substituents which are respectively bound to the phenyl
radical via an
identical atom selected from the group consisting of oxygen, sulphur and
nitrogen;
109

or represents a -C(=O)-NR13R14 group;
R11 represents a radical selected from the group consisting of phenyl,
indolyl,
(1,3)-benzodioxolyl, pyridinyl, (1,4)-benzodioxanyl and naphthyl, wherein the
radical
can in each case optionally be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, CI, Br, -CF3, -
SF5, -OH,
-O-CH3, -O-C2H5, -O-CF3, phenyl, 3-chloro-4-fluorophenyl, 4-methylpiperidinyl,
piperidinyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,
tert-butyl,
-NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH-CH3 and -S(=O)2-NH-C2H5 and/or
bound via a -(CH2) group;
R13 represents a radical selected from the group consisting of phenyl,
naphthyl, (1,4)-
benzodioxanyl, pyridinyl, quinolinyl and isoquinolinyl, wherein the radical
can in each
case optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently
of one another from the group consisting of -SF5, F, CI, Br, -CF3, -OH, -O-
CH3,
-O-C2H5, -NH2, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl, tert-
butyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-S(=O)2-CH3, -NH-S(=O)2-
C2H5,
-N[S(=O)2-CH3]2, -N[S(=O)2-C2H5]2, -S(=O)2-NH-CH3 and -S(=O)2-NH-C2H5 and/or
bound via a -(CH2) group;
R12 and R14, independently of one another, each represent a hydrogen radical;
or
R13 and R14 respectively form together with the nitrogen atom connecting them
as ring
member
a (3,4)-dihydro-1H-isoquinolinyl radical which can be substituted with 1, 2,
3, 4 or 5
substituents selected independently of one another from the group consisting
of -OH,
-O-CH3 and -O-C2H5.
3. A compound, enantiomer, diastereomer, racemate, mixture, salt or
solvate according to claim 1, wherein:
110

n is equal to 1,
I.)
R1 represents a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of cyclopropyl,
cyclobutyl,
cyclopentyl, cyclohexyl and cycloheptyl;
represents a phenyl radical
or represents a -C(=O)-NR11R12 group;
R2, R7 and R8 each represent a hydrogen radical;
and
R3, R4, R5, R6, independently of one another, each
represent a hydrogen radical or
a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
or
II.)
R1 and R3 together represent a -(CH2)4 group;
R2, R4, R7 and R8 each represent a hydrogen radical;
and
R5 and R6, independently of one another, each
111

represent a hydrogen radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
or
Ill.)
R1, R2, R7 and R8 each represent a hydrogen radical
and
R3, R4, R5 and R6, independently of one another, each represent a methyl or
ethyl
radical;
and in each case
R9 represents a hydrogen radical;
represents a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
or represents a phenyl radical;
R10 represents a radical selected from the group consisting of methyl, ethyl,
n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of phenyl,
2-methanesulphonamidephenyl, 2-ethanesulphonamidephenyl, 2-
trifluoromethylphenyl, 2-trifluoromethylsulphanylphenyl, 2-ethylphenyl, 2-tert-
butylphenyl, 2-ethylaminosulphonylphenyl, 2-methylaminosulphonylphenyl,
2-bromophenyl, 2-chlorophenyl, 2-fluorophenyl, 2-methylphenyl,
112

2-trifluoromethoxyphenyl, 2-methoxyphenyl, 2-ethoxyphenyl, 2-propylphenyl,
2-iodophenyl, 3-chlorophenyl, 3-methylphenyl, 3-tert-butylphenyl,
3-trifluoromethylsulphanylphenyl, 3-trifluoromethylphenyl, 3-
methanesulphonamidephenyl, 3-ethanesulphonamidephenyl, 3-fluorophenyl,
3-propylphenyl, 3-isopropylphenyl, 3-bromophenyl, 3-methoxyphenyl, 3-
ethylphenyl,
3-ethylaminosulphonylphenyl, 3-methylaminosulphonylphenyl, 3-ethoxyphenyl,
3-trifluoromethoxyphenyl, 3-iodophenyl, 4-methylaminosulphonylphenyl,
4-ethylaminosulphonylphenyl, 4-methanesulphonamidephenyl,
4-ethanesulphonamidephenyl, 4-bromophenyl, 4-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-tert-butylphenyl, 4-trifluoromethylsulphanylphenyl, 4-
methylphenyl,
4-isopropylphenyl, 4-trifluoromethylphenyl, 4-propylphenyl, 4-iodophenyl,
4-trifluoromethoxyphenyl, 4-ethylphenyl, 4-ethoxyphenyl,
2-fluoro-3-trifluoromethylphenyl, (2,3)-difluorophenyl, (2,3)-dimethylphenyl,
(2,3)-dichlorophenyl, 3-fluoro-2-trifluoromethylphenyl, (2,4)-dichlorophenyl,
(2,4)-difluorophenyl, 4-fluoro-2-trifluoromethylphenyl, (2,4)-dimethoxyphenyl,
2-
chloro-4-fluorophenyl, (2,4)-dibromophenyl, 2-fluoro-4-trifluoromethylphenyl,
(2,5)-difluorophenyl, 2-fluoro-5-trifluoromethylphenyl, 5-fluoro-2-
trifluoromethylphenyl,
5-chloro-2-trifluoromethylphenyl, 5-bromo-2-trifluoromethylphenyl,
(2,5)-dimethoxyphenyl, (2,5)-bis-trifluoromethylphenyl, (2,5)-dichlorophenyl,
(2,5)-dibromophenyl, 2-fluoro-6-trifluoromethylphenyl, (2,6)-dimethoxyphenyl,
(2,6)-dimethylphenyl, (2,6)-dichlorophenyl, 2-chloro-6-fluorophenyl, 2-bromo-6-
chlorophenyl, 2-bromo-6-fluorophenyl, (2,6)-difluorophenyl, (2,6)-difluoro-3-
methylphenyl, (2,6)-dibromophenyl, (2,6)-dichlorophenyl, 3-chloro-2-
fluorophenyl,
(3,4)-dichlorophenyl, 4-fluoro-3-trifluoromethylphenyl, 3-fluoro-4-
trifluoromethylphenyl, (3,4)-difluorophenyl, 4-chloro-3-trifluoromethyl, 4-
bromo-3-
methylphenyl, 4-bromo-5-methylphenyl, 3-chloro-4-fluorophenyl,
(3,4)-dibromophenyl, 4-chloro-3-methylphenyl, 4-bromo-3-methylphenyl, 4-fluoro-
3-
methylphenyl, (3,5)-dimethoxyphenyl, (3,5)-bis-trifluoromethylphenyl,
(3,5)-difluorophenyl, (3,5)-dichlorophenyl, 3-fluoro-5-trifluoromethylphenyl,
5-fluoro-3-
trifluoromethylphenyl, (3,5)-dibromophenyl, 5-chloro-4-fluorophenyl, 5-bromo-4-
methylphenyl, (2,3,4)-trifluorophenyl, (2,3,4)-trichlorophenyl, (2,3,6)-
trifluorophenyl,
113

5-chloro-2-methoxyphenyl, (2,3)-difluoro-4-methylphenyl, (2,4,5)-
trifluorophenyl,
(2,4,5)-trichlorophenyl, (2,4)-dichloro-5-fluorophenyl, (2,4,6)-
trichlorophenyl, (2,4,6)-
trimethylphenyl, (2,4,6)-trifluorophenyl, (2,4,6)-trimethoxyphenyl, (2,3,4,5)-
tetrafluorophenyl, 4-methoxy-2,3,6-trimethylphenyl, 4-methoxy-2,3,6-
trimethylphenyl,
4-chloro-2,5-dimethylphenyl, 2-chloro-6-fluoro-3-methylphenyl, 6-chloro-2-
fluoro-3-
methyl, (2,3,4,5,6)-pentafluorophenyl, 3-fluoro-4-methylsulphonamidophenyl,
3-chloro-4-methylsulphonamidophenyl, 3-bromo-4-methylsulphonamidophenyl,
3-methoxy-4-methylsulphonamidophenyl, 3-hydroxy-4-methylsulphonamidophenyl,
3-trifluoromethyl-4-methylsulphonamidophenyl, 3-trifluoromethoxy-4-
methylsulphonamidophenyl, 3-methyl-4-methylsulphonamidophenyl, 3-ethyl-4-
methylsulphonamidophenyl, 3-isopropyl-4-methylsulphonamidophenyl, 3-propyl-4-
methylsulphonamidophenyl, 3-tert-butyl-4-methylsulphonamidophenyl, 3-fluoro-4-
phenylsulphonamidophenyl, 3-chloro-4-phenylsulphonamidophenyl, 3-bromo-4-
phenylsulphonamidophenyl, 3-methoxy-4-phenylsulphonamidophenyl, 3-hydroxy-4-
phenylsulphonamidophenyl, 3-trifluoromethyl-4-phenylsulphonamidophenyl,
3-trifluoromethoxy-4-phenylsulphonamidophenyl, 3-methyl-4-
phenylsulphonamidophenyl, 3-ethyl-4-phenylsulphonamidophenyl, 3-isopropyl-4-
phenylsulphonamidophenyl, 3-propyl-4-phenylsulphonamidophenyl, 3-tert-butyl-4-
phenylsulphonamidophenyl, 4-fluoro-3-methylsulphonamidophenyl, 4-chloro-3-
methylsulphonamidophenyl, 4-bromo-3-methylsulphonamidophenyl, 4-methoxy-3-
methylsulphonamidophenyl, 4-hydroxy-3-methylsulphonamidophenyl,
4-trifluoromethyl-3-methylsulphonamidophenyl, 4-trifluoromethoxy-3-
methylsulphonamidophenyl, 4-methyl-3-methylsulphonamidophenyl, 4-ethyl-3-
methylsulphonamidophenyl, 4-isopropyl-3-methylsulphonamidophenyl, 4-propyl-3-
methylsulphonamidophenyl, 4-tert-butyl-3-methylsulphonamidophenyl, 4-fluoro-3-
phenylsulphonamidophenyl, 4-chloro-3-phenylsulphonamidophenyl, 4-bromo-3-
phenylsulphonamidophenyl, 4-methoxy-3-phenylsulphonamidophenyl, 4-hydroxy-3-
phenylsulphonamidophenyl, 4-trifluoromethyl-3-phenylsulphonamidophenyl,
4-trifluoromethoxy-3-phenylsulphonamidophenyl, 4-methyl-3-
phenylsulphonamidophenyl, 4-ethyl-3-phenylsulphonamidophenyl, 4-isopropyl-3-
114

phenylsulphonamidophenyl, 4-propyl-3-phenylsulphonamidophenyl and 4-tert-butyl-
3-
phenylsulphonamidophenyl;
represents a radical selected from the group consisting of benzyl, phenethyl,
thiazolyl, naphthyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl and pyridinyl,
wherein
the cyclic portion of the above-mentioned radicals can optionally be
substituted with
1, 2, 3, 4 or 5 substituents selected independently of one another from the
group
consisting of F, CI, Br, I, -CF3, -OH, -O-CH3, -O-C2H5, methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl;
or represents a -C(=O)-NR13R14 group;
R11 represents a radical selected from the group consisting of phenyl,
indolyl,
pyridinyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl and naphthyl, wherein the
radical
can in each case optionally be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, CI, Br, -CF3, -
SF5, -OH,
-O-CH3, -O-C2H5, -O-CF3, piperidinyl, 4-methylpiperidinyl, 3-chloro-4-
fluorophenyl,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
NH-S(=O)2-
CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH-CH3 and -S(=O)2-NH-C2H5 and/or bound via a
-(CH2) group;
R13 represents a radical selected from the group consisting of phenyl,
naphthyl,
(1,4)-benzodioxanyl, pyridinyl, quinolinyl and isoquinolinyl, wherein the
radical can in
each case optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of one another from the group consisting of -SF5, F, CI, Br, -
CF3, -OH,
-O-CH3, -O-C2H5, -NH2, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl,
tert-butyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-S(=O)2-CH3, -NH-S(=O)2-
C2H5, -N[S(=O)2-CH3]2, -N[S(=O)2-C2H5]2, -S(=O)2-NH-CH3 and -S(=O)2-NH-C2H5
and/or bound via a -(CH2) group;
R12 and R14, independently of one another, each represent a hydrogen radical;
or
115

R13 and R14 respectively form together with the nitrogen atom connecting them
as ring
member
a (3,4)-dihydro-1H-isoquinolinyl radical which can be substituted with 1, 2,
3, 4 or 5
substituents selected independently of one another from the group consisting
of -OH,
-O-CH3 and -O-C2H5.
4. A compound, enantiomer, stereoisomer, racemate, mixture, salt or
solvate according to claim 1, selected from the group consisting of:
[1] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
aminobenzylamide;
[2] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
methanesulphonylaminobenzylamide;
[3] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
methanesulphonylaminobenzylamide;
[4] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
isoquinolin-5-ylamide;
[5] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-(4-thiazol-2-
ylpiperazin-1-yl)methanone;
[6] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-(4-thiazol-2-
ylpiperazin-1-yl)methanone;
[7] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-
fluoro-4-methanesulphonylaminobenzylamide;
[8] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(3-
trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone;
116

[9] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(3-
trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone;
[10] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(4-
hydroxyphenyl)piperazin-1-yl]methanone;
[11] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(4-
hydroxyphenyl)piperazin-1-yl]methanone;
[12] (8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-(6,7-dihydroxy-3,4-
dihydro-1H-isoquinolin-2-yl)methanone;
[13] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(6-
methylpyridazin-3-yl)piperazin-1-yl]methanone;
[14] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(6-
methylpyridazin-3-yl)piperazin-1-yl]methanone;
[15] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-(4-pyrimidin-2-
ylpiperazin-1-yl)methanone;
[16] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-(4-pyrimidin-2-
ylpiperazin-1-yl)methanone;
[17] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(4-chloro-
[1,2,5]thiadiazol-3-yl)piperazin-1-yl]methanone;
[18] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-(6,7-dimethoxy-
3,4-dihydro-1H-isoquinolin-2-yl)methanone;
[19] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-(6,7-dimethoxy-
3,4-
dihydro-1H-isoquinolin-2-yl)methanone;
[20] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(4-chloro-
[1,2,5]thiadiazol-3-yl)piperazin-1-yl]methanone;
117

[21] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(3-
chloropyridin-2-yl)-[1,4]diazepan-1-yl]methanone;
[22] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(3-
chloropyridin-
2-yl)-[1,4]diazepan-1-yl]methanone;
[23] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(pyridin-4-ylmethyl)amide;
[24] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(pyridin-4-ylmethyl)amide;
[25] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-
fluoro-4-methanesulphonylaminobenzylamide;
[26] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
hydroxy-3-methoxybenzylamide;
[27] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
hydroxy-3-methoxybenzylamide;
[28] trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(3-
chloropyridin-2-yl)piperazin-1-yl]methanone;
[29] cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-[4-(3-
chloropyridin-
2-yl)piperazin-1-yl]methanone;
[30] 3',4',4a',5',6',7',8',8a'-octahydro-1'H,4H-spiro[isoxazol-5,2'-
naphthalene]-3-carboxylic acid-(4-tert-butylphenyl)amide;
[31] 3',4',4a',5',6',7',8',8a'-octahydro-1'H,4H-spiro[isoxazol-5,2'-
naphthalene]-3-carboxylic acid-(4-tert-butylbenzyl)amide;
[32] 3',4',4a',5',6',7',8',8a'-octahydro-1'H,4H-spiro[isoxazol-5,2'-
naphthalene]-3-carboxylic acid-3-fluoro-4-methanesulphonylaminobenzylamide;
118

[33] 3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4-tert-
butylphenyl)amide;
[34] 3-phenyl-3',4',4a',5',6',7',8',8a'-octahydro-1'H,4H-spiro[isoxazol-
5,2'-
naphthalene];
[35] 3,8-diphenyl-1-oxa-2-azaspiro[4.5]dec-2-ene;
[36] 8-phenyl-3-p-tolyl-1-oxa-2-azaspiro[4.5]dec-2-ene;
[37] 8 phenyl-3-(4-trifluormethylphenyl)-1-oxa-2-azaspiro[4.5]dec-2-ene;
[38] 7,7,9,9-tetramethyl-3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene;
[39] 3-(4-tert-butylphenyl)-8-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene;
[40] 4-tert-butyl-3-phenyl-3',4',4a',5',6',7',8',8a'-octahydro-1'H,4H-
spiro[isoxazol-5,2'-naphthalene];
[41] 3-(4-tert-butylphenyl)-7,7,9,9-tetramethyl-1-oxa-2-azaspiro[4.5]dec-2-
ene;
[42] 8-phenyl-3-pyridin-2-yl-1-oxa-2-azaspiro[4.5]dec-2-ene;
[43] 8-(1,1-dimethylpropyl)-3-pyridin-2-yl-1-oxa-2-azaspiro[4.5]dec-2-ene;
[44] 3-(4-tert-butylphenyl)-8-(1,1-dimethylpropyl)-1-oxa-2-azaspiro[4.5]dec-
2-ene;
[45] 3-(4-tert-butylphenyl)-8-ethyl-1-oxa-2-azaspiro[4.5]dec-2-ene;
[46] cis-[3-(4-tert-butylphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl]-[4-(3-
chloropyridin-2-yl)piperazin-1-yl]methanone;
[47] trans-[3-(4-tert-butylphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl]-[4-
(3-
chloropyridin-2-yl)piperazin-1-yl]methanone;
119

[48] cis-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-(3-phenyl-1-oxa-2-
azaspiro[4.5]dec-2-en-8-yl)methanone;
[49] trans-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-(3-phenyl-1-oxa-2-
azaspiro[4.5]dec-2-en-8-yl)methanone;
[50] 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4-tert-
butylphenyl)amide;
[51] 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-cis-(4-tert-
butylphenyl)amide;
[52] 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-cis-3-fluoro-
4-methanesulphonylaminobenzylamide;
[53] 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-trans-3-
fluoro-4-methanesulphonylaminobenzylamide;
[54] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(4-tert-
butylphenyl)amide;
[55] 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-trans-(4-
tert-
butylphenyl)amide;
[56] 8-tert-butyl-N-(4-(methylsulphonamido)benzyl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[57] N-(4-tert-butylphenyl)-3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxamide hydrochloride;
[58] ((5R,8R)-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)(4-(3-
chloropyridin-2-yl)-2,6-dimethylpiperazin-1-yl)methanone;
[59] ((5S,8S)-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)(4-(3-
chloropyridin-2-yl)-2,6-dimethylpiperazin-1-yl)methanone;
120

[60] ((5R,8R)-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)(4-(3-
chloropyridin-2-yl)-2-methylpiperazin-1-yl)methanone;
[61] ((5S,8S)-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)(4-(3-
chloropyridin-2-yl)-2-methylpiperazin-1-yl)methanone;
[62] (4-(3-chloropyridin-2-yl)piperazin-1-yl)(3-(3-methoxyphenyl)-1-oxa-2-
azaspiro[4.5]dec-2-en-8-yl)methanone;
[63] 3-(3-methoxyphenyl)-N-(4-(trifluormethoxy)benzyl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide;
[64] N-(1H-indol-5-yl)-3-(3-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-ene-
8-carboxamide;
[65] N-(3-fluoro-4-(methylsulphonamido)benzyl)-3-(3-methoxyphenyl)-1-oxa-
2-azaspiro[4.5]dec-2-ene-8-carboxamide;
[66] N-(4-tert-butylphenyl)-3-(3-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-
ene-8-carboxamide;
[67] N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(3-methoxyphenyl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide;
[68] N-(4-tert-butylphenyl)-3-(4-fluorophenyl)-1-oxa-2-azaspiro[4.5]dec-2-
ene-8-carboxamide;
[69] (5R,8R)-3-phenyl-N-((2-(piperidin-1-yl)-6-(trifluormethyl)pyridin-3-
yl)methyl)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide;
[70] (5R,8R)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluormethyl)pyridin-3-
yl)methyl)-3-phenyl-1-oxa-2-azaspiro[4.5]-dec-2-ene-8-carboxamide;
[71] (5S,8S)-N-((2-(3-chloro-4-fluorophenyl)-6-(trifluormethyl)pyridin-
3-
yl)methyl)-3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide;
121

[72] (5S,8S)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluormethyl)pyridin-3-
yl)methyl)-3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide;
[73] (5S,8S)-3-phenyl-N-((2-(piperidin-1-yl)-6-(trifluormethyl)pyridin-3-
yl)methyl)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide;
[74] (5R,8R)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-phenyl-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide;
[75] (5S,8S)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-phenyl-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide;
[79] 8-tert-butyl-N-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[80] N-(3-fluoro-4-(methylsulphonamido)benzyl)-8-tert-pentyl-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[81] N-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-8-tert-pentyl-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[82] 8-cyclohexyl-N-(3-fluoro-4-(methylsulphonamido)benzyl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[83] 8-tert-butyl-N-(7-hydroxynaphthalen-1-yl)-1-oxa-2-azaspiro[4.5]dec-2-
ene-3-carboxamide;
[84] N-(4-tert-butylphenyl)-3-(4-(3-chloropyridin-2-yl)piperazin-1-
carbonyl)-1-
oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide;
[85] N-(4-tert-butylbenzyl)-3-(4-(3-chloropyridin-2-yl)piperazin-1-
carbonyl)-1-
oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide;
[86] 8-tert-butyl-N-(5-hydroxynaphthalen-1-yl)-1-oxa-2-azaspiro[4.5]dec-2-
ene-3-carboxamide;
122

[87] 8-tert-butyl-N-(2-fluoro-5-(methylsulphonamido)phenyl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[88] 8-tert-butyl-N-(2-fluoro-5-(N-
(methylsulphonyl)methylsulphonamido)phenyl)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-
carboxamide;
[89] 8-tert-butyl-N-(4-fluoro-3-(methylsulphonamido)phenyl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[90] 8-tert-butyl-N-(3-fluoro-4-(methylsulphonamido)phenyl)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide;
[91] 8-tert-butyl-N-(3-fluoro-4-(N-
(methylsulphonyl)methylsulphonamido)phenyl)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-
carboxamide;
[92] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
pentafluorosulphanylbenzylamide;
[93] 3-(3-methoxyphenyI)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-
(4-pentafluorosulphanylphenyl)amide;
enantiomers thereof, stereoisomers thereof, diastereoisomers thereof, mixtures
of
enantiomers thereof, mixtures of diastereoisomers thereof, salts thereof and
solvates
thereof.
5. A process for preparing a substituted spiro compound of general
formula I as defined in claim 1, wherein:
A) i) a compound of general formula II,
123

<IMG>
wherein n and R2 to R9 are as defined in claim 1 for the compound of general
formula I and R1 is as defined in claim 1 except for a -C(=O)-NR11R12 group or
represents -C(=O)-OR;
wherein R represents a linear or branched C1-6 alkyl radical; is reacted in a
reaction
medium in the presence of at least one base with a compound of general formula
III,
<IMG>
wherein R10 is as defined in claim 1 except for a -C(=O)-NR13R14 group or
represents
-C(=O)-OR; wherein R represents a linear or branched C1-6 alkyl radical; to
form at
least one compound of general formula IV,
<IMG>
124

wherein n and R2 to R9 are as defined in claim 1 for the compound of general
formula I, R1 is as defined in claim 1 for the compound of general formula I
except for
a -C(=O)-NR11R12 group or represents -C(=O)-OR, and R10 is as defined in claim
1
for the compound of general formula l except for a -C(=O)-NR13R14 group or
represents -C(=O)-OR; wherein R independently of one another respectively
represents a linear or branched C1-6 alkyl radical; and the compound of
general
formula IV is optionally purified and/or isolated;
and (ii) optionally the compound of general formula IV, wherein n and R2 to R9
are as
defined in claim 1 for the compound of general formula I, R1 represents -C(=O)-
OR;
wherein R is as defined in claim 1 for the compound of general formula I and
R10 is
as defined in claim 1 for the compound of general formula I except for a -
C(=O)-
NR13R14 group; is reacted in a reaction medium in the presence of a base, to
form a
compound of general formula V,
<IMG>
wherein n and R2 to R9 are as defined in claim 1 for the compound of general
formula I, R1 represents -C(=O)-OH and R10 is as defined in claim 1 for the
compound of general formula I except for a -C(=O)-NR13R14 group; and the
compound of general formula V is optionally purified and/or isolated;
and (iii) the compound of general formula V is reacted in a reaction medium in
the
presence of a coupling reagent, optionally in the presence of a base, with a
compound of general formula HNR11R12, wherein R11 and R12 are as defined in
claim 1 for the compound of general formula I, to form the compound of general
125

formula I, wherein n and R2 to R9 are as defined in claim 1 for the compound
of
general formula I, R1 represents a -C(=O)-NR11R12 group; wherein R11 and R12
are as
defined in claim 1 for the compound of general formula I and R10 is as defined
in
claim 1 for the compound of general formula I, except for a -C(=O)-NR13R14
group;
and the compound of general formula I is optionally purified and/or isolated;
or
B) i) optionally a compound of general formula IV, wherein n and R2 to R9 are
as
defined in claim 1 for the compound of general formula I, R1 is as defined in
claim 1
for the compound of general formula I, except for a -C(=O)-NR11R12 group and
R10
represents a -C(=O)-OR group; wherein R represents a linear or branched C1-6
alkyl
radical; is reacted in a reaction medium in the presence of a base, to form a
compound of general formula VI,
<IMG>
wherein n and R2 to R9 are as defined in claim 1 for the compound of general
formula I, R1 is as defined in claim 1 for the compound of general formula I,
except for
a -C(=O)-NR11R12 group and R10 represents -C(=O)-OH; and the compound of
general formula VI is optionally purified and/or isolated;
and (ii) the compound of general formula VI is reacted in a reaction medium in
the
presence of at least one coupling reagent, optionally in the presence of at
least one
base, with a compound of general formula HNR13R14, wherein R13 and R14 are as
defined in claim 1 for the compound of general formula I, to form the compound
of
126

general formula I, wherein n and R2 to R9 are as defined in claim 1 for the
compound
of general formula l, R1 is as defined in claim 1 for the compound of general
formula l, except for a -C(=O)-NR11R12 group and R1 represents a -C(=O)-
NR13R14
group; wherein R13 and R14 are as defined in claim 1 for the compound of
general
formula I; and the compound of general formula I is optionally purified and/or
isolated.
6. A process according to claim 5, wherein, in step A) ii), the base is an
alkali metal hydroxide.
7. A process according to claim 6, wherein the alkali metal hydroxide is
lithium hydroxide.
8. A process according to claim 5, wherein, in step B) i), the base is an
alkali metal hydroxide.
9. A process according to claim 8, wherein the alkali metal hydroxide is
lithium hydroxide.
10. A pharmaceutical composition comprising a compound, enantiomer,
diastereomer, racemate, mixture, salt or solvate as defined in any one of
claims 1
to 4, wherein the salt or solvate is a physiologically acceptable salt or
solvate and a
physiologically compatible adjuvant.
11. A pharmaceutical composition according to claim 10 for treatment of
pain.
12. A pharmaceutical composition according to claim 11, wherein the pain
is selected from the group consisting of acute pain, chronic pain and
neuropathic
pain.
13. A pharmaceutical composition according to claim 10 for treatment or
prophylaxis of a disease selected from the group consisting of arthralgia;
migraine;
depression; neuropathy; a nerve injury; a neurodegenerative disease; a
cognitive
dysfunction; epilepsy; a respiratory disease; coughing; urinary incontinence;
OAB
127

(overactive bladder); stomach ulcers; irritable bowel syndrome; a stroke; an
irritation
of the eyes; an irritation of the skin; a neurotic skin disease; an
inflammatory disease;
diarrhoea; pruritus; an eating disorder; medication dependency; medication
abuse;
withdrawal symptoms in medication dependency; development of tolerance to
medication; drug addiction; drug abuse; withdrawal symptoms in drug addiction;
alcohol addiction; alcohol abuse and withdrawal symptoms in alcohol addiction.
14. A pharmaceutical composition according to claim 13, wherein the
neurodegenerative disease is multiple sclerosis, Parkinson's disease or
Huntington's
disease.
15. A pharmaceutical composition according to claim 13, wherein the
cognitive dysfunction is a cognitive deficiency.
16. A pharmaceutical composition according to claim 15, wherein the
cognitive deficiency is paramnesia.
17. A pharmaceutical composition according to claim 13, wherein the
respiratory disease is asthma or pneumonia.
18. A pharmaceutical composition according to claim 13, wherein the
inflammatory disease is an intestinal inflammation.
19. A pharmaceutical composition according to claim 13, wherein the eating
disorder is bulimia, cachexia, anorexia or obesity.
20. A pharmaceutical composition according to claim 13, wherein the
disease is the development of tolerance to medication, and the medication is a
natural or a synthetic opioid.
21. A pharmaceutical composition according to claim 10 for diuresis.
22. A pharmaceutical composition according to claim 10 for antinatriuresis.
128

23. A pharmaceutical composition according to claim 10 for influencing a
patient's cardiovascular system.
24. A pharmaceutical composition according to claim 10 for increasing
vigilance.
25. A pharmaceutical composition according to claim 10 for increasing
libido.
26. A pharmaceutical composition according to claim 10 for modulating
motor activity.
27. A pharmaceutical composition according to claim 10 for anxiolysis.
28. A pharmaceutical composition according to claim 10 for local
anaesthetic.
29. A pharmaceutical composition according to claim 10 for inhibiting
undesirable side effects.
30. A pharmaceutical composition according to claim 29, wherein the
undesirable side effects are undesirable side effects of hyperthermia,
hypertension or
bronchoconstriction.
31. A pharmaceutical composition according to claim 29, wherein the
undesirable side effects are undesirable side effects triggered by
administration of a
vanilloid receptor 1 (VR1/TRPV1) agonist.
32. A pharmaceutical composition according to claim 31, wherein the
vanilloid receptor 1 (VR1/TRPV1) agonist is selected from the group consisting
of
capsaicin, resiniferatoxin, olvanil, arvanil, SDZ-249665, SDZ-249482, nuvanil
and
capsavanil.
129

33. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for treatment or prophylaxis of pain.
34. A use according to claim 33, wherein the pain is selected from the
group consisting of acute pain, chronic pain and neuropathic pain.
35. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for treatment or prophylaxis of a disease selected
from
the group consisting of arthralgia; migraine; depression; neuropathy; a nerve
injury; a
neurodegenerative disease; a cognitive dysfunction; epilepsy; a respiratory
disease;
coughing; urinary incontinence; OAB (overactive bladder); stomach ulcers;
irritable
bowel syndrome; a stroke; an irritation of the eyes; an irritation of the
skin; a neurotic
skin disease; an inflammatory disease; diarrhoea; pruritus; an eating
disorder;
medication dependency; medication abuse; withdrawal symptoms in medication
dependency; development of tolerance to medication; drug addiction; drug
abuse;
withdrawal symptoms in drug addiction; alcohol addiction; alcohol abuse and
withdrawal symptoms in alcohol addiction.
36. A use according to claim 35, wherein the neurodegenerative disease is
multiple sclerosis, Parkinson's disease or Huntington's disease.
37. A use according to claim 35, wherein the cognitive dysfunction is a
cognitive deficiency.
38. A use according to claim 37, wherein the cognitive deficiency is
paramnesia.
39. A use according to claim 35, wherein the respiratory disease is asthma
or pneumonia.
40. A use according to claim 35, wherein the inflammatory disease is an
intestinal inflammation.
130

41. A use according to claim 35, wherein the eating disorder is bulimia,
cachexia, anorexia or obesity.
42. A use according to claim 35, wherein the disease is the development of
tolerance to medication, and the medication is a natural or a synthetic
opioid.
43. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for diuresis.
44. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for antinatriuresis.
45. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for influencing a patient's cardiovascular system.
46. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for increasing vigilance.
47. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for increasing libido.
48. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for modulating motor activity.
49. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for anxiolysis.
131

50. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for local anaesthetic.
51. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for inhibiting undesirable side effects.
52. A use according to claim 51, wherein the undesirable side effects are
undesirable side effects of hyperthermia, hypertension or bronchoconstriction.
53. A use according to claim 51, wherein the undesirable side effects are
undesirable side effects triggered by administration of a vanilloid receptor 1
(VR1/TRPV1) agonist.
54. A use according to claim 53, wherein the vanilloid receptor
1 (VR1/TRPV1) agonist is selected from the group consisting of capsaicin,
resiniferatoxin, olvanil, arvanil, SDZ-249665, SDZ-249482, nuvanil and
capsavanil.
55. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for treatment or
prophylaxis of
pain.
56. A use according to claim 55, wherein the pain is selected from the
group consisting of acute pain, chronic pain and neuropathic pain.
57. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for treatment or
prophylaxis of a
disease selected from the group consisting of arthralgia; migraine;
depression;
neuropathy; a nerve injury; a neurodegenerative disease; a cognitive
dysfunction;
epilepsy; a respiratory disease; coughing; urinary incontinence; OAB
(overactive
bladder); stomach ulcers; irritable bowel syndrome; a stroke; an irritation of
the eyes;
an irritation of the skin; a neurotic skin disease; an inflammatory disease;
diarrhoea;
pruritus; an eating disorder; medication dependency; medication abuse;
withdrawal
132

symptoms in medication dependency; development of tolerance to medication;
drug
addiction; drug abuse; withdrawal symptoms in drug addiction; alcohol
addiction;
alcohol abuse and withdrawal symptoms in alcohol addiction.
58. A use according to claim 57, wherein the neurodegenerative disease is
multiple sclerosis, Parkinson's disease or Huntington's disease.
59. A use according to claim 57, wherein the cognitive dysfunction is a
cognitive deficiency.
60. A use according to claim 59, wherein the cognitive deficiency is
paramnesia.
61. A use according to claim 57, wherein the respiratory disease is asthma
or pneumonia.
62. A use according to claim 57, wherein the inflammatory disease is an
intestinal inflammation.
63. A use according to claim 57, wherein the eating disorder is bulimia,
cachexia, anorexia or obesity.
64. A use according to claim 57, wherein the disease is the development of
tolerance to medication, and the medication is a natural or a synthetic
opioid.
65. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for diuresis.
66. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for antinatriuresis.
67. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for influencing a
patient's
cardiovascular system.
133

68. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for increasing
vigilance.
69. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for increasing libido.
70. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for modulating motor
activity.
71. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for anxiolysis.
72. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for local anaesthetic.
73. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 for inhibiting
undesirable side
effects.
74. A use according to claim 73, wherein the undesirable side effects are
undesirable side effects of hyperthermia, hypertension or bronchoconstriction.
75. A use according to claim 73, wherein the undesirable side effects are
undesirable side effects triggered by administration of a vanilloid receptor 1
(VR1/TRPV1) agonist.
76. A use according to claim 75, wherein the vanilloid receptor
1 (VR1/TRPV1) agonist is selected from the group consisting of capsaicin,
resiniferatoxin, olvanil, arvanil, SDZ-249665, SDZ-249482, nuvanil and
capsavanil.
77. A use of a compound, enantiomer, diastereomer, racemate, mixture,
salt or solvate as defined in any one of claims 1 to 4 in preparation of a
pharmaceutical composition for prophylaxis or treatment of a disease selected
from
the group consisting of a respiratory disease; coughing; an irritation of the
eyes; an
irritation of the skin; a neurotic skin disease and an inflammatory disease.
134

78. A use according to claim 77, wherein the respiratory disease is asthma
or pneumonia.
79. A use according to claim 77, wherein the inflammatory disease is an
intestinal inflammation.
80. A use of a compound as defined in any one of claims 1 to 4 for
prophylaxis or treatment of a disease selected from the group consisting of a
respiratory disease; coughing; an irritation of the eyes; an irritation of the
skin; a
neurotic skin disease and an inflammatory disease.
81. A use according to claim 80, wherein the respiratory disease is asthma
or pneumonia.
82. A use according to claim 80, wherein the inflammatory disease is an
intestinal inflammation.
83. A pharmaceutical composition according to claim 10 for prophylaxis or
treatment of a disease selected from the group consisting of a respiratory
disease;
coughing; an irritation of the eyes; an irritation of the skin; a neurotic
skin disease and
an inflammatory disease.
84. A pharmaceutical composition according to claim 83, wherein the
respiratory disease is asthma or pneumonia.
85. A pharmaceutical composition according to claim 83, wherein the
inflammatory disease is an intestinal inflammation.
135

Description

CA 02608319 2007-11-13
GRA3304/A-PCT
Substituted spiro-compounds and the use thereof for producing medicaments
The present invention relates to substituted Spiro compounds, to processes for
preparing them, to medicaments comprising these compounds and to the use of
these compounds for producing medicaments.
The treatment of pain, in particular of neuropathic pain, is of great
importance in
medicine. Effective pain therapies are in demand across the globe. The urgent
need
for action to provide patient-friendly and targeted treatment of chronic and
non-
chronic states of pain, meaning the successful and satisfactory treatment of
the
patient's pain, is also reflected in the large number of scientific studies
which have
recently appeared in the field of applied analgesics or basic research in
nociception.
A suitable starting point for the treatment of pain, in particular of
neuropathic pain, is
provided by the subtype 1 vanilloid receptor (VR1/TRPV1) which is often also
referred to as a capsaicin receptor. This receptor is stimulated, inter alia,
by
vanilloids, such as for example capsaicin, heat and protons and plays a
central role in
the production of pain. In addition, it is important for a large number of
further
physiological and pathophysiological processes such as, for example, migraine;
depression; neurodegenerative diseases; cognitive diseases; panic attacks;
epilepsy;
coughing; diarrhoea; pruritus; disturbances of the cardiovascular system;
eating
disorders; medication dependency; medication abuse and in particular urinary
incontinence.
An object of the present invention was therefore to provide new compounds
which
are suitable, in particular, as pharmacological active ingredients in
medicaments,
preferably in medicaments for the treatment of disturbances or diseases which
are
transmitted, at least in some cases, by vanilloid receptors 1 (VR1/TRPV1
receptors).
It has surprisingly been found that substituted spiro compounds of general
formula I
as indicated below are suitable for combating pain and display outstanding
affinity to
the subtype 1 vanilloid receptor (VR1/TRPV1 receptor) and are therefore
suitable, in
particular, for the prophylaxis and/or treatment of disturbances or diseases
transmitted, at least in some cases, by vanilloid receptors 1 (VR1/TRPV1).
1

CA 02608319 2007-11-13
GRA3304/A-PCT
The present invention therefore relates to substituted Spiro compounds of
general
formula I,
0407
R3 Fx Fx R8
R,
R2
R5 R10
R6 R9
wherein
is equal to 0, 1 or 2,
I.)
R1 represents a linear or branched, saturated or unsaturated, unsubstituted
or at
least singly substituted aliphatic radical optionally having at least one
heteroatom as chain member;
an unsubstituted or at least singly substituted, unsaturated or saturated
cycloaliphatic radical which optionally has at least one heteroatom as ring
member and can be bound via a linear or branched, unsubstituted or at least
singly substituted alkylene, alkenylene or alkinylene group optionally having
at
least one heteroatom as chain member and/or condensed with an
unsubstituted or at least singly substituted mono- or polycyclic ring system;
an unsubstituted or at least singly substituted aryl or heteroaryl radical
which
can be bound via a linear or branched, unsubstituted or at least singly
substituted alkylene, alkenylene or alkinylene group optionally having at
least
one heteroatom as chain member and/or condensed with an unsubstituted or
at least singly substituted mono- or polycyclic ring system;
2

CA 02608319 2007-11-13
GRA3304/A-PCT
_c(.0)_NRi Ri2
or a group;
and
R2, R3, R4, R5, R6, R7 and R8, independently of one another, each
represent a hydrogen radical or
a linear or branched, saturated or unsaturated, unsubstituted or at least
singly
substituted aliphatic radical optionally having at least one heteroatom as
chain
member;
or
II.)
R1 and R3 together represent a -(CH2)p group wherein p = 3, 4, 5 or 6;
and
R2, R4, R5, R6, R7 and R8, independently of one another, each
represent a hydrogen radical
or a linear or branched, saturated or unsaturated, unsubstituted or at least
singly substituted aliphatic radical optionally having at least one heteroatom
as
chain member;
Or
III.)
R1, R2, R7 and R8 each represent a hydrogen radical
3

CA 02608319 2007-11-13
GRA3304/A-PCT
and
R3, R4, R5 and R6, independently of one another, each
represent a linear or branched, saturated or unsaturated, unsubstituted or at
least singly substituted aliphatic radical optionally having at least one
heteroatom as chain member;
and in each case
R9 represents a hydrogen radical;
a linear or branched, saturated or unsaturated, unsubstituted or at least
singly
substituted aliphatic radical optionally having at least one heteroatom as
chain
member;
an unsubstituted or at least singly substituted, unsaturated or saturated
cycloaliphatic radical which optionally has at least one heteroatom as ring
member and can be bound via a linear or branched, unsubstituted or at least
singly substituted alkylene, alkenylene or alkinylene group optionally having
at
least one heteroatom as chain member and/or condensed with an
unsubstituted or at least singly substituted mono- or polycyclic ring system;
or an unsubstituted or at least singly substituted aryl or heteroaryl radical
which can be bound via a linear or branched, unsubstituted or at least singly
substituted alkylene, alkenylene or alkinylene group optionally having at
least
one heteroatom as chain member and/or condensed with an unsubstituted or
at least singly substituted mono- or polycyclic ring system;
Rlo represents a linear or branched, saturated or unsaturated,
unsubstituted or at
least singly substituted aliphatic radical optionally having at least one
heteroatom as chain member;
4

CA 02608319 2007-11-13
GRA3304/A-PCT
an unsubstituted or at least singly substituted, unsaturated or saturated
cycloaliphatic radical which optionally has at least one heteroatom as ring
member and can be bound via a linear or branched, unsubstituted or at least
singly substituted alkylene, alkenylene or alkinylene group optionally having
at
least one heteroatom as chain member and/or condensed with an
unsubstituted or at least singly substituted mono- or polycyclic ring system;
an unsubstituted or at least singly substituted phenyl radical,
an unsubstituted or at least singly substituted phenyl radical which is
condensed with an unsubstituted or at least singly substituted mono- or
polycyclic ring system,
an unsubstituted or at least singly substituted naphthyl or heteroaryl radical
which can be condensed with an unsubstituted or at least singly substituted
mono- or polycyclic ring system,
an unsubstituted or at least singly substituted aryl or heteroaryl radical
which is
bound via a -(CH2)-, -(CH2)2- or -(CH2)3 group and can optionally be
condensed with an unsubstituted or at least singly substituted mono- or
polycyclic ring system;
or a -C(=0)-NR13R14 group;
R11 and R13, independently of one another, each
represent a linear or branched, saturated or unsaturated, unsubstituted or at
least singly substituted aliphatic radical;
an unsubstituted or at least singly substituted, unsaturated or saturated
cycloaliphatic radical which optionally has at least one heteroatom as ring
member and can be bound via a linear or branched, unsubstituted or at least
singly substituted alkylene, alkenylene or alkinylene group optionally having
at

CA 02608319 2007-11-13
GRA3304/A-PCT
least one heteroatom as chain member and/or condensed with an
unsubstituted or at least singly substituted mono- or polycyclic ring system;
or an unsubstituted or at least singly substituted aryl or heteroaryl radical
which can be bound via a -(CH2)-, -(CH2)2- or -(CH2)3 group and/or condensed
with an unsubstituted or at least singly substituted mono- or polycyclic ring
system;
R12 and R14, independently of one another, each
represent a hydrogen radical;
a linear or branched, saturated or unsaturated, unsubstituted or at least
singly
substituted aliphatic radical;
an unsubstituted or at least singly substituted, unsaturated or saturated
cycloaliphatic radical which optionally has at least one heteroatom as ring
member and can be bound via a linear or branched, unsubstituted or at least
singly substituted alkylene, alkenylene or alkinylene group optionally having
at
least one heteroatom as chain member and/or condensed with an
unsubstituted or at least singly substituted mono- or polycyclic ring system;
or an unsubstituted or at least singly substituted aryl or heteroaryl radical
which can be bound via a -(CH2) group and/or condensed with an
unsubstituted or at least singly substituted mono- or polycyclic ring system;
or
R11 and R12 or R13 and R14 respectively form together with the
nitrogen atom connecting them as ring member an unsubstituted or at least
singly substituted, unsaturated or saturated heterocycloaliphatic radical
which
optionally has at least one further heteroatom as ring member and can be
condensed with an unsubstituted or at least singly substituted mono- or
polycyclic ring system;
6

CA 02608319 2007-11-13
GRA3304/A-PCT
wherein
the substituents of the above-mentioned heterocycloaliphatic radical formed by
R11
and R12 or R13 and R14 can be selected independently of one another from the
group
consisting of oxo (=0), thioxo (=S), F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-
C1_5 alkyl, -
NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-C1_5 alkyl, -Ci_5 alkyl, -0-C(=0)-C1_5
alkyl, -NH-
C1_5 alkyl, -N(C1_5 alky02, -NH-C(=0)-0-C1_5 alkyl, -C(=0)-NH2, -C(=0)-NH-C1.5
alkyl, -
C(=0)-N-(C1_5 alky1)2, cyclohexyl, cyclopentyl, pyridinyl, pyridazinyl,
pyrimidinyl,
[1,2,5]-thiadiazolyl, thiazolyl, -(CH2)-benzo[b]furanyl, -0-phenyl, -0-benzyl,
phenyl
and benzyl, wherein in each case the cyclic portion of the radicals
pyrimidinyl, [1,2,51-
thiadiazolyl, thiazolyl, pyridinyl, cyclopentyl, cyclohexyl, pyridazinyl, -0-
phenyl, -0-
benzyl, phenyl, -(CH2)-benzo[b]furanyl and benzyl can be substituted with
substituents selected independently of one another from the group consisting
of F,
Cl, Br, -OH, -CF3, -SF5, -CN, -NO2, -C1_5 alkyl, -0-C1_5 alkyl, -0-CF3, -S-
CF3, phenyl
and -0-benzyl,
and
the substituents of the above-mentioned aliphatic radicals can be selected
independently of one another from the group consisting of F, Cl, Br, I, -CN, -
NO2, -
OH, -SH and -NH2;
in each case optionally in the form of one of their pure stereoisomers, in
particular
enantiomers or diastereomers, their racemates or in the form of a mixture of
stereoisomers, in particular of enantiomers and/or diastereomers, in any
desired
mixing ratio, or respectively in the form of corresponding salts, or
respectively in the
form of corresponding solvates.
Preferably, the radicals R10, R11, R12, R13 and =--.14
have alkylene, alkenylene or
alkinylene groups which can be respectively substituted with substituents
selected
independently of one another from the group consisting of F, Cl, Br, -OH, -SH,
-NH2, -
ON, -NO2 and phenyl; wherein the phenyl radical can be substituted with 1, 2,
3, 4 or
substituents selected independently of one another from the group consisting
of
7

CA 02608319 2007-11-13
GRA3304/A-PCT
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
n-pentyl,
isopentyl and neopentyl.
Preferably, the radical R10, in any of the definitions indicated in the
present
document, can represent an unsubstituted or at least singly substituted phenyl
radical, on the condition that not one of the meta positions and the para
position of
this phenyl radical are substituted with substituents which are respectively
bound via
an identical atom selected from the group consisting of oxygen, sulphur and
nitrogen.
This condition rules out the substituents mentioned in a corresponding
position in
document WO 2005/21515 Al.
Preferably, the radical R1 can comprise a phenyl radical as defined above or
an
unsubstituted or at least singly substituted phenyl radical which is condensed
with an
unsubstituted or at least singly substituted mono- or polycyclic ring system,
or
represents an unsubstituted or at least singly substituted naphthyl or
heteroaryl
radical which can be condensed with an unsubstituted or at least singly
substituted
mono- or polycyclic ring system which is selected from the group consisting of
naphthyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl, thiophenyl, furanyl,
pyrrolyl,
pyrazolyl, pyranyl, pyridinyl, imidazolyl, indolyl, isoindolyl,
benzo[b]furanyl,
benzo[b]thiophenyl, thiazolyl, oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl,
pyrimidinyl,
indazolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl,
benzimidazolyl,
benzoxazolyl, benzotriazolyl, benzisoxazolyl, [1,2,3,4]-tetrahydronaphthyl,
[1,2,3,4]-
tetrahydroquinolinyl, [1,2,3,4]-tetrahydroisoquinolinyl, [1,2,3,4]-
tetrahydroquinazolinyl;
2H-benzo[1.4]oxazin-3(4H)-onyl, (3,4)-dihyd roq uinolin-2(1 H)-onyl, [3,4]-
dihydro-2H-
1,4-benzoxazinyl and benzothiazolyl, wherein the radicals can be respectively
unsubstituted or at least singly substituted.
Aliphatic radicals include in the sense of the present invention acyclic
saturated or
unsaturated hydrocarbon radicals which can be branched or straight chained and
unsubstituted or singly substituted or multiply substituted by the same or
different
substituents, containing preferably 1 to 20 (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13,
14, 15, 16, 17, 18, 19 or 20), particularly preferably 1 to 12 (i.e. 1, 2, 3,
4, 5, 6, 7, 8, 9,
10, 11 or 12), most particularly preferably 1 to 6 (i.e. 1, 2, 3, 4, 5 or 6)
carbon atoms,
i.e. C1-201 C1-12, C1-6 alkyls, C2-20, C2-12, C2-6 alkenyls and C2-20, C2-12,
C2-6 alkinyls.
8

CA 02608319 2007-11-13
GRA3304/A-PCT
Alkenyls have at least one C-C double bond and alkinyls at least one C-C
triple bond.
Advantageously, aliphatic radicals can be selected from the group comprising
methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-
pentyl, isopentyl,
neopentyl, n-hexyl, 2-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-
dodecyl,
n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-
octadecyl, n-
nonadecyl, n-eicosanyl, ethenyl (vinyl), ethinyl, propenyl (-CH2CH=CH2,
-CH=CH-CH3, -C(=CH2)-CH3), 2-methylpropenyl, propinyl (-CH2-CECH, -CEC-CH3),
butenyl, butinyl, pentenyl, pentinyl, hexenyl, hexinyl, octenyl and octinyl.
The above-mentioned aliphatic radicals can preferably have 1, 2 or 3
heteroatoms
selected from the group comprising oxygen, sulphur and nitrogen, i.e. -N(H)-
and -
N(C1_6 alkyl).
Examples of aliphatic radicals having 1, 2 or 3 heteroatoms include
-(CH2)-(CH2)-0-CH3, -(CH2)-(CH2)-(CH2)-0-CH3, -(CH2)-(CH2)-(CH2)-N(C2H5)-
(C2H5),
-(CH2)-(CH2)-S-CH3, -(CH2)-(CH2)-(CH2)-S-CH3, -(CH2)-(CH2)-(CH2)-N(CH3)-(CH3)
and -(CH2)-0-CH3.
In relation to aliphatic radicals, the term "substituted" - unless otherwise
defined -
refers in the sense of the present invention to the single or multiple
substitution,
preferably the single, double, triple, quadruple, quintuple, sextuple,
septuple, octuple
or nonuple substitution, of one or more hydrogen atoms by, for example, F, Cl,
Br, I, -
CN, -NO2, -OH, -SH and -NH2, the multiple substitution being carried out
either on
different or on identical atoms several times, for example twice or three
times, for
example three times on the same carbon atom as in the case of -CF3 or -CH2CF3
or
at various locations as in the case of -CH(OH)-CH=CCI-CH2CI. The multiple
substitution can be carried out with the same or with different substituents.
Preferred
substituted aliphatic radicals include -CH2-CI, -CH2-Br, -CH2-CH2-CI, -CH2-CH2-
Br, -
CH2-CH2-CH2-Br and -CH2-CH2-CH2-Cl.
Cycloaliphatic radicals in the sense of the present invention are cyclic
saturated or
unsaturated hydrocarbon radicals containing preferably 3, 4, 5, 6,7, 8,9, 10,
11, 12,
13, 14, 15 or 16, particularly preferably 3, 4, 5, 6, 7 or 8 carbon atoms,
wherein each
radical can be unsubstituted or singly substituted or multiply substituted by
the same
9

CA 02608319 2007-11-13
GRA3304/A-PCT
or different substituents. Cycloaliphatic radicals preferably have 1, 2, 3, 4
or 5
heteroatoms selected independently of one another from the group consisting of
oxygen, nitrogen (NH) and sulphur as ring members.
Examples of cycloaliphatic radicals which can optionally be bridged with 1 or
2 linear
or branched C1-5 alkylene groups and condensed with a mono- or polycyclic ring
system include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl,
cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloheptyl,
cyclopentenyl,
cyclohexenyl, cycloheptenyl, [6,6]-dimethy143.1.1]-bicycloheptyl, adamantyl,
oxiranyl,
aziridinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl,
isoxazolidinyl,
isothioazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl,
(1,2,4)-
oxadiazolidinyl, (1,2,4)-thiadiazolidinyl, (1,2,4)-triazolidin-3-yl, (1,3,4)-
thiadiazolidinyl,
(1,3,4)-triazolidin-1-yl, (1,3,4)-triazolidin-2-yl, (2,3)-dihydrofuryl, (2,5)-
dihydrofuryl,
(2,3)-dihydrothienyl, (2,5)-dihydrothienyl, (2,3)-dihydropyrrolyl, (2,5)-
dihydropyrrolyl,
(2,3)-dihydroisoxazolyl, (4,5)-dihydroisoxazolyl, (2,5)-dihydroisothiazolyl,
(2,3)-
dihydropyrazolyl, (4,5)-dihydropyrazolyl, (2,5)-dihydropyrazolyl, (2,3)-
dihydrooxazolyl,
(4,5)-dihydrooxazolyl, (2,5)-dihydrooxazolyl, (2,3)-dihydrothiazolyl, (4,5)-
dihydrothiazolyl, (2,5)-dihydrothiazolyl, (2,3)-dihydroimidazolyl, (4,5)-
dihydrolmidazolyl, (2,5)-dihydroimidazolyl, morpholinyl, piperidinyl,
piperazinyl,
tetrahydropyridazinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, (1,3,5)-
tetrahydrotriazinyl, (1,2,4)-tetrahydrotriazin-1-yl, (1,2,4)-tetrahydrotriazin-
3-yl, (1,3)-
dihydrooxazinyl, (1,3)-dithian-2-yl, tetrahydropyranyl, (1,3)-dioxolan-2-yl,
(3,4,5,6)-
tetrahydropyridin-2-yl, (1 ,2,5,6)-tetrahydropyridin-1-yl, (1 ,2,3,4)-
tetrahydropyridin-1-yl,
(1,2)-dihydropyridin-1-yl, (1,4)-dihydropyridin-1-yl, 4H-1,3-thiazinyl, 4H-1,3-
benzothiazin-2-yl, (1,1)-dioxo-2,3,4,5-tetrahydrothien-2-yl, 2H-1,4-
benzothiazinyl,
(1,3)-dihydrooxazin-2-yl, hexahydroazepin-1-yl, (1,4)-diazepanyl,
thiomorpholinyl,
dithiolanyl, indanyl, indenyl, (1,4)-benzodioxanyl, (1,2,3,4)-
tetrahydronaphthyl,
(1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroquinazolinyl, (1,3,4,5)-
tetrahydropyrido[4,3-b]indolyl, (3,4)-dihydro-1H-isoquinolinyl,
decahydroquinolin-1-yl,
(1,2,3,4)-tetrahydroisoquinolin-1-yl, decahydroisoquinolin-1-y1 and (1,3,4,9)-
tetrahydro-[b]-carbolinyl.
A mono- or polycyclic ring system refers in the sense of the present invention
to
mono- or polycyclic hydrocarbon radicals which are saturated or unsaturated
and can

CA 02608319 2007-11-13
GRA3304/A-PCT
optionally have 1, 2, 3, 4 or 5 heteroatom(s) as ring member(s) which are
selected
independently of one another from the group consisting of oxygen, nitrogen and
sulphur. A mono- or polycyclic ring system of this type can, for example, be
condensed (anellated) with an aryl radical or a heteroaryl radical.
If a polycyclic ring system such as, for example, a bicyclic ring system is
present, the
various rings can, each independently of one another, have a differing degree
of
saturation, i.e. be saturated or unsaturated. Preferably, a polycyclic ring
system is a
bicyclic ring system.
Examples of aryl radicals which are condensed with a mono- or polycyclic ring
system include [1,3]-benzodioxolyl, [1,4]-benzodioxanyl, [1,2,3,4]-
tetrahydronaphthyl,
[1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-tetrahydroisoquinolinyl, [1,2,3,4]-
tetrahydroquinazolinyl, 2H-benzo[1.4]oxazin-3(4H)-onyl, (3,4)-dihydroquinolin-
2(1H)-
onyl and [3,4]-dihydro-2H-1,4-benzoxazinyl.
In relation to cycloaliphatic radicals and mono- or polycyclic ring systems,
the term
"substituted" ¨ unless otherwise defined ¨ refers in the sense of the present
invention
to the single or multiple substitution, preferably the single, double, triple,
quadruple,
quintuple, sextuple, septuple, octuple or nonuple substitution, of one or more
hydrogen atoms by, for example, oxo (=0), thioxo (=S), F, Cl, Br, I, -CN, -
CF3, -SF5, -
OH, -0-C1_5 alkyl, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-C1_5 alkyl, -Ci_5
alkyl, -C(=0)-
OH, -C(=0)-0-Ci_5 alkyl, -0-C(=0)-C1_5 alkyl, -NH-C1_5 alkyl, -N(C1_5 alky1)2,
-NH-
C(=0)-0-C1_5 alkyl, -C(=0)-H, -C(=0)-C1..5 alkyl, -C(=0)-NH2, -C(=0)-NH-C1_5
alkyl,
C(=0)-N-(C1_5 alky1)2, -S(=0)2-C1_5 alkyl, -S(=0)2 phenyl, -NH-S(=0)2-C1_5
alkyl, -
S(=0)2-NH-C1_5 alkyl, cyclohexyl, cyclopentyl, pyridinyl, pyridazinyl, -(CI-
12)-
benzo[b]furanyl, -0-phenyl, -0-benzyl, phenyl and benzyl, wherein in each case
the
cyclic portion of the radicals pyridinyl, cyclopentyl, cyclohexyl,
pyridazinyl, -S(=0)2
phenyl, -0-phenyl, -0-benzyl, phenyl, -(CH2)-benzo[b]furanyl and benzyl can be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of F, Cl, Br, -OH, -CF3, -SF5, -ON, -NO2, -C1_5
alkyl, -0-C1-5
alkyl, -0-CF3, -S-CF3, phenyl and -0-benzyl. The multiple substitution be
carried out
either on different or on identical atoms several times, for example twice or
three
11

CA 02608319 2007-11-13
GRA3304/A-PCT
times. The multiple substitution can be carried out with the same or with
different
substituents.
The expression aryl radical refers for the purposes of the present invention
preferably
to a radical which is selected from the group comprising phenyl, naphthyl,
phenanthrenyl and anthracenyl and is unsubstituted or singly or multiply
substituted
by the same or different substituents. Particularly preferably, the aryl is an
unsubstituted or singly substituted phenyl, 1-naphthyl or 2-naphthyl or a
phenyl, 1-
naphthyl or 2-naphthyl substituted several times, for example twice, three,
four or five
times, by the same or different substituents.
Heteroaryl radicals in the sense of the present invention are heterocycles
which are
heteroaromatic. Heteroaryl radicals have preferably 5 to 14 members, i.e. 5,
6, 7, 8,
9, 10, 11, 12, 13 or 14 members, and have preferably 1, 2, 3, 4 or 5
heteroatoms
selected independently of one another from the group comprising oxygen,
nitrogen
and sulphur. Each heteroaryl radical can be unsubstituted or singly
substituted or
substituted several times, for example twice, three, four or five times, by
the same or
different substituents.
Examples of heteroaryl radicals in the sense of the present invention include
thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyranyl, pyridinyl, imidazolyl,
indolyl, isoindolyl,
benzo[b]furanyl, benzo[b]thiophenyl, thiazolyl, oxazolyl, isoxazolyl,
pyridazinyl,
pyrazinyl, pyrimidinyl, indazolyl, quinazolinyl, quinoxalinyl, quinolinyl,
isoquinolinyl,
benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl,
benzo[2,1,3]thiadiazolyl, [1,2,3]-benzothiadiazolyl, [2,1,3]-benzoxadiazoly1
and
[1,2,3]-benzoxadiazolyl.
In relation to aryl and heteroaryl radicals, in the sense of the present
invention,
"substituted" refers to the single or multiple, for example the single,
double, triple,
quadruple or quintuple, substitution of one or more hydrogen atoms of the ring
system by suitable substituents. Insofar as these suitable substituents are
not defined
in relation to aryl or heteroaryl radicals elsewhere in the description or in
the claims,
suitable substituents include F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-01_10
alkyl, -NH2, -
NO2, -SH, -S-
C1.5 alkyl, -C1.5 alkyl, -C(=0)-0H, -C(=0)-0-C1.5 alkyl, -
12

CA 02608319 2007-11-13
GRA3304/A-PCT
0-C(=0)-C1_5 alkyl, -NH-C1..5 alkyl, -N(C1_5 alky1)2, -NH-C(=0)-0-C1_5 alkyl, -
C(=0)-H,
-C(=0)-C1_5 alkyl, -C(=0)-NH2, -C(=0)-NH-C1_5 alkyl, C(=0)-N-(C1_5 alky1)2, -
S(=0)2-
01-5 alkyl, -S(=0)2 phenyl, -NH-S(=0)2-C1_5 alkyl, -N[S(=02)-C1_5 -NH-
S(=0)2-
C1_5 alkylenephenyl, -NH-S(=0)2-C1_5 alkylenenaphthyl, -NH-S(=0)2 phenyl, -NH-
S(0)2 naphthyl, -S(=0)2-NH-C1.5 alkyl, cyclohexyl, cyclopentyl, piperidinyl,
morpholinyl, pyrrolidinyl, pyridinyl, pyridazinyl, -(CH2)-benzo[b]furanyl, -0-
phenyl, -0-
benzyl, phenyl and benzyl, wherein in each case the cyclic portion of the
radicals
pyridinyl, cyclopentyl, cyclohexyl, piperidinyl, morpholinyl, pyrrolidinyl,
pyridazinyl, -
S(=0)2 phenyl, -0-phenyl, -0-benzyl, phenyl, -(CH2)-benzo[b]furanyl, -NH-
S(=0)2-C1_
alkylenephenyl, -NH-S(=0)2-C1_5 alkylenenaphthyl, -NH-S(=0)2 phenyl, -NH-
S(=0)2
naphthyl and benzyl can be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, Cl, Br, -OH, -
CF3, -SF5,
-CN, -NO2, -C1_5 alkyl, -0-C1_5 alkyl, -0-CF3, -S-CF3, phenyl and -0-benzyl.
The
multiple substitution is carried out with the same or with different
substituents.
The radicals selected from the group consisting of naphthyl, (1,3)-
benzodioxolyl,
(1,4)-benzodioxanyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyranyl,
pyridinyl,
imidazolyl, indolyl, isoindolyl, benzo[b]furanyl, benzo[b]thiophenyl,
thiazolyl, oxazolyl,
isoxazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indazolyl, quinazolinyl,
quinoxalinyl,
quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, benzotriazolyl,
benzisoxazolyl,
[1,2,3,4]-tetrahydronaphthyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-
tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl, 2H-benzo[1.4]oxazin-
3(4H)-
onyl, (3,4)-dihydroquinolin-2(1H)-onyl, [3,4]-dihydro-2H-1,4-benzoxazinyl and
benzothiazolyl can be substituted like the above-mentioned aryl and heteroaryl
radicals.
If R2 represents a substituted phenyl radical, this substituted phenyl radical
can
particularly preferably be selected from the group consisting of biphenyl, 2-
pentafluorosulphanylphenyl, 2-methanesulphonamidephenyl, 2-
ethanesulphonamidephenyl, 2-trifluoromethylphenyl, 2-butoxyphenyl, 2-(1,1)-
dimethylpropylphenyl, 2-nitrophenyl, 2-ethylbenzoate, 2-acetamidephenyl, 2-
dimethylaminophenyl, 2-diethylaminophenyl, 2-aminophenyl, 2-
benzenesulphonamide, 2-trifluoromethylsulphanylphenyl, 2-ethylphenyl, 2-tert-
butylphenyl, 2-methylbenzoate, 2-methanesulphonylphenyl, 2-
13

CA 02608319 2007-11-13
GRA3304/A-PCT
ethylaminosulphonylphenyl, 2-methylaminosulphonylphenyl, 2-bromophenyl, 2-
chlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethoxyphenyl, 2-
methoxyphenyl, 2-ethoxyphenyl, 2-propylphenyl, 2-cyanophenyl, 2-acetyl phenyl,
2-
isopropyl phenyl, 2-iodophenyl, 3-pentafluorosulphanylphenyl, 3-chlorophenyl,
3-
methylphenyl, 3-butoxyphenyl, 3-nitrophenyl, 3-tert-butylphenyl, 3-
trifluoromethylsulphanylphenyl, 3-trifluoromethylphenyl, 3-
methanesulphonylphenyl,
3-methanesulphonamidephenyl, 3-ethanesulphonamidephenyl, 3-
benzenesulphonamide, 3-ethylbenzoate, 3-fluorophenyl, 3-propylphenyl, 3-
isopropylphenyl, 3-bromophenyl, 3-dimethylaminophenyl, 3-(1,1)-
dimethylpropylphenyl, 3-acetamidephenyl, 3-diethylaminophenyl, 3-aminophenyl,
3-
methoxyphenyl, 3-ethylphenyl, 3-ethylaminosulphonylphenyl, 3-
methylaminosulphonylphenyl, 3-ethoxyphenyl, 3-cyanophenyl, 3-iodophenyl, 3-
trifluoromethoxyphenyl, 3-acetylphenyl, 4-methanesulphonylphenyl, 4-
methylaminosulphonylpheny1,-4-ethylaminosulphonylphenyl, 4-
methanesulphonamidephenyl, 4-ethanesulphonamidephenyl, 4-
pentafluorosulphanylphenyl, 4-bromophenyl, 4-methoxyphenyl, 4-chlorophenyl, 4-
benzenesulphonamide, 4-fluorophenyl, 4-tert-butylphenyl, 4-cyanophenyl, 4-
butoxyphenyl, 4-nitrophenyl, 4-trifluoromethylsulphanylphenyl, 4-methylphenyl,
4-
isopropylphenyl, 4-trifluoromethylphenyl, 4-dimethylaminophenyl, 4-
propylphenyl, 4-
diethylaminophenyl, 4-ethyl benzoate, 4-aminophenyl, 4-iodophenyl, 4-
trifluoromethoxyphenyl, 4-(1,1)-dimethylpropylphenyl, 4-(3,5-
dichlorophenylsulphamoyl) phenyl, 4-acetamidephenyl, 4-ethylphenyl, 4-
ethoxyphenyl, 4-methylbenzoate, 4-acetyl phenyl, 2-fluoro-3-
trifluoromethylphenyl,
(2,3)-difluorophenyl, (2,3)-dimethylphenyl, (2,3)-dichlorophenyl, 3-fluoro-2-
trifluoromethylphenyl, (2,4)-dichlorophenyl, (2,4)-difluorophenyl, 4-fluoro-2-
trifluoromethylphenyl, (2,4)-dimethoxyphenyl, 2-chloro-4-fluorophenyl, 2-
chloro-4-
nitrophenyl, (2,4)-dibromophenyl, 2-fluoro-4-trifluoromethylphenyl, (2,5)-
difluorophenyl, 2-fluoro-5-trifluoromethylphenyl, 5-fluoro-2-
trifluoromethylphenyl, 5-
chloro-2-trifluoromethylphenyl, 5-bromo-2-trifluoromethylphenyl, (2,5)-
dimethoxyphenyl, (2,5)-bis-trifluoromethylphenyl, (2,5)-dichlorophenyl, (2,5)-
dibromophenyl, 2-methoxy-5-nitrophenyl, 2-fluoro-6-trifluoromethylphenyl,
(2,6)-
dimethoxyphenyl, (2,6)-dimethylphenyl, (2,6)-dichlorophenyl, 2-chloro-6-
fluorophenyl,
2-bromo-6-chlorophenyl, 2-bromo-6-fluorophenyl, (2,6)-difluorophenyl, (2,6)-
difluoro-
3-methylphenyl, (2,6)-dibromophenyl, (2,6)-dichlorophenyl, 3-chloro-2-
fluorophenyl,
14

CA 02608319 2007-11-13
GRA3304/A-PCT
(3,4)-dichlorophenyl, 4-chloro-3-nitrophenyl, 4-fluoro-3-
trifluoronnethylphenyl, 3-fluoro-
4-trif9uoromethylphenyl, (3,4)-difluorophenyl, 4-chloro-3-trifluoromethyl, 4-
bromo-3-
methylphenyl, 4-bromo-5-methylphenyl, 3-chloro-4-fluorophenyl, 4-fluoro-3-
nitrophenyl, 4-bromo-3-nitrophenyl, (3,4)-dibromophenyl, 4-chloro-3-
methylphenyl, 4-
bromo-3-methylphenyl, 4-fluoro-3-methylphenyl, 4-methyl-3-nitrophenyl, (3,5)-
dimethoxyphenyl, (3,5)-bis-trifluoromethylphenyl, (3,5)-difluorophenyl, (3,5)-
dinitrophenyl, (3,5)-dichlorophenyl, 3-fluoro-5-trifluoromethylphenyl, 5-
fluoro-3-
trifluoromethylphenyl, (3,5)-dibromophenyl, 5-chloro-4-fluorophenyl, 5-bromo-4-
methylphenyl, (2,3,4)-trifluorophenyl, (2,3,4)-trichlorophenyl, (2,3,6)-
trifluorophenyl, 5-
chloro-2-methoxyphenyl, (2,3)-difluoro-4-methylphenyl, (2,4,5)-
trifluorophenyl,
(2,4,5)-trichlorophenyl, (2,4)-dichloro-5-fluorophenyl, (2,4,6)-
trichlorophenyl, (2,4,6)-
trimethylphenyl, (2,4,6)-trifluorophenyl, (2,4,6)-trimethoxyphenyl, (2,3,4,5)-
tetrafluorophenyl, 4-methoxy-2,3,6-trimethylphenyl, 4-methoxy-2,3,6-
trimethylphenyl,
4-chloro-2,5-dimethylphenyl, 2-chloro-6-fluoro-3-methylphenyl, 6-chloro-2-
fluoro-3-
methyl and (2,3,4,5,6)-pentafluorophenyl.
The above-mentioned linear or branched alkylene, alkenylene or alkinylene
groups
preferably have 1 to 5 carbon atoms, i.e. the groups are C1_5 alkylene, C2-5
alkenylene
or C2_5 alkinylene groups which can be respectively unsubstituted or
substituted with
1, 2, 3, 4 or 5 substituents selected independently of one another from the
group
consisting of F, Cl, Br, -OH, -SH, -N H2, -CN, -NO2 and phenyl, wherein the
phenyl
radical can be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of
one another from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-
butyl,
isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl and neo-pentyl.
The above-mentioned alkylene, alkenylene or alkinylene groups optionally each
have
1 or 2 heteroatom(s) selected from the group consisting of oxygen, nitrogen,
i.e. -
N(H)- and -N(C1_6 alkyl)-, and sulphur as chain member(s).
Preferably, alkylene groups can be selected from the group consisting of -
(CH2)-, -
(CH2)2-, -C(H)(CH3)-, -C(CH3)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -C(H)(CH3)-
(CH2)-, -
C(H)(C2H5)-(CH2)-, -C(phenyl)2-, -C(H)(phenyI)-, -(CH2)-0-, -(CH2)-N(CH3)-, -
(CH2)-S-
, -(CH2)-(CH2)-N(CH3)- and -(CH2)-(CH2)-N(C2H5)-.

CA 02608319 2007-11-13
GRA3304/A-PCT
Preferably, alkenylene groups can be selected from the group consisting of -
CH=CH-
, -C(CH3)=CH-, -C(C2H5)=CH-, -CH=C(CH3)-, -CH=C(C2H5)-, -CH=C(phenyI)-, -
CH=C(p-toly1), -C(phenyl)=CH- and -C(p-tolyI)=CH-.
Preferably, an alkinylene group can represent
Preferred are substituted Spiro compounds of the above-indicated general
formula I,
wherein
n is equal to 0, 1 or 2,
I.)
R1 represents a linear or branched, saturated or unsaturated, optionally
substituted C1_10 aliphatic radical;
an unsaturated or saturated, optionally substituted 3, 4, 5, 6,
7, 8 or 9-membered cycloaliphatic radical which can be condensed with a
saturated, unsaturated or aromatic, optionally substituted mono- or polycyclic
ring system;
an optionally substituted 5 to 14-membered aryl or heteroaryl radical which
can be condensed with a saturated or unsaturated, optionally substituted
mono- or polycyclic ring system,
a -C(=0)-NR11R12 group,
or -(CHR15)-Xe-(CHR16)f-Yg-(CHR17)h-Zk-R18 wherein e = 0 or 1, f = 0 or 1, g =
0 or 1, h = 0 or 1 and k = 0 or 1, wherein X, Y and Z, independently of one
another, each represent 0, S, NH, N(CH3), N(C2H5) or N[CH(CH3)2];
and
16

CA 02608319 2007-11-13
GRA3304/A-PCT
R2, R3, R4, R5, .-µ6,
K R7 and R8, independently of one another, each
represent a hydrogen radical
or a linear or branched, saturated or unsaturated, optionally substituted Ci-
io
aliphatic radical;
Or
II.)
R1 and R3 together represent a -(CH2)p group wherein p = 3, 4, 5 or 6;
and
R2, R4, R5, R6, R7 and R8, independently of one another, each
represent a hydrogen radical
or a linear or branched, saturated or unsaturated, optionally substituted C1-
10
aliphatic radical;
or
Ill.)
Fe, -2,
K R7 and R8 each represent a hydrogen radical
and
R3, R4, R5 and R6, independently of one another, each
represent a linear or branched, saturated or unsaturated, optionally
substituted
Ci_io aliphatic radical;
17

CA 02608319 2007-11-13
GRA3304/A-PCT
and in each case
R9 represents a hydrogen radical;
a linear or branched, saturated or unsaturated, optionally substituted C1-10
aliphatic radical;
an unsaturated or saturated, optionally substituted 3, 4, 5, 6,
7, 8 or 9-membered cycloaliphatic radical which can be condensed with a
saturated, unsaturated or aromatic, optionally substituted mono- or polycyclic
ring system;
an optionally substituted 5 to 14-membered aryl or heteroaryl radical which
can be condensed with a saturated or unsaturated, optionally substituted
mono- or polycyclic ring system;
or represents L -(CHR19)-Xq-(CHR29)r-Ys-
(cHR2i,)t_-,_
R22 wherein q = 0 or 1, r =
0 or 1,s = 0 or 1, t = 0 or 1 and u = 0 or 1, wherein X, Y and Z,
independently
of one another, each represent 0, S, NH, N(CH3), N(C2H5) or N[CH(CH3)2];
represents a linear or branched, saturated or unsaturated, optionally
substituted C1_10 aliphatic radical;
an unsaturated or saturated, optionally substituted 3, 4, 5, 6,
7, 8 or 9-membered cycloaliphatic radical which can be condensed with a
saturated, unsaturated or aromatic, optionally substituted mono- or polycyclic
ring system and/or bound via a -(CH2)v group wherein v = 1, 2, 3, 4 or 5;
a phenyl radical which can be substituted with 1, 2, 3, 4 or 5 substituents
selected independently of one another from the group consisting of F, Cl, Br,
I,
-ON, -CF3, -SF5, -OH, -0-01-5 alkyl, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-C1-5
alkyl, -Co alkyl, -C(=0)-0H, -C(=0)-0-C1_5 alkyl, -0-C(=0)-C1_5 alkyl, -NH-C1-
alkyl, -N(C1_5 alky1)2, -NH-C(=0)-0-C1_5 alkyl, -C(=0)-H, -C(=0)-C1.5 alkyl, -
18

= CA 02608319 2007-11-13
GRA3304/A-PCT
C(=0)-NH2, -C(=0)-NH-C1_5 alkyl, C(=0)-N-(C1_5 alky1)2, -S(=0)2-C1_5 alkyl, -
S(=0)2 phenyl, -NH-S(=0)2-C1_5 alkyl, -NH-S(=0)2-C1_5 alkylenephenyl, -NH-
S(=0)2-C1_5 alkylenenaphthyl, -NH-S(=0)2 phenyl, -NH-S(=0)2 naphthyl,
cyclohexyl, cyclopentyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl,
pyridinyl, pyridazinyl, -(CH2)-benzo[b]furanyl, -0-phenyl, -0-benzyl, phenyl
and
benzyl, wherein in each case the cyclic portion of the radicals pyridinyl,
cyclopentyl, cyclohexyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl,
pyridazinyl, -S(=0)2 phenyl, -0-phenyl, -0-benzyl, phenyl, -(CF12)-
benzo[b]furanyl, -NH-S(=0)2-C1_5 alkylenephenyl, -NH-S(=0)2-C1-5
alkylenenaphthyl, -NH-S(=0)2 phenyl, -NH-S(=0)2 naphthyl and benzyl can be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another from the group consisting of F, Cl, Br, -OH, -CF3, -SF5, -CN, -NO2, -
C1_
alkyl, -0-Ci_5 alkyl, -0-CF3, -S-CF3, phenyl and -0-benzyl,
on the condition that not one of the meta positions and the para position of
this
phenyl radical are substituted with substituents which are respectively bound
to the phenyl radical via an identical atom selected from the group consisting
of oxygen, sulphur and nitrogen;
represents an optionally substituted radical selected from the group
consisting
of naphthyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl, thiophenyl, furanyl,
pyrrolyl, pyrazolyl, pyranyl, pyridinyl, imidazolyl, indolyl, isoindolyl,
benzo[b]furanyl, benzo[b]thiophenyl, thiazolyl, oxazolyl, isoxazolyl,
pyridazinyl,
pyrazinyl, pyrimidinyl, indazolyl, quinazolinyl, quinoxalinyl, quinolinyl,
isoquinolinyl, benzimidazolyl, benzoxazolyl, benzotriazolyl, benzisoxazolyl,
[1,2,3,4]-tetrahydronaphthyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-
tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl; 2H-benzo[1.4]oxazin-
3(4H)-onyl, (3,4)-dihydroquinolin-2(1H)-onyl, [3,4]-dihydro-2H-1,4-
benzoxazinyl and benzothiazolyl;
an optionally substituted 5 to 14-membered aryl or heteroaryl radical which
can be condensed with a saturated or unsaturated, optionally substituted
mono- or polycyclic ring system and/or is bound via a -(CH2)-, -(CH2)2- or -
(CH2)3 group;
19

CA 02608319 2007-11-13
GRA3304/A-PCT
or represents a -C(=0)-NR13R14 group;
R11 and R13, independently of one another, each
represent a linear or branched, saturated or unsaturated, optionally
substituted
C1_10 aliphatic radical;
an unsaturated or saturated, optionally substituted 3, 4, 5, 6,
7, 8 or 9-membered cycloaliphatic radical which can be condensed with a
saturated, unsaturated or aromatic, optionally substituted mono- or polycyclic
ring system and/or bound via a -(CH2)w group wherein w = 1, 2, 3, 4 or 5;
or an optionally substituted 5 to 14-membered aryl or heteroaryl radical which
can be condensed with a saturated or unsaturated, optionally substituted
mono- or polycyclic ring system and/or bound via a -(CH2)-, -(CH2)2- or -
(CH2)3
group;
R12 and R14, independently of one another, each
represent a hydrogen radical;
a linear or branched, saturated or unsaturated, optionally substituted C1_10
aliphatic radical;
an unsaturated or saturated, optionally substituted 3, 4, 5, 6,
7, 8 or 9-membered cycloaliphatic radical which can be condensed with a
saturated, unsaturated or aromatic, optionally substituted mono- or polycyclic
ring system and/or bound via a -(CH2)c group wherein w = 1, 2, 3, 4 or 5;
represent an optionally substituted 5 to 14-membered aryl or heteroaryl
radical
which can be condensed with a saturated or unsaturated, optionally
substituted mono- or polycyclic ring system and/or bound via a -(CH2) group;

CA 02608319 2007-11-13
GRA3304/A-PCT
Or
R11 and R12 or R13 and R14 respectively form together with the nitrogen atom
connecting them as ring member a saturated or unsaturated, optionally
substituted 4,
5, 6, 7, 8 or 9-membered heterocycloaliphatic radical which can be condensed
with a
saturated, unsaturated or aromatic, optionally substituted mono- or polycyclic
ring
system,
R15, R16, R17, R19, R20 and K=-=21,
independently of one another, each
represent a hydrogen radical
or a linear or branched, saturated or unsaturated, optionally substituted C1-
10
aliphatic radical;
and
R18 and R22, independently of one another, each
represent a linear or branched, saturated or unsaturated, optionally
substituted
Ci_io aliphatic radical;
an unsaturated or saturated, optionally substituted 3, 4, 5, 6,
7, 8 or 9-membered cycloaliphatic radical which can be condensed with a
saturated, unsaturated or aromatic, optionally substituted mono- or polycyclic
ring system;
or an optionally substituted 5 to 14-membered aryl or heteroaryl radical which
can be condensed with a saturated or unsaturated, optionally substituted
mono- or polycyclic ring system;
wherein
the above-mentioned C110 aliphatic radicals can in each case optionally be
21

= CA 02608319 2007-11-13
GRA3304/A-PCT
substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituents selected
independently of one
another from the group consisting of F, Cl, Br, I, -CN, -NO2, -OH, -SH and -M-
12;
the above-mentioned cycloaliphatic radicals can in each case optionally be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of oxo (=0), thioxo (=S), F, Cl, Br, 1, -CN, -CF3, -
SF5, -OH, -
0-C1_5 alkyl, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-C1_5 alkyl, -C1_5 alkyl, -
C(=0)-0H, -
C(=0)-0-C1_5 alkyl, -0-C(=0)-C1_5 alkyl, -NH-C1_5 alkyl, -N(C1_5 alky1)2, -NH-
O(=0)-0-
Cis alkyl, -C(=0)-H, -C(=0)-C1.5 alkyl, -C(=0)-NH2, -C(=0)-NH-C1_5 alkyl,
C(=0)-N-
(C1_5 alky1)2, -S(=0)2-01.5 alkyl, -S(=0)2 phenyl, -NH-S(=0)2-C1_5 alkyl, -
S(=0)2-NH-
C1_5 alkyl, cyclohexyl, cyclopentyl, pyridinyl, pyridazinyl, -(CH2)-
benzo[b]furanyl, -0-
phenyl, -0-benzyl, phenyl and benzyl, wherein in each case the cyclic portion
of the
radicals pyridinyl, cyclopentyl, cyclohexyl, pyridazinyl, -S(=0)2 phenyl, -0-
phenyl, -0-
benzyl, phenyl, -(CH2)-benzo[b]furanyl and benzyl can be substituted with 1,
2, 3, 4
or 5 substituents selected independently of one another from the group
consisting of
F, Cl, Br, -OH, -CF3, -SF5, -CN, -NO2, -C1_5 alkyl, -0-C1_5 alkyl, -0-CF3, -S-
CF3,
phenyl and -0-benzyl,
and the above-mentioned cycloaliphatic radicals can in each case optionally
have 1,
2, 3, 4 or 5 heteroatom(s) selected independently of one another from the
group
consisting of oxygen, nitrogen and sulphur as ring member(s);
the above-mentioned heterocycloaliphatic radicals formed by R11 and R12 or R13
and
R14 can in each case optionally be substituted with 1, 2, 3, 4 or 5
substituents
selected independently of one another from the group consisting of oxo (=0),
thioxo
(=S), F, 01, Br, I, -CN, -CF3, -SF5, -OH, -0-Oi_5 alkyl, -NH2, -NO2, -0-CF3, -
S-CF3, -
SH, -S-01_5 alkyl, -01_5 alkyl, -0-O(=0)-01_5 alkyl, -NH-01_5 alkyl, -N(C1_5
alky1)2,
O(=0)-0-01.5 alkyl, -C(=0)-NH2, -O(=0)-NH-01_5 alkyl, -O(=0)-N-(O1_5 alky02,
cyclohexyl, cyclopentyl, pyridinyl, pyridazinyl, pyrimidinyl, [1,2,5]-
thiadiazolyl,
thiazolyl, -(CH2)-benzo[b]furanyl, -0-phenyl, -0-benzyl, phenyl and benzyl,
wherein in
each case the cyclic portion of the radicals pyrimidinyl, [1,2,5]-
thiadiazolyl, thiazolyl,
pyridinyl, cyclopentyl, cyclohexyl, pyridazinyl, -0-phenyl, -0-benzyl, phenyl,
-(CH2)-
benzo[b]furanyl and benzyl can be substituted with 1, 2, 3, 4 or 5
substituents
22

CA 02608319 2007-11-13
GRA3304/A-PCT
selected independently of one another from the group consisting of F, Cl, Br, -
OH, -
CF3, -SF5, -CN, -NO2, -C1_5 alkyl, -0-C1_5 alkyl, -0-CF3, -S-CF3, phenyl and -
0-benzyl,
and the above-mentioned heterocycloaliphatic radicals formed by R11 and R12 or
R13
and R14 can in each case optionally have 1, 2 or 3 additional heteroatom(s)
selected
independently of one another from the group consisting of oxygen, nitrogen and
sulphur as ring member(s);
the rings of the above-mentioned mono- or polycyclic ring systems can in each
case
optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of
one another from the group consisting of oxo (=0), thioxo (=S), F, Cl, Br, I, -
CN, -
CF3, -SF5, -OH, -0-01-5 alkyl, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-C1_5 alkyl,
-C1-5
alkyl, -C(=0)-0H, -C(=0)-0-C1_5 alkyl, -0-C(=0)-C1_5 alkyl, -NH-C1_5 alkyl, -
N(C1-5
alky02, -NH-C(=0)-0-C1_5 alkyl, -C(=0)-H, -C(=0)-C1_5 alkyl, -C(=0)-NH2, -
C(=0)-NH-
C1_5 alkyl, C(=0)-N-(C1_5 alky1)2, -S(=0)2-C1_5 alkyl, -S(=0)2 phenyl, -NH-
S(=0)2-C1-5
alkyl, -S(=0)2-NH-C1_5 alkyl, cyclohexyl, cyclopentyl, pyridinyl, pyridazinyl,
-(CH2)-
benzo[b]furanyl, -0-phenyl, -0-benzyl, phenyl and benzyl, wherein in each case
the
cyclic portion of the radicals pyridinyl, cyclopentyl, cyclohexyl,
pyridazinyl, -S(=0)2
phenyl, -0-phenyl, -0-benzyl, phenyl, -(CH2)-benzo[b]furanyl and benzyl can be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -NO2, -C1_5
alkyl, -0-01-5
alkyl, -0-CF3, -S-CF3, phenyl and -0-benzyl,
and the rings of the above-mentioned mono- or polycyclic ring systems each
have 5,
6 or 7 members and can in each case optionally have 1, 2, 3, 4 or 5
heteroatom(s) as
ring member(s) selected independently of one another from the group consisting
of
oxygen, nitrogen and sulphur;
and, unless otherwise defined, the above-mentioned radicals selected from the
group
consisting of phenyl, naphthyl (1,3)-benzodioxolyl, (1,4)-benzodioxanyl,
thiophenyl,
furanyl, pyrrolyl, pyrazolyl, pyranyl, pyridinyl, imidazolyl, indolyl,
isoindolyl,
benzo[b]furanyl, benzo[b]thiophenyl, thiazolyl, oxazolyl, isoxazolyl,
pyridazinyl,
pyrazinyl, pyrimidinyl, indazolyl, quinazolinyl, quinoxalinyl, quinolinyl,
isoquinolinyl,
benzimidazolyl, benzoxazolyl, benzotriazolyl, benzisoxazolyl, [1,2,3,4]-
23

CA 02608319 2007-11-13
GRA3304/A-PCT
tetrahydronaphthyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-
tetrahydroisoquinolinyl,
[1,2,3,4]-tetrahydroquinazolinyl; 2H-benzo[1.4]oxazin-3(4H)-onyl, (3,4)-
dihydroquinolin-2(1H)-onyl, [3,4]-dihydro-2H-1,4-benzoxazinyl and
benzothiazolyl and
aryl or heteroaryl radicals can in each case optionally be substituted with 1,
2, 3, 4 or
substituents selected independently of one another from the group consisting
of F,
Cl, Br, I, -ON, -CF3, -SF5, -OH, -0-01-5 alkyl, -NH2, -NO2, -0-CF3, -S-CF3, -
SH,
alkyl, alkyl, -C(.0)-0H, -C(=0)-0-C1_5 alkyl, -0-0(=0)-C1_5 alkyl, -NH-01_5
alkyl,
-N(01_5 alky1)2, -NH-C(=0)-0-01_5 alkyl, -0(=0)-H, -C(=0)-01_5 alkyl, -0(=0)-
NF12, -
0(=0)-NH-01.5 alkyl, C(=0)-N-(C1_5 alky1)2, -S(=0)2-C1_5 alkyl, -S(=0)2
phenyl, -NH-
S(=0)2-01_5 alkyl, -N[S(=02)-01_5 -S(=0)2-NH-C1_5 alkyl, cyclohexyl,
cyclopentyl, piperidinyl, pyrrolidinyl, morpholinyl, pyridinyl, pyridazinyl, -
(0H2)-
benzo[b]furanyl, -0-phenyl, -0-benzyl, phenyl and benzyl, wherein in each case
the
cyclic portion of the radicals pyridinyl, cyclopentyl, cyclohexyl,
piperidinyl, pyrrolidinyl,
morpholinyl, pyridazinyl, -S(=0)2 phenyl, -0-phenyl, -0-benzyl, phenyl, -(CH2)-
benzo[b]furanyl and benzyl can be substituted with 1, 2, 3, 4 or 5
substituents
selected independently of one another from the group consisting of F, CI, Br, -
OH, -
CF3, -SF5, -ON, -NO2, -Ci_5 alkyl, -0-C1_5 alkyl, -0-CF3, -S-CF3, phenyl and -
0-benzyl,
and the above-mentioned heteroaryl radicals can in each case optionally have
1, 2,
3, 4 or 5 heteroatom(s) selected independently of one another from the group
consisting of oxygen, nitrogen and sulphur as ring member(s);
in each case optionally in the form of one of their pure stereoisomers, in
particular
enantiomers or diastereomers, their racemates or in the form of a mixture of
stereoisomers, in particular of enantiomers and/or diastereomers, in any
desired
mixing ratio, or respectively in the form of corresponding salts, or
respectively in the
form of corresponding solvates.
A person skilled in the art will understand that for n is equal to 1, the
following
general formula la is obtained:
R3 R4R7 R8
R1 = as-- N
R2
R5 R10
R6 R9
24

CA 02608319 2007-11-13
GRA3304/A-PCT
la
Particularly preferred are substituted Spiro compounds of the above-indicated
general
formula I, wherein
n is equal to 1;
I.)
R1 represents a radical selected from the group consisting of methyl,
ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-
pentyl, sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of cyclopropyl,
cyclabutyl, cyclopentyl, cyclohexyl and cycloheptyl;
represents a radical selected from the group consisting of phenyl and
naphthyl, wherein the radical can in each case optionally be substituted with
1,
2, 3, 4 or 5 substituents selected independently of one another from the group
consisting of F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-CH3, -0-C2H5, -NH2, -NO2,
-
0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, isopropyl, n-
butyl, sec-butyl, isobutyl, tert-butyl, -C(=0)-0H, -C(=0)-0-CH3, -C(=0)-0-
C2H5, -C(=0)-0-C(CH3)3, -0-C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3, -
N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-
C2H5, -NH-C(=0)-0-C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-
C(CH3)3, -C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2 and
-C(=0)-N-(C2H5)2;
_c(=0)-NR11R12
represents a group;
or represents -(CHR15)-R15 or -(CHR15)-(CHR16)-R15;

CA 02608319 2007-11-13
GRA3304/A-PCT
and
R2, R3, R4, R5, R6, R7 and R8, independently of one another, each
represent a hydrogen radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
or
II.)
R1 and R3 together represent a -(CH2)p group wherein p = 3 or 4;
and
R2, R4, R5, 6, 1-( ¨R7 and R8, independently of one another, each
represent a hydrogen radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
or
III.)
R1, 2, 1- -R7 and R8 each represent a hydrogen radical
and
26

CA 02608319 2007-11-13
= GRA3304/A-PCT
R3, R4, R5 and R6, independently of one another, each
represent a radical selected from the group consisting of methyl, ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-
pentyl, sec-pentyl, n-hexyl and n-heptyl;
and in each case
R9 represents a hydrogen radical;
represents a radical selected from the group consisting of methyl, ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-
pentyl, sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of phenyl and
naphthyl, wherein the radical can in each case optionally be substituted with
1,
2, 3, 4 or 5 substituents selected independently of one another from the group
consisting of F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-CH3, -0-C2H5, -NH2, -NO2,
-
0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, isopropyl, n-
butyl, sec-butyl, isobutyl, tert-butyl, -C(=0)-0H, -C(=0)-0-CH3, -C(=0)-0-
C2H5, -C(=0)-0-C(CH3)3, -0-C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3, -
N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-
C2H5, -NH-C(=0)-0-C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-
C(CH3)3, -C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2 and
-C(=0)-N-(C2H5)2;
or represents -(OHR19)-R22 or -(CHR19)-(CHR20)-R22;
R10 represents a radical selected from the group consisting of
methyl, ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-
pentyl, sec-pentyl, n-hexyl, n-heptyl, vinyl, 1-propenyl, 2-propenyl, 1-
butenyl,
2-butenyl, 3-butenyl, 2-methyl-1-propenyl, ethinyl, 1-propinyl, 2-propinyl, 1-
butinyl, 2-butinyl and 3-butinyl;
27

CA 02608319 2007-11-13
4
GRA3304/A-PCT
represents a radical selected from the group consisting of cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl,
cycloheptenyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl,
pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl and thiomorpholinyl which
can
be bound via a -(CH2)- or -(C H2)2 group;
represents a radical selected from the group consisting of phenyl, naphthyl,
benzyl, phenethyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl, thiophenyl,
furanyl, pyrrolyl, pyrazolyl, pyranyl, pyridinyl, imidazolyl, indolyl,
isoindolyl,
benzo[b]furanyl, benzo[b]thiophenyl, thiazolyl, oxazolyl, isoxazolyl,
pyridazinyl,
pyrazinyl, pyrimidinyl, indazolyl, quinazolinyl, quinoxalinyl, quinolinyl,
isoquinolinyl, benzimidazolyl, benzoxazolyl, benzotriazolyl, benzisoxazolyl,
[1,2,3,4]-tetrahydronaphthyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-
tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl, [3,4]-dihydro-2H-
1,4-
benzoxazinyl and benzothiazolyl, wherein the radical can in each case
optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of one another from the group consisting of F, Cl, Br, I, -CN, -
CF3, -SF5, -OH, -0-CH3, -0-021-15, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -
S-C2H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-
butyl, -C(=0)-0H, -C(=0)-0-CH3, -C(=0)-0-C2H5, -C(=0)-0-C(CH3)3, -0-
C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3, -N(CH3)2, -N(C2H5)2, -NH-
CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-C2H5, -NH-C(=0)-0-
C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-C(CH3)3, -C(=0)-NH2, -
C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2, -C(=0)-N-(C2H5)2, -
S(=0)2-CH3, -S(=0)2-C2H5, -S(=0)2 phenyl, -NH-S(=0)2-CH3, -NH-S(=0)2-
C2H5, -NH-S(0)2 phenyl, -S(=0)2-NH-CH3, -S(=0)2-NH-C2H5, cyclohexyl,
cyclopentyl, pyridinyl, pyridazinyl, -(CH2)-benzo[b]furanyl, -0-phenyl, -0-
benzyl, phenyl and benzyl, wherein in each case the cyclic portion of the
radicals pyridinyl, cyclopentyl, cyclohexyl, pyridazinyl, -S(=0)2 phenyl, -NH-
S(0)2 phenyl, -0-phenyl, -0-benzyl, phenyl, -(CH2)-benzo[b]furanyl and
benzyl can be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of one another from the group consisting of F, Cl, Br, -OH, -
CF3,
-SF5, -ON, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl,
tert-butyl, -0-CH3, -0-02H5, -0-CF3, -S-CF3, phenyl and -0-benzyl;
28

CA 02608319 2007-11-13
G RA3304/A-P CT
on the condition that not one of the meta positions and the para position of
this
phenyl radical are substituted with substituents which are respectively bound
to the phenyl radical via an identical atom selected from the group consisting
of oxygen, sulphur and nitrogen;
or represents a -C(=0)-NR13R14 group;
R11 represents a radical selected from the group consisting of phenyl,
naphthyl,
indolyl, pyridinyl, (1,3)-benzodioxoly1 and (1,4)-benzodioxanyl, wherein the
radical can in each case optionally be substituted with 1, 2, 3, 4 or 5
substituents selected independently of one another from the group consisting
of F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-
CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-
butyl, isobutyl, tert-butyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -C(=0)-
CH3, -C(=0)-C2H5, -C(=0)-C(CH3)3, -C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-NH-
C2H5, -C(=0)-N-(CH3)2, -C(=0)-N-(C2H5)2, -S(=0)2-CH3, -S(=0)2-02H5, -NH-
S(=0)2-0H3, -NH-S(=0)2-C2H5, -S(=0)2-NH-CH3, -S(=0)2-NH-02H5,
piperidinyl, 4-methylpiperidinyl and phenyl; wherein the phenyl radical can be
substituted with 1, 2 or 3 substituents selected from the group consisting of
F,
Cl and Br; and/or bound via a -(CH2) group or -(CH2)2 group;
R13 represents a radical selected from the group consisting of phenyl,
naphthyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl, pyridinyl, quinazolinyl,
quinoxalinyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzotriazolyl,
benzoxazolyl, benzisoxazolyl and benzothiazolyl, wherein the radical can in
each case optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of one another from the group consisting of F, CI, Br, I, -ON, -
CF3, -SF5, -OH, -0-CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -
S-02H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-
butyl, -C(=0)-0H, -C(=0)-0-CH3, -C(=0)-0-C2H5, -C(=0)-0-C(CH3)3, -0-
C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3, -N(CH3)2, -N(C2H5)2, -NH-
CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-C2H5, -NH-C(=0)-0-
C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-C(CH3)3, -C(=0)-NH2, -
29

CA 02608319 2007-11-13
GRA3304/A-PCT
C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(0H3)2, -C(=0)-N-(C2H5)2, -
S(=0)2-CH3, -S(=0)2-C2H5, -NH-S(=0)2-CH3, -NH-S(=0)2-02H5, -N[S(=0)2-
CH3A2, -N[S(=0)2-C2FIA2, -S(=0)2-NH-CH3 and -S(=0)2-NH-02H5 and/or
bound via a -(CH2)- or -(CH2)2 group;
R12 and R14, independently of one another, each represent a hydrogen radical;
or
R11 and R12 or R13 and R14 respectively form together with the nitrogen atom
connecting them as ring member a radical selected from the group consisting of
pyrrolidinyl, piperidinyl, (1,3,4,5)-tetrahydropyrido[4,3-b]indolyl, (3,4)-
dihydro-1H-
isoquinolinyl, (1,3,4,9)-tetrahydro-[13]-carbolinyl, imidazolidinyl, (1,3)-
thiazolidinyl,
piperazinyl, morpholinyl, azepanyl, diazepanyl and thiomorpholinyl, wherein
the
radical can in each case optionally be substituted with 1, 2, 3, 4 or 5
substituents
selected independently of one another from the group consisting of oxo (=0),
thioxo
(=S), F, CI, Br, -OH, -0-CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-
CH3, -5-
C2H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-
butyl, -
N(CH3)2, -N(02H5)2, -NH-CH3, pyridinyl, pyridazinyl, pyrimidinyl, [1,2,5]-
thiadiazolyl,
thiazolyl, phenyl and benzyl, wherein in each case the cyclic portion of the
radicals
pyrimidinyl, [1,2,5]-thiadiazolyl, thiazolyl, pyridinyl, pyridazinyl, phenyl
and benzyl can
be substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of F, CI, Br, -OH, -CF3, methyl, ethyl, n-propyl,
isopropyl, n-
butyl, sec-butyl, isobutyl, tert-butyl, -0-CH3, -0-C2H5, -0-CF3 and -S-CF3;
R15, R16, R19 and R29, independently of one another, each represent a hydrogen
radical;
and
R18 and R22, independently of one another, each represent a radical selected
from
the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl,
cyclopentenyl, cyclohexenyl, cycloheptenyl, imidazolidinyl, tetrahydrofuranyl,
tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl and

CA 02608319 2007-11-13
GRA3304/A-PCT
thiomorpholinyl,
or represent a radical selected from the group consisting of phenyl, naphthyl,
(1,3)-
benzodioxolyl, (1,4)-benzodioxanyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl,
pyranyl,
pyridinyl, imidazolyl, indolyl, isoindolyl, benzo[b]furanyl,
benzo[b]thiophenyl, thiazolyl,
oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indazolyl,
quinazolinyl,
quinoxalinyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzotriazolyl,
benzoxazolyl,
benzisoxazolyl and benzothiazolyl.
Most particularly preferred are substituted Spiro compounds of the above-
indicated
general formula I, wherein
n is equal to 1,
I.)
R1 represents a radical selected from the group consisting of methyl,
ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-
pentyl, sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl;
represents a phenyl radical
or represents a -C(=0)-NR11R12 group;
R2, R7 and R8 each represent a hydrogen radical;
and
R3, R4, R5, R6, independently of one another, each
represent a hydrogen radical
31

CA 02608319 2007-11-13
µ .
GRA3304/A-PCT
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
II.)
R1 and R3 together represent a -(C H2)4 group;
R2, R4, R7 and R8 each represent a hydrogen radical;
and
R5 and R6, independently of one another, each
represent a hydrogen radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
or
III.)
R1, -2,
K R7 and R8 each represent a hydrogen radical
and
R3, R4, R5 and R6, independently of one another, each represent a methyl or
ethyl
radical;
and in each case
32

= CA 02608319 2007-11-13
=
GRA3304/A-PCT
R9 represents a hydrogen radical;
represents a radical selected from the group consisting of methyl, ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-
pentyl, sec-pentyl, n-hexyl and n-heptyl;
or represents a phenyl radical;
R19 represents a radical selected from the group consisting of
methyl, ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-
pentyl, sec-pentyl, n-hexyl and n-heptyl;
represents a phenyl radical of general formula XX
is A
A
=
XX,
wherein the line represents the bond of this phenyl radical to the Spiro
compound of general formula I;
and A, B and C each represent a substituent selected independently of one
another from the group consisting of H, F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-
CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl,
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
cyclohexyl,
cyclopentyl, -C(=0)-0H, -C(=0)-0-CH3, -C(=0)-0-C2H5, -C(=0)-0-C(CH3)3, -
0-C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3, -N(CH3)2, -N(C2H5)2, -NH-
CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-C2H5, -NH-C(=0)-0-
C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-C(CH3)3, -C(=0)-NH2, -
C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2, -C(=0)-N-(C2H5)2, -
S(=0)2-CH3, -S(=0)2-C2H5, -S(=0)2 phenyl, -NH-S(=0)2-CH3, -NH-S(=0)2-
33

= CA 02608319 2007-11-13
GRA3304/A-PCT
C2H5, -S(=0)2-NH-CH3, -S(=0)2-NH-02H5 and -NH-S(=0)2 phenyl;
on the condition that not one of positions A and position B of this phenyl
radical are substituted with substituents which are respectively bound to the
phenyl radical via an identical atom selected from the group consisting of
oxygen, sulphur and nitrogen;
represents a radical selected from the group consisting of benzyl, phenethyl,
naphthyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl, thiophenyl, furanyl,
pyrroly1 pyrazolyl, pyranyl, pyridinyl, imidazolyl, indolyl, isoindolyl,
benzo[b]furanyl, benzo[b]thiophenyl, thiazolyl, oxazolyl, isoxazolyl,
pyridazinyl,
pyrazinyl, pyrimidinyl, indazolyl, quinazolinyl, quinoxalinyl, quinolinyl,
isoquinolinyl, benzimidazolyl, benzoxazolyl, benzotriazolyl, benzisoxazolyl,
[1,2,3,4]-tetrahydronaphthyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-
tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl, 2H-benzo[1.4]oxazin-
3(4H)-onyl, (3,4)-dihydroquinolin-2(1H)-onyl, [3,4]-dihydro-2H-1,4-
benzoxazinyl and benzothiazolyl, wherein the respective cyclic portion of the
above-mentioned radicals can in each case optionally be substituted with 1, 2,
3, 4 or 5 substituents selected independently of one another from the group
consisting of F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-CH3, -0-C2H5, -NH2, -NO2,
-
0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, isopropyl, n-
butyl, sec-butyl, isobutyl, tert-butyl, -C(=0)-0H, -C(=0)-0-CH3, -C(=0)-0-
C2H5, -C(=0)-0-C(CH3)3, -0-C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3, -
N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-
C2H5, -NH-C(=0)-0-C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-
C(CH3)3, -C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2, -
C(=0)-N-(C2H5)2, -S(=0)2-CH3, -S(=0)2-C2H5, -S(=0)2 phenyl, -NH-S(=0)2-
CH3, -NH-S(=0)2-C2H5, -S(=0)2-NH-CH3, -S(=0)2-NH-C2H5, cyclohexyl,
cyclopentyl, pyridinyl, pyridazinyl, -(CH2)-benzo[b]furanyl, -0-phenyl, -0-
benzyl, phenyl and benzyl; wherein in each case the cyclic portion of the
radicals pyridinyl, cyclopentyl, cyclohexyl, pyridazinyl, -S(=0)2 phenyl, -0-
phenyl, -0-benzyl, phenyl, -(CH2)-benzo[b]furanyl and benzyl can be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another from the group consisting of F, Cl, Br, -OH, -CF3, -SF5, -CN, -NO2,
34

CA 02608319 2007-11-13
GRA3304/A-PCT
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
0-
CH3, -0-C2H5, -0-CF3, -S-CF3, phenyl and -0-benzyl;
or represents a -C(=0)-NR13R14 group;
R11 represents a radical selected from the group consisting of phenyl,
indolyl,
(1,3)-benzodioxolyl, pyridinyl, (1,4)-benzodioxanyl and naphthyl, wherein the
radical can in each case optionally be substituted with 1, 2, 3, 4 or 5
substituents selected independently of one another from the group consisting
of F, CI, Br, -CF3, -SF5, -OH, -0-CH3, -0-C2H5, -0-CF3, phenyl, 3-chloro-4-
fluorophenyl, 4-methylpiperidinyl, piperidinyl, methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, -NH-S(=0)2-CH3, -NH-S(=0)2-C2H5, -
S(=0)2-NH-CH3 and -S(=0)2-NH-C2H5 and/or bound via a -(CH2) group;
R13 represents a radical selected from the group consisting of phenyl,
naphthyl,
(1,3)-benzodioxolyl, (1,4)-benzodioxanyl, pyridinyl, quinolinyl and
isoquinolinyl, wherein the radical can in each case optionally be substituted
with 1, 2, 3, 4 or 5 substituents selected independently of one another from
the
group consisting of -SF5, F, CI, Br, -CF3, -OH, -0-CH3, -0-02H5, -N H2,
methyl,
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
N(0H3)2, --
N[S(=0)2-CH3)]2, -N[S(=0)2-C2H51, N(C2H5)2, -NH-CH3, -NH-02H5, -NH-
S(=0)2-CH3, -NH-S(=0)2-C2H5, -S(=0)2-NH-CH3 and -S(=0)2-NH-C2H5 and/or
bound via a -(CH2) group;
R12 and R14, independently of one another, each represent a hydrogen radical;
or
R11 and R12 or R13 and R14 respectively form together with the nitrogen atom
connecting them as ring member
a (3,4)-dihydro-1H-isoquinolinyl radical which can be substituted with 1,2, 3,
4
or 5 substituents selected independently of one another from the group
consisting of -OH, -0-CH3 and -0-C2H5;

CA 02608319 2007-11-13
GRA3304/A-PCT
or form together with the nitrogen atom connecting them a radical selected
from the group consisting of piperazinyl, 2-methylpiperazinyl, (2,6)-
dimethylpiperazinyl and diazepanyl, wherein the radical on a nitrogen atom
can be respectively substituted with a substituent selected from the group
consisting of pyridinyl, pyridazinyl, pyrimidinyl, [1,2,5]-thiadiazolyl,
thiazolyl and
phenyl, wherein in each case the cyclic portion of the substituents
pyrimidinyl,
[1,2,5]-thiadiazolyl, thiazolyl, pyridinyl, pyridazinyl and phenyl can be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another from the group consisting of F, Cl, Br, -OH, -CF3, methyl, ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl;
in each case optionally in the form of one of their pure stereoisomers, in
particular
enantiomers or diastereomers, their racemates or in the form of a mixture of
stereoisomers, in particular of enantiomers and/or diastereomers, in any
desired
mixing ratio, or respectively in the form of corresponding salts, or
respectively in the
form of corresponding solvates.
Also most particularly preferred are substituted spiro compounds of the above-
indicated general formula I, wherein
n is equal to 1,
I.)
R1 represents a radical selected from the group consisting of methyl,
ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of cyclopropyl,
cyclobutyl,
cyclopentyl, cyclohexyl and cycloheptyl;
represents a phenyl radical
36

CA 02608319 2007-11-13
GRA3304/A-PCT
or represents a _c(=0)_NR1 Ri2 group;
R2, R7 and R8 each represent a hydrogen radical;
and
R3, R4, R5, R6, independently of one another, each
represent a hydrogen radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl, n-
butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl, n-hexyl
and n-heptyl;
or
II.)
R1 and R3 together represent a -(CH2)4 group;
R2, R4, R7 and R8 each represent a hydrogen radical;
and
R5 and R6, independently of one another, each
represent a hydrogen radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl, n-
butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl, n-hexyl
and n-heptyl;
or
37

. CA 02608319 2007-11-13
GRA3304/A-PCT
Ill.)
R1, R2, R7 and R8 each represent a hydrogen radical
and
R3, R4, R5 and R6, independently of one another, each represent a methyl or
ethyl
radical;
and in each case
R9 represents a hydrogen radical;
represents a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl, sec-
pentyl, n-hexyl and n-heptyl;
or represents a phenyl radical;
Rlo represents a radical selected from the group consisting of methyl,
ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-
dimethylpropyl, n-pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of phenyl, 2-
methanesulphonamidephenyl, 2-ethanesulphonamidephenyl, 2-
trifluoromethylphenyl,
2-trifluoromethylsulphanylphenyl, 2-ethylphenyl, 2-tert-butylphenyl, 2-
ethylaminosulphonylphenyl, 2-methylaminosulphonylphenyl, 2-bromophenyl, 2-
chlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethoxyphenyl, 2-
methoxyphenyl, 2-ethoxyphenyl, 2-propylphenyl, 2-iodophenyl, 3-chlorophenyl, 3-
methylphenyl, 3-tert-butylphenyl, 3-trifluoromethylsulphanylphenyl, 3-
trifluoromethylphenyl, 3-methanesulphonamidephenyl, 3-
ethanesulphonamidephenyl,
3-fluorophenyl, 3-propylphenyl, 3-isopropylphenyl, 3-bromophenyl, 3-
methoxyphenyl,
3-ethylphenyl, 3-ethylaminosulphonylphenyl, 3-methylaminosulphonylphenyl, 3-
ethoxyphenyl, 3-trifluoromethoxyphenyl, 3-iodophenyl, 4-
38

CA 02608319 2007-11-13
GRA3304/A-PCT
methylaminosulphonylphenyl, 4-ethylaminosulphonylphenyl, 4-
methanesulphonamidephenyl, 4-ethanesulphonamidephenyl, 4-bromophenyl, 4-
methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-tert-butylphenyl, 4-
trifluoromethylsulphanylphenyl, 4-methylphenyl, 4-isopropylphenyl, 4-
trifluoromethylphenyl, 4-propylphenyl, 4-iodophenyl, 4-trifluoromethoxyphenyl,
4-
ethylphenyl, 4-ethoxyphenyl, 2-fluoro-3-trifluoromethylphenyl, (2,3)-
difluorophenyl,
(2,3)-dimethylphenyl, (2,3)-dichlorophenyl, 3-fluoro-2-trifluoromethylphenyl,
(2,4)-
dichlorophenyl, (2,4)-difluorophenyl, 4-fluoro-2-trifluoromethylphenyl, (2,4)-
dimethoxyphenyl, 2-chloro-4-fluorophenyl, (2,4)-dibromophenyl, 2-fluoro-4-
trifluoromethylphenyl, (2,5)-difluorophenyl, 2-fluoro-5-trifluoromethylphenyl,
5-fluoro-
2-trifluoromethylphenyl, 5-chloro-2-trifluoromethylphenyl, 5-bromo-2-
trifluoromethylphenyl, (2,5)-dimethoxyphenyl, (2,5)-bis-
trifluoronnethylphenyl, (2,5)-
dichlorophenyl, (2,5)-dibromophenyl, 2-fluoro-6-trifluoromethylphenyl, (2,6)-
dimethoxyphenyl, (2,6)-dimethylphenyl, (2,6)-dichlorophenyl, 2-chloro-6-
fluorophenyl,
2-bromo-6-chlorophenyl, 2-bromo-6-fluorophenyl, (2,6)-difluorophenyl, (2,6)-
difluoro-
3-methylphenyl, (2,6)-dibromophenyl, (2,6)-dichlorophenyl, 3-chloro-2-
fluorophenyl,
(3,4)-dichlorophenyl, 4-fluoro-3-trifluoromethylphenyl, 3-fluoro-4-
trifluoromethylphenyl, (3,4)-difluorophenyl, 4-chloro-3-trifluoromethyl, 4-
bromo-3-
methylphenyl, 4-bromo-5-methylphenyl, 3-chloro-4-fluorophenyl, (3,4)-
dibromophenyl, 4-chloro-3-methylphenyl, 4-bromo-3-methylphenyl, 4-fluoro-3-
methylphenyl, (3,5)-dimethoxyphenyl, (3,5)-bis-trifluoromethylphenyl, (3,5)-
difluorophenyl, (3,5)-dichlorophenyl, 3-fluoro-5-trifluoromethylphenyl, 5-
fluoro-3-
trifluoromethylphenyl, (3,5)-dibromophenyl, 5-chloro-4-fluorophenyl, 5-bromo-4-
methylphenyl, (2,3,4)-trifluorophenyl, (2,3,4)-trichlorophenyl, (2,3,6)-
trifluorophenyl, 5-
chloro-2-methoxyphenyl, (2,3)-difluoro-4-methylphenyl, (2,4,5)-
trifluorophenyl,
(2,4,5)-trichlorophenyl, (2,4)-dichloro-5-fluorophenyl, (2,4,6)-
trichlorophenyl, (2,4,6)-
trimethylphenyl, (2,4,6)-trifluorophenyl, (2,4,6)-trimethoxyphenyl, (2,3,4,5)-
tetrafluorophenyl, 4-methoxy-2,3,6-trimethylphenyl, 4-methoxy-2,3,6-
trimethylphenyl,
4-chloro-2,5-dimethylphenyl, 2-chloro-6-fluoro-3-methylphenyl, 6-chloro-2-
fluoro-3-
methyl, (2,3,4,5,6)-pentafluorophenyl, 3-fluoro-4-methylsulphonamidophenyl, 3-
chloro-4-methylsulphonamidophenyl, 3-bromo-4-methylsulphonamidophenyl, 3-
methoxy-4-methylsulphonamidophenyl, 3-hydroxy-4-methylsulphonamidophenyl, 3-
trifluoromethy1-4-methylsulphonamidophenyl, 3-trifluoromethoxy-4-
methylsulphonamidophenyl, 3-methyl-4-methylsulphonamidophenyl, 3-ethyl-4-
39

CA 02608319 2007-11-13
GRA3304/A-PCT
methylsulphonamidophenyl, 3-isopropyl-4-methylsulphonamidophenyl, 3-propy1-4-
methylsulphonamidophenyl, 3-tert-butyl-4-methylsulphonamidophenyl, 3-fluoro-4-
phenylsulphonamidophenyl, 3-chloro-4-phenylsulphonamidophenyl, 3-bromo-4-
phenylsulphonamidophenyl, 3-methoxy-4-phenylsulphonamidophenyl, 3-hydroxy-4-
phenylsulphonamidophenyl, 3-trifluoromethy1-4-phenylsulphonamidophenyl, 3-
trifluoromethoxy-4-phenylsulphonamidophenyl, 3-methy1-4-
phenylsulphonamidophenyl, 3-ethyl-4-phenylsulphonamidophenyl, 3-isopropy1-4-
phenylsulphonamidophenyl, 3-propy1-4-phenylsulphonamidophenyl, 3-tert-buty1-4-
phenylsulphonamidophenyl,
4-fluoro-3-methylsulphonamidophenyl, 4-chloro-3-methylsulphonamidophenyl, 4-
bromo-3-methylsulphonamidophenyl, 4-methoxy-3-methylsulphonamidophenyl, 4-
hydroxy-3-methylsulphonamidophenyl, 4-trifluoromethy1-3-
methylsulphonamidophenyl, 4-trifluoromethoxy-3-methylsulphonamidophenyl, 4-
methy1-3-methylsulphonamidophenyl, 4-ethyl-3-methylsulphonamidophenyl, 4-
isopropy1-3-methylsulphonamidophenyl, 4-propy1-3-methylsulphonamidophenyl, 4-
tert-buty1-3-methylsulphonamidophenyl, 4-fluoro-3-phenylsulphonamidophenyl, 4-
chloro-3-phenylsulphonamidophenyl, 4-bromo-3-phenylsulphonamidophenyl, 4-
methoxy-3-phenylsulphonamidophenyl, 4-hydroxy-3-phenylsulphonamidophenyl, 4-
trifluoromethy1-3-phenylsulphonamidophenyl, 4-trifluoronnethoxy-3-
phenylsulphonamidophenyl, 4-methyl-3-phenylsulphonamidophenyl, 4-ethy1-3-
phenylsulphonamidophenyl, 4-isopropyl-3-phenylsulphonamidophenyl, 4-propy1-3-
phenylsulphonamidophenyl and 4-tert-butyl-3-phenylsulphonamidophenyl;
represents a radical selected from the group consisting of benzyl, phenethyl,
thiazolyl, naphthyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl and pyridinyl,
wherein
the cyclic portion of the above-mentioned radicals can optionally be
substituted with
1, 2, 3, 4 or 5 substituents selected independently of one another from the
group
consisting of F, Cl, Br, I, -CF3, -OH, -0-CH3, -0-C2H5, methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl;
or represents a -C(=0)-NR13R14 group;
R11 represents a radical selected from the group consisting of phenyl,
indolyl,
pyridinyl, (1,3)-benzodioxolyl, (1,4)-benzodioxanyl and naphthyl, wherein the
radical

CA 02608319 2007-11-13
GRA3304/A-PCT
can in each case optionally be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, Cl, Br, -CF3, -
SF5, -OH,
-0-CH3, -0-02H5, -0-CF3, piperidinyl, 4-methylpiperidinyl, 3-chloro-4-
fluorophenyl,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
NH-S(=0)2-
CH3, -NH-S(=0)2-C2H5, -S(=0)2-NH-CH3 and -S(=0)2-NH-C2H5 and/or bound via a -
(CH2) group;
R13 represents a radical selected from the group consisting of phenyl,
naphthyl,
(1,3)-benzodioxolyl, (1,4)-benzodioxanyl, pyridinyl, quinolinyl and
isoquinolinyl, wherein the radical can in each case optionally be substituted
with 1, 2,
3, 4 or 5 substituents selected independently of one another from the group
consisting of -SF5, F, Cl, Br, -CF3, -OH, -0-CH3, -0-C2H5, -NH2, methyl,
ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -N(CH3)2, -
N(02H5)2, -NH-
CH3, -NH-C2H5, -NH-S(=0)2-CH3, -NH-S(=0)2-02H5, -N[S(=0)2-CF13A2, -N[S(=0)2-
021-15)]2, -S(=0)2-NH-CH3 and -S(=0)2-NH-02H5 and/or bound via a -(CH2) group;
R12 and R14, independently of one another, each represent a hydrogen radical;
Or
R11 and R12 or R13 and R14 respectively form together with the nitrogen atom
connecting them as ring member
a (3,4)-dihydro-1H-lsoquinolinyl radical which can be substituted with 1, 2,
3, 4 or 5
substituents selected independently of one another from the group consisting
of -OH,
-0-CH3 and -0-C2H5;
or form together with the nitrogen atom connecting them a radical selected
from the
group consisting of piperazinyl, 2-methylpiperazinyl, (2,6)-
dimethylpiperazinyl and
diazepanyl, wherein the radical on a nitrogen atom can be respectively
substituted
with a substituent selected from the group consisting of pyridinyl,
pyridazinyl,
pyrimidinyl, [1,2,5]-thiadiazolyl, thiazolyl and phenyl, wherein in each case
the cyclic
portion of the substituents pyrimidinyl, [1,2,5]-thiadiazolyl, thiazolyl,
pyridinyl,
pyridazinyl and phenyl can be substituted with 1, 2, 3, 4 or 5 substituents
selected
41

CA 02608319 2013-03-21
29732-50
independently of one another from the group consisting of F, Cl, Br, -OH, -
CF3,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-
butyl;
in each case optionally in the form of one of their pure stereoisomers, in
particular
enantiomers or diastereomers, their racemates or in the form of a mixture of
stereoisomers, in particular of enantiomers and/or diastereomers, in any
desired
mixing ratio, or respectively in the form of corresponding salts, or
respectively in the
form of corresponding solvates.
According to one aspect of the present invention, there is provided a
substituted Spiro
compound of general formula I,
m4o7 8
R1
R3 rµ R it 0__N
R2
R5 R10
R6 R9
wherein:
n is equal to 1;
I.)
R1 represents a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl and n-heptyl;
represents a radical selected from the group consisting of cyclopropyl,
cyclobutyl,
cyclopentyl, cyclohexyl and cycloheptyl;
42

CA 02608319 2013-03-21
29732-50
represents a phenyl radical, wherein the radical can in each case optionally
be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -0-Cl-I3, -0-
C2H5,
-NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, -C(=0)-0H, -C(=0)-0-CH3, -C(=0)-0-
C2H5,
-C(=0)-0-C(CH3)3, -0-C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3, -N(CH3)2,
-N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-C2H5, -NH-C(=0)-
0-C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-C(CH3)3, -C(=0)-NI-12,
-C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2 and -C(=0)-N-(C2H5)2;
or represents a -C(=0)-NR11R12 group;
and
R2, R3, R4, R5, R6, R7 and Ws, independently of one another, each represent a
hydrogen radical or
a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
II.)
R1 and R3 together represent a -(CH2)p group wherein p = 4;
and
R2, R4, R5, R6, R7 and Fe, independently of one another, each represent a
hydrogen
radical
or a radical selected from the group consisting of methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-pentyl, sec-
pentyl,
n-hexyl and n-heptyl;
or
42a

CA 02608319 2013-03-21
29732-50
III.)
R1, R2, R7 and Fe each represent a hydrogen radical
and
R3, R4, R5 and R6, independently of one another, each
represent a radical selected from the group consisting of methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl, and n-heptyl;
and in each case
R9 represents a hydrogen radical;
R19 represents a radical selected from the group consisting of methyl, ethyl,
n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, (1,1)-dimethylpropyl, n-
pentyl,
sec-pentyl, n-hexyl, n-heptyl, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-
butenyl,
3-butenyl, 2-methyl-1-propenyl, ethinyl, 1-propinyl, 2-propinyl, 1-butinyl, 2-
butinyl and
3-butinyl;
represents a phenyl or pyridinyl radical, wherein the radical can in each case
optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of
one another from the group consisting of F, Cl, Br, I, -CN, -CF3, -SF5, -OH, -
0-CH3,
-0-C2H5, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl, ethyl, n-
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -C(=0)-0H, -C(=0)-0-CH3, -
C(=0)-
0-C2H5, -C(=0)-0-C(CH3)3, -0-C(=0)-CH3, -0-C(=0)-C2H5, -0-C(=0)-C(CH3)3,
-N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=0)-0-CH3, -NH-C(=0)-0-C2H5,
-NH-C(=0)-0-C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-C(CF13)3,
-C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2, -C(=0)-N-(C2H5)2,
-S(=0)2-CH3, -S(=0)2-C2H5, -S(=0)2 phenyl, -NH-S(=0)2-CH3, -NH-S(=0)2-C2H5,
-NH-S(=0)2 phenyl, -S(=0)2-NH-CH3, -S(=0)2-NH-C2H5, cyclohexyl, cyclopentyl,
42b

CA 02608319 2013-03-21
29732-50
pyridinyl, pyridazinyl, -(CH2)-benzo[b]furanyl, -0-phenyl, -0-benzyl, phenyl
and
benzyl,
on the condition that not one of the meta positions and the para position of
this
phenyl radical are substituted with substituents which are respectively bound
to the
phenyl radical via an identical atom selected from the group consisting of
oxygen,
sulphur and nitrogen;
or represents a -C(=0)-NR13R14 group;
R11 representsa radical selected from the group consisting of phenyl,
naphthyl,
indolyl, pyridinyl, (1,3)-benzodioxolyland (1,4)-benzodioxanyl, wherein the
radical
can in each case optionally be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, Cl, Br, I, -CN, -
CF3,
-SF5, -OH, -0-CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
N(CH3)2,
-N(C2H5)2, -NH-CH3, -NH-C2H5, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-C(CH3)3, -C(=0)-
NH2, -C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2, -C(=0)-N-(C2H5)2, -S(=0)2-
CH3, -S(=0)2-C2H5, -NH-S(=0)2-CH3, -NH-S(=0)2-C2H5, -S(=0)2-NH-CH3, -S(=0)2-
NH-C2H5, piperidinyl, 4-methylpiperidinyl and phenyl; wherein the phenyl
radical can
be substituted with 1, 2 or 3 substituents selected from the group consisting
of F, Cl
and Br; and/or bound via a -(CH2) group or -(CH2)2 group;
R12 represents a hydrogen radical; or
R11 and R12 form together with the nitrogen atom connecting them as ring
member a
piperazinyl radical, wherein the radical can optionally be substituted with 1,
2, 3, 4 or
5 substituents selected independently of one another from the group consisting
of
oxo (=0), thioxo (=S), F, Cl, Br, -OH, -0-CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-
CF3,
-SH, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl,
tert-butyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, pyridinyl, pyridazinyl, pyrimidinyl,
[1,2,5]-thiadiazolyl, thiazolyl, phenyl and benzyl; wherein in each case the
cyclic
portion of the radicals pyrimidinyl, [1,2,5]-thiadiazolyl, thiazolyl,
pyridinyl, pyridazinyl,
42c

CA 02608319 2013-03-21
29732-50
phenyl and benzyl can be substituted with 1, 2, 3, 4 or 5 substituents
selected
independently of one another from the group consisting of F, Cl, Br, -OH, -
CF3,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
0-CH3,
-0-C2H5, -0-CF3 and -S-CF3;
R'3 representsa radical selected from the group consisting of phenyl,
pyridinyl,
naphtyl, (1,4)-benzodioxanyl, quinolinyl and isoquinolinyl, wherein the
radical can in
each case optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of one another from the group consisting of F, Cl, Br, I, -CN, -
CF3,
-SF5, -OH, -0-CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -
C(=0)-0H,
-C(=0)-0-CH3, -C(=0)-0-C2H5, -C(=0)-0-C(CH3)3, -0-C(=0)-CH3, -0-C(=0)-C2H5,
-0-C(=0)-C(CH3)3, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NH-C(=0)-0-CH3,
-NH-C(=0)-0-C2H5, -NH-C(=0)-0-C(CH3)3, -C(=0)-H, -C(=0)-CH3, -C(=0)-C2H5,
-C(=0)-C(CH3)3, -C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-NH-C2H5, -C(=0)-N-(CH3)2,
-C(=0)-N-(C2H5)2, -S(=0)2-CH3, -S(=0)2-C2H5, -NH-S(=0)2-CH3, -NH-S(=0)2-C2H5,
-N[S(=0)2-CH3)12, -N[S(=0)2-C2F15)]2, -S(=0)2-NH-CH3 and -S(=0)2-NH-C2H5
and/or
bound via a -(C H2) group or -(CH2)2 group;
R14 represents a hydrogen radical; or
R13 and R14 respectively form together with the nitrogen atom connecting them
as ring
member a radical selected from the group consisting of pyrrolidinyl,
piperidinyl,
(1,3,4,5)-tetrahydropyrido[4,3-blindolyl, (3,4)-dihydro-1H-isoquinolinyl,
(1,3,4,9)-
tetrahydro-[b]-carbolinyl, imidazolidinyl, (1,3)-thiazolidinyl, piperazinyl,
morpholinyl,
azepanyl, diazepanyl and thiomorpholinyl, wherein the radical can in each case
optionally be substituted with 1, 2, 3, 4 or 5 substituents selected
independently of
one another from the group consisting of oxo (=0), thioxo (=S), F, Cl, Br, -
OH,
-0-CH3, -0-C2H5, -NH2, -NO2, -0-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, methyl,
ethyl,
n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -N(CH3)2, -
N(C2F15)2,
-NH-CH3, pyridinyl, pyridazinyl, pyrimidinyl, [1,2,5]-thiadiazolyl, thiazolyl,
phenyl and
benzyl, wherein in each case the cyclic portion of the radicals pyrimidinyl,
42d

CA 02608319 2013-03-21
29732-50
[1,2,5]-thiadiazolyl, thiazolyl, pyridinyl, pyridazinyl, phenyl and benzyl can
be
substituted with 1, 2, 3, 4 or 5 substituents selected independently of one
another
from the group consisting of F, Cl, Br, -OH, -CF3, methyl, ethyl, n-propyl,
isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, -0-CH3, -0-C2H5, -0-CF3 and -S-CF3;
or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a
mixture of
enantiomers thereof, a mixture of diastereomers thereof, a salt thereof or a
solvate
thereof.
Still more preferred are spiro compounds of general formula I selected from
the group
consisting of
[1] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
aminobenzylamide
[2] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
methanesulphonylaminobenzylamide
[3] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
methanesulphonylaminobenzylamide
[4] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
isoquinolin-5-ylamide
[5] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-thiazol-2-
ylpiperazin-1-yl)methanone
[6] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-thiazol-
2-
ylpiperazin-1-yl)nethanone
[7] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-
fluoro-4-methanesulphonylaminobenzylamide
[8] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-
trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone
42e

CA 02608319 2013-03-21
29732-50
=
[9] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-[4-(3-
trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone
[10] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.51dec-2-en-3-y1)44-(4-
hydroxyphenyppiperazin-1-yllmethanone
[11] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-[4-(4-
hydroxyphenyl)piperazin-1-yl]methanone
[12] (8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(6,7-dihydroxy-3,4-
dihydro-1H-isoquinolin-2-yl)methanone
[13] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-[4-(6-
methylpyridazin-3-yl)piperazin-1-yl]methanone
[14] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-[4-(6-
methylpyridazin-3-yl)piperazin-1-yl]methanone
[15] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-pyrimidin-2-
ylpiperazin-1-yl)methanone
[16] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-pyrimidin-2-
ylpiperazin-1-yl)methanone
42f

CA 02608319 2007-11-13
GRA3304/A-PCT
[17] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(4-chloro-
[1,2,5]thiadiazol-3-yl)piperazin-1-yl]methanone
[18] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(6,7-dimethoxy-
3,4-
dihydro-1H-isoquinolin-2-yl)methanone
[19] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(6,7-dimethoxy-3,4-
dihydro-1H-isoquinolin-2-yl)methanone
[20] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(4-chloro-
[1,2,5]thiadiazol-3-yl)piperazin-1-yl]methanone
[21] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-
chloropyridin-2-y1)-
[1,4]diazepan-1-yl]methanone
[22] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-chloropyridin-
2-y1)-
[1,4]diazepan-1-yl]methanone
[23] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(pyridin-4-
ylmethyl)amide
[24] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(pyridin-4-
ylmethyl)amide
[25] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-
fluoro-4-
methanesulphonylaminobenzylamide
[26] trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
hydroxy-
3-methoxybenzylamide
[27] cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
hydroxy-3-
methoxybenzylamide
[28] trans-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-[4-(3-
chloropyridin-2-
yl)piperazin-1-yl]methanone
[29] cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-[4-(3-chloropyridin-
2-
yl)piperazin-1-yl]methanone
[30] 3',4',4a',5',6',7',8',8a'-octahydro-11H,4H-spiro[isoxazol-5,2'-
naphthalene]-3-
carboxylic acid-(4-tert-butylphenyl)amide
[31] 3',4',4a',5',6',7',8',8a'-octahydro-111-1,4H-spiro[isoxazol-5,2'-
naphthalene]-3-
carboxylic acid-(4-tert-butylbenzyl)amide
[32] 3',4',4a',5',6',7',8',8a'-octahydro-1'H,4H-spiro[isoxazol-5,2'-
naphthalene]-3-
carboxylic acid-3-fluoro-4-methanesulphonylaminobenzylamide
[33] 3-methy1-1-oxa-2-azasp1ro[4.5]dec-2-ene-8-carboxylic acid-(4-tert-
butylphenyl)amide
[34] 3-pheny1-3",4",4a",5",6",7",8",8a"-octahydro-1"H,4H-spiro[isoxazol-
5,2"-
naphthalene]
[35] 3,8-dipheny1-1-oxa-2-azaspiro[4.5]dec-2-ene
[36] 8 pheny1-3-p-tolyI-1-oxa-2-azaspiro[4.5]dec-2-ene
[37] 8 phenyl-3-(4-trifluormethylpheny1)-1-oxa-2-azaspiro[4.5]dec-2-ene
[38] 7,7,9,9-tetramethy1-3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene
[39] 3-(4-tert-butylphenyI)-8 pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene
[40] 4-tert-buty1-3-pheny1-3",4",4a",5",6",7",8",8a"-octahydro-1"H,4H-
spiro[isoxazol-
5,2"-naphthalene]
[41] 3-(4-tert-butylpheny1)-7,7,9,9-tetramethy1-1-oxa-2-azaspiro[4.5]dec-2-ene
[42] 8 phenyl-3-pyridin-2-y1-1-oxa-2-azaspiro[4.5]dec-2-ene
[43] 8-(1,1-dimethylpropy1)-3-pyridin-2-y1-1-oxa-2-azaspiro[4.5]dec-2-ene
[44] 3-(4-tert-butylpheny1)-8-(1,1-dimethylpropy1)-1-oxa-2-azaspiro[4.5]dec-2-
ene
[45] 3-(4-tert-butylpheny1)-8-ethyl-1-oxa-2-azaspiro[4.5]dec-2-ene
[46] cis-[3-(4-tert-butylpheny1)-1-oxa-2-azaspiro[4.5]dec-2-en-8-y1]-[4-(3-
chloropyridin-2-yl)piperazin-1-yl]methanone
43

CA 02608319 2007-11-13
GRA3304/A-PCT
[47] trans-[3-(4-tert-butylpheny1)-1-oxa-2-azaspiro[4.5]dec-2-en-8-y1]-[4-(3-
chloropyridin-2-yl)piperazin-1-yl]methanone
[48] cis44-(3-chloropyridin-2-yOpiperazin-1-y1]-(3-pheny1-1-oxa-2-
azaspiro[4.5]dec-
2-en-8-yOmethanone
[49] trans-[4-(3-chloropyridin-2-yl)piperazin-1-y1]-(3-pheny1-1-oxa-2-
azaspiro[4.5]dec-2-en-8-yl)methanone
[50] 3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4-tert-
butylphenyl)amide
[51] 3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-cis-(4-tert-
butylphenyl)amide
[52] 3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-cis-3-fluoro-4-
methanesulphonylaminobenzylamide
[53] 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-trans-3-fluoro-
4-
methanesulphonylaminobenzylamide
[54] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(4-tert-
butyl-
phenyl)amide
[55] 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-trans-(4-tert-
butylphenyl)amide
[56] 8-tert-butyl-N-(4-(methylsulphonamido)benzy1)-1-oxa-2-azaspiro[4.5]dec-2-
ene-3-carboxamide
[57] N-(4-tert-butylpheny1)-3-methy1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxamide
hydrochloride
[58] ((5R,8R)-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)(4-(3-
chloropyridin-2-
y1)-2,6-dimethylpiperazin-1-yl)methanone
[59] ((5S,8S)-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)(4-(3-
chloropyridin-2-
y1)-2,6-dimethylpiperazin-1-yOmethanone
[60] ((5R,8R)-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)(4-(3-
chloropyridin-2-
y1)-2-methylpiperazin-1-yl)methanone
[61] ((5S,8S)-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)(4-(3-
chloropyridin-2-
y1)-2-methylpiperazin-1-yOmethanone
[62] (4-(3-chloropyridin-2-yl)piperazin-1-y1)(3-(3-methoxypheny1)-1-oxa-2-
azaspiro[4.5]dec-2-en-8-yl)methanone
[63] 3-(3-methoxypheny1)-N-(4-(trifluormethoxy)benzy1)-1-oxa-2-
azaspiro[4.5]dec-2-
ene-8-carboxamide
[64] N-(1H-indo1-5-y1)-3-(3-methoxypheny1)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxamide
[65] N-(3-fluoro-4-(methylsulphonamido)benzyI)-3-(3-methoxypheny1)-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
[66] N-(4-tert-butylpheny1)-3-(3-methoxypheny1)-1-oxa-2-azaspiro[4.5]dec-2-ene-
8-
carboxamide
[67] N-(2,3-dihydrobenzo[b][1,4]dioxin-6-y1)-3-(3-methoxypheny1)-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
[68] N-(4-tert-butylpheny1)-3-(4-fluoropheny1)-1-oxa-2-azaspiro[4.5]dec-2-ene-
8-
carboxamide
[69] (5R,8R)-3-phenyl-N-((2-(piperidin-1-y1)-6-(trifluormethyppyridin-3-
y1)methyl)-1-
oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
[70] (5R,8R)-N4(2-(4-methylpiperidin-1-y1)-6-(trifluormethyl)pyridin-3-
yOrnethyl)-3-
phenyl-1 -oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
[71] (5S,8S)-N4(2-(3-chloro-4-fluoropheny1)-6-(trifluormethyl)pyridin-3-
yOmethyl)-3-
phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
44

CA 02608319 2007-11-13
=
GRA3304/A-PCT
[72] (5S,8S)-N4(2-(4-methylpiperidin-1-y1)-6-(trifluormethyppyridin-3-
yOmethyl)-3-
phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
[73] (5S,8S)-3-phenyl-N4(2-(piperidin-1-y1)-6-(trifluormethyppyridin-3-
yOmethyl)-1-
oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
[74] (5R,8R)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-y1)-3-pheny1-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
[75] (5S,8S)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-y1)-3-pheny1-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
[79] 8-tert-butyl-N-(2,3-dihydrobenzo[b][1,4]dioxin-5-y1)-1-oxa-2-
azaspiro[4.5]dec-2-
ene-3-carboxamide
[80] N-(3-fluoro-4-(methylsulphonamido)benzy1)-8-tert-penty1-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide
[81] N-(2,3-dihydrobenzo[b][1,4]dioxin-5-y1)-8-tert-penty1-1-oxa-2-
azaspiro[4.5]dec-
2-ene-3-carboxamide
[82] 8-cyclohexyl-N-(3-fluoro-4-(methylsulphonamido)benzyI)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide
[83] 8-tert-butyl-N-(7-hydroxynaphthalen-1-yI)-1-oxa-2-azaspiro[4.5]dec-2-ene-
3-
carboxamide
[84] N-(4-tert-butylpheny1)-344-(3-chloropyridin-2-y1)piperazin-1-carbony1)-1-
oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
[85] N-(4-tert-butylbenzy1)-3-(443-chloropyridin-2-y1)piperazin-1-carbonyl)-1-
oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
[86] 8-tert-butyl-N-(5-hydroxynaphthalen-1-y1)-1-oxa-2-azaspiro[4.5]dec-2-ene-
3-
carboxamide
[87] 8-tert-butyl-N-(2-fluoro-5-(methylsulphonamido)phenyI)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide
[88] 8-tert-butyl-N-(2-fluoro-5-(N-(methylsulphonyl)methylsulphonamido)phenyI)-
1-
oxa-2-azaspiro[4.5]dec-2-ene-3-carboxamide
[89] 8-tert-butyl-N-(4-fluoro-3-(methylsulphonamido)phenyI)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide
[90] 8-tert-butyl-N-(3-fluoro-4-(methylsulphonamido)phenyI)-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide
[91] 8-tert-butyl-N-(3-fluoro-44N-(nnethylsulphonyl)methylsulphonamido)pheny1)-
1-
oxa-2-azaspiro[4.5]dec-2-ene-3-carboxamide
[92] 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
pentafluorosulphanylbenzylamide
and
[93] 3-(3-methoxyphenyI)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4-
pentafluorosulphanylphenyl)amide;
in each case optionally in the form of one of their pure stereoisomers, in
particular
enantiomers or diastereomers, their racemates or in the form of a mixture of
stereoisomers, in particular of enantiomers and/or diastereomers, in any
desired
mixing ratio, or respectively in the form of corresponding salts, or
respectively in the
form of corresponding solvates.

CA 02608319 2007-11-13
GRA3304/A-PCT
Preference may also be given to substituted spiro compounds according to the
invention which in a FLIPR assay in a concentration of 10 pM display
inhibition of the
Ca2+ ion inflow in dorsal root ganglia of rats of at least 10 %, preferably of
at least 30
/0, particularly preferably of at least 50 /0, most particularly preferably
of at least 70
%, even more preferably of at least 90 A), compared to the maximum achievable
inhibition of the Ca2+ ion inflow with capsaicin in a concentration of 10 pM.
In the FLIPR assay, the Ca2+ inflow is quantified using a Ca2+-sensitive dye
(type
Fluo-4, Molecular Probes Europe By, Leiden, Netherlands) in a fluorescent
imaging
plate reader (FLIPR, Molecular Devices, Sunnyvale, USA), as described
hereinafter.
The present invention further relates to a process for preparing compounds
according
to the invention of the above-indicated general formula I in which at least
one
compound of general formula II,
(Rlm R4
R2
HN
)n 0¨N
wherein n and R2 to R9 areas defined above and R1 is as defined above except
for a
12
_c(=0)_NR11-1-<group or represents -C(=0)-0R; wherein R represents a linear or
branched C1_6 alkyl radical; is reacted in a reaction medium in the presence
of at
least one base, preferably at least one organic base, with at least one
compound of
general formula III,
CI Rlo
N,
OH
Ill
wherein R1 is as defined above except for a -C(=0)-NR13rc.-'14 group or
represents -
C(=0)-0R; wherein R represents a linear or branched C1_6 alkyl radical; to
form at
least one compound of general formula IV,
46

CA 02608319 2007-11-13
GRA3304/A-PCT
R3 R4 R7 R8
R1N N
R2 n _____________________________________ R1 0
R5
R6 R9
IV
wherein n and R2 to R9 are as defined above, R1 is as defined above except for
a -
12
c(=0)_NR11-1-< group or represents -C(=0)-OR, and R1 is as defined above
except
for a -C(=0)-NR13R14 group or represents -C(=0)-0R; wherein R independently of
one another respectively represents a linear or branched C1..6 alkyl radical;
and the at
least one compound of general formula IV is optionally purified and/or
isolated;
and optionally at least one compound of general formula IV, wherein n and R2
to R9
are as defined above, R1 represents -C(=0)-0R; wherein R is as defined above
and
R1 is as defined above except for a -C(=0)-NR13Kr'14 group; in a reaction
medium in
the presence of at least one base, preferably in the presence of at least one
alkali
metal hydroxide salt, particularly preferably in the presence of lithium
hydroxide, to
form at least one compound of general formula V,
R3 R4R7 R8
R1
R2
R5 R10
R6 R9
V
wherein n and R2 to R9 are as defined above, R1 represents -C(=0)-OH and R1
is as
defined above except for a -C(=0)-NR13R14 group; is reacted and the at least
one
compound of general formula V is optionally purified and/or isolated;
and at least one compound of general formula V is reacted in a reaction medium
in
the presence of at least one coupling reagent, optionally in the presence of
at least
one base, with a compound of general formula HNR11r<r'12, wherein R11 and R12
are as
47

= CA 02608319 2007-11-13
GRA3304/A-PCT
defined above, to form at least one compound of general formula I, wherein n
and R2
to R9 are as defined above, R1 represents a -C(=0)-NR11-12
group; wherein R11 and
R12 are as defined above and R1 is as defined above except for a -C(=0)-
NR13R14
group; and the at least one compound of general formula I is optionally
purified
and/or isolated; or
optionally at least one compound of general formula IV, wherein n and R2 to R9
are
as defined above, R1 is as defined above except for a -C(=0)-NR11R12 group and
R1
represents a -C(=0)-OR group; wherein R represents a linear or branched C1-6
alkyl
radical; is reacted in a reaction medium in the presence of at least one base,
preferably in the presence of at least one alkali metal hydroxide salt,
particularly
preferably in the presence of lithium hydroxide, to form at least one compound
of
general formula VI,
R3 R4 R7 R8
R1 411 0
R2
R10
R6 R9
VI
wherein n and R2 to R9 are as defined above, R1 is as defined above except for
a -
12
c(=0)_NR11¨I-K group and R19 represents -C(=0)-0H; and the at least one
compound
of general formula VI is optionally purified and/or isolated;
and at least one compound of general formula VI is reacted in a reaction
medium in
the presence of at least one coupling reagent, optionally in the presence of
at least
one base, with a compound of general formula HNR13R14, wherein R13 and R14 are
as
defined above, to form at least one compound of general formula I, wherein n
and R2
to R9 are as defined above, R1 is as defined above except for a -C(=0)-NR11R12
group and R1 represents a -C(=0)-NR13R14 group; wherein R13 and R14 are as
defined above; and the at least one compound of general formula I is
optionally
purified and/or isolated.
48

. CA 02608319 2007-11-13
,
,
GRA3304/A-PCT
The processes according to the invention for preparing substituted Spiro
compounds
of the above-indicated general formula I are also represented in the following
Diagrams 1, 2 and 3.
R4 R7
R3 n.b8 CI R10
R1=
rµ
¨ I
R2 NOH
R-,it R9 + n
R6
II III
1.11
0 R4R7
R3 R4R7 Rs
RO
R3 R8 . 0,N R1 0,N
I I
R2 R2 OR
R5n R10
R5 n
R6 R9 R6 R9 0
2., IV 2., IV
0 R4R7
R3 R4R7 R8
R3 Rs
4, 0,N R1 0,N
HO
I11) I
R2 R2 OH
R" n R10 R5 n
R6 R9 R6 R9 0
3.1 V 31 VI
0 R4R7
R3 R4R7 R8
R3 R8
R1 0,N
R11R12N R2 iii 0,N
I R2e 411)n I
NR13R1
R10 4
F
R' n
R6 R9
R6 R9 0
I I
Diagram 1.
In step 1, compounds of general formula II are reacted in a reaction medium,
preferably in a reaction medium selected from the group consisting of
methanol,
49

CA 02608319 2007-11-13
GRA3304/A-PCT
tetrahydrofuran, dichloromethane and corresponding mixtures, in the presence
of at
least one base, preferably in the presence of at least one base selected from
the
group consisting of sodium hydrogen carbonate, lithium hydroxide,
triethylamine or
N-diisopropylethylamine, with compounds of general formula III at temperatures
between 0 C and 100 C, to form compounds of general formula IV.
In step 2, compounds of general formula IV, wherein R1 or R1 represents -
C(=0)-R,
are reacted in a reaction medium, preferably in a reaction medium selected
from the
group consisting of methanol, ethanol, water, isopropanol and corresponding
mixtures, in the presence of at least one base, preferably in the presence of
lithium
hydroxide monohydrate, at temperatures between 0 C and 50 C to form
compounds of general formula II.
In step 3, compounds of the above-indicated general formula V are reacted with
amines of general formula HNR11R12 or compounds of the above-indicated formula
VI
are reacted with amines of general formula HNR13R14 in a reaction medium,
preferably selected from the group consisting of diethyl ether,
tetrahydrofuran,
acetonitrile, methanol, ethanol, dimethylformamide, dichloromethane and
corresponding mixtures, optionally in the presence of at least one coupling
reagent,
preferably selected from the group consisting of 1-benzotriazolyloxy-tris-
(dimethylamino)phosphonium hexafluorophosphate (BOP), dicyclohexylcarbodiimide
(DCC), N,N`-carbonyldiimidazole, N,N'-diisopropylcarbodiimide, N'-(3-
dimethylaminopropy1)-N-ethylcarbodiimide (EDCI), N-[(dimethyamino)-1H-1, 2, 3-
triazolo[4, 5-b]pyridin-1-ylmethylene]-N-methylmethanaminium
hexafluorophosphate
N-oxide (HATU), 0-(benzotriazol-1-y1)-N,N,N`,N4etramethyluronium
hexafluorophosphate (HBTU), 0-(benzotriazol-1-y1)-N,N,N`,N`-tetramethyluronium
tetrafluoroborate (TBTU), 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-
azabenzotriazole (HOAt), optionally in the presence of at least one inorganic
base,
preferably selected from the group consisting of potassium carbonate and
caesium
carbonate, or an organic base, preferably selected from the group consisting
of
triethylamine, 4-methylmorpholine, pyridine, N,N-dimethylaminopyridine and
diisopropylethylamine, preferably at temperatures of -70 C to 100 C, to form
compounds of general formula I, wherein R1 represents -C(=0)-NHR11R12 or R1
represents -C(=0)-NHR13R14.

= CA 02608319 2007-11-13
=
GRA3304/A-PCT
The compounds of general formula II may be obtained as illustrated in Diagram
2.
R4 R7 R4 R7
R' R3
R8 R8 9
R1 R1 R
0
R2 it RR 5=n
R6 R6
VII II
Diagram 2.
Compounds of general formula VII, wherein n and R1 to R8 are as defined above,
are
reacted in a reaction medium, preferably in a reaction medium selected from
the
group consisting of tetrahydrofuran, toluene, diethyl ether and corresponding
mixtures, with a reagent for converting carbonyl groups into double bonds,
preferably
with a Wittig reagent of general formula R3P(CH2)R9X; wherein R represents an
aryl
radical, X represents a halogen atom and R9 is as defined above; or a Wittig-
Horner
reagent of general formula (R0)2-P(=0)-(CH2)-R9, wherein R represents an aryl
radical and R9 is as defined above, particularly preferably with
methyltriphenylphosphonium bromide, at temperatures between 0 C and 30 C in
the presence of a base, preferably in the presence of an alkali metal
alcoholate salt,
particularly preferably in the presence of potassium tert-butylate, to form
compounds
of general formula II.
The compounds of general formula III may be obtained as illustrated in Diagram
3.
R10
Ci R10
II I
N, N,
OH OH
51
VIII III

CA 02608319 2007-11-13
GRA3304/A-PCT
Diagram 3.
Compounds of general formula VIII, wherein R19 is as defined above or
represents -
C(=0)-OR, are reacted in a reaction medium, preferably in a reaction medium
selected from the group consisting of tetrahydrofuran, dimethylformamide,
dichloromethane, toluene, diethyl ether and corresponding mixtures, with N-
chlorosuccinimide at temperatures between 0 and 50 C to form compounds of
general formula III.
The compounds of the above-indicated formulae R3P(CH2)R9X, (R0)2-P(=0)-(CH2)-
R9, HNR11R12, HNR13R14, VII and VIII are each commercially available and can
also
be prepared using conventional processes known to a person skilled in the art.
The above-described reactions can each be carried out under the conventional
conditions with which a person skilled in the art is familiar, for example
with regard to
pressure or the order in which the components are added. If appropriate, a
person
skilled in the art can determine by simple preliminary tests the procedure
which is
optimal under the respective conditions. The intermediate and end products
obtained
as a result of the above-described reactions can each, if it is desirable
and/or
necessary, be purified and/or isolated using conventional methods known to a
person
skilled in the art. Suitable purification processes include, for example,
extraction
processes and chromatographic processes such as column chromatography or
preparative chromatography. All of the above-described process steps and in
each
case also the purification and/or isolation of intermediate or end products
can be
carried out partly or completely under an inert gas atmosphere, preferably
under a
nitrogen atmosphere.
The substituted spiro compounds according to the invention of the above-
mentioned
general formula I and la, referred to hereinafter simply as spiro compounds of
general formula I, and corresponding stereoisomers can be isolated both in the
form
of their free bases, their free acids and also in the form of corresponding
salts, in
particular physiologically compatible salts. The free bases of the respective
substituted spiro compounds according to the invention of the above-mentioned
52

CA 02608319 2007-11-13
G RA3304/A-P CT
general formula I and of corresponding stereoisomers can, for example, be
converted
by reaction with an inorganic or organic acid, preferably with hydrochloric
acid,
hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, p-
toluenesulphonic acid, carbonic acid, formic acid, acetic acid, oxalic acid,
succinic
acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid,
glutamic acid or
aspartic acid, into the corresponding salts, preferably physiologically
compatible
salts. The free bases of the respective substituted Spiro compounds of the
above-
mentioned general formula I and of corresponding stereoisomers can also be
converted with the free acid or a salt of a sugar substitute, such as, for
example,
saccharin, cyclamate or acesulfame, into the corresponding physiologically
compatible salts. Accordingly, the free acids of the substituted Spiro
compounds of
the above-mentioned general formula I and of corresponding stereoisomers can
be
converted by reaction with a suitable base into the corresponding
physiologically
compatible salts. Examples include the alkali metal salts, alkaline-earth
metal salts or
ammonium salts [NHõR4,], wherein x = 0, 1, 2, 3 or 4 and R represents a linear
or
branched C1-4 alkyl radical.
The substituted spiro compounds according to the invention of the above-
mentioned
general formula I and of corresponding stereoisomers can optionally also be
obtained, like the corresponding acids, the corresponding bases or salts of
these
compounds, using conventional methods known to a person skilled in the art in
the
form of their solvates, preferably in the form of their hydrates.
If the substituted Spiro compounds according to the invention of the above-
mentioned
general formula I are obtained after preparation thereof in the form of a
mixture of
their stereoisomers, preferably in the form of their racemates or other
mixtures of
their various enantiomers and/or diastereomers which can be separated and
optionally isolated using conventional methods known to a person skilled in
the art.
Examples include chromatographic separation processes, in particular liquid
chromatography processes under normal pressure or under elevated pressure,
preferably MPLC and HPLC processes, and fractionated crystallisation
processes.
These allow, in particular, the separation from one another of individual
enantiomers
of diastereomeric salts formed, for example, by means of HPLC on a chiral
stationary
53

CA 02608319 2007-11-13
GRA3304/A-PCT
phase or by means of crystallisation with chiral acids, for example (+)-
tartaric acid, (-
)-tartaric acid or (+)-10-camphorsulphonic acid.
The substituted spiro compounds according to the invention of the above-
mentioned
general formula I and corresponding stereoisomers and in each case the
corresponding acids, bases, salts and solvates are toxicologically safe and
are
therefore suitable as pharmaceutical active ingredients in medicaments.
The present invention therefore further relates to a medicament comprising at
least
one spiro compound according to the invention of the above-indicated general
formula I, in each case optionally in the form of one of its pure
stereoisomers, in
particular enantiomers or diastereomers, its racemates or in the form of a
mixture of
stereoisomers, in particular of enantiomers and/or diastereomers, in any
desired
mixing ratio, or respectively in the form of a corresponding salt, or
respectively in the
form of a corresponding solvate, and optionally one or more pharmaceutically
compatible adjuvants.
These medicaments according to the invention are suitable, in particular, for
vanilloid
receptor 1 (VR1/TRPV1) regulation, preferably for vanilloid receptor 1
(VR1/TRPV1)
inhibition and/or for vanilloid receptor 1 (VR1/TRPV1) stimulation.
Also preferably, the medicaments according to the invention are suitable for
the
prophylaxis and/or treatment of disturbances or diseases transmitted, at least
in
some cases, by vanilloid receptors 1.
Preferably, the medicament according to the invention is suitable for the
treatment
and/or prophylaxis of one or more diseases selected from the group consisting
of
pain, preferably of pain selected from the group consisting of acute pain,
chronic
pain, neuropathic pain and visceral pain; arthralgia; migraine; depression;
neuropathy; nerve injuries; neurodegenerative diseases, preferably selected
from the
group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's
disease and
Huntington's disease; cognitive dysfunctions, preferably cognitive
deficiencies,
particularly preferably paramnesia; epilepsy; respiratory diseases, preferably
selected
from the group consisting of asthma and pneumonia; coughing; urinary
incontinence;
54

CA 02608319 2007-11-13
GRA3304/A-PCT
OAB (overactive bladder); stomach ulcers; irritable bowel syndrome; strokes;
irritations of the eyes; irritations of the skin; neurotic skin diseases;
inflammatory
diseases, preferably intestinal inflammations; diarrhoea; pruritus; eating
disorders,
preferably selected from the group consisting of bulimia, cachexia, anorexia
and
obesity; medication dependency; medication abuse; withdrawal symptoms in
medication dependency; development of tolerance to medication, preferably to
natural or synthetic opioids; drug addiction; drug abuse; withdrawal symptoms
in drug
addiction; alcohol addiction; alcohol abuse and withdrawal symptoms in alcohol
addiction; for diuresis; for antinatriuresis; for influencing the
cardiovascular system;
for increasing vigilance; for increasing libido; for modulating motor
activity; for
anxiolysis; for local anaesthetics and/or for inhibiting undesirable side
effects,
preferably selected from the group consisting of hyperthermia, hypertension
and
bronchoconstriction, triggered by = the administration of vanilloid receptor 1
(VR1/TRPV1 receptor) agonists, preferably selected from the group consisting
of
capsaicin, resiniferatoxin, olvanil, arvanil, SDZ-249665, SDZ-249482, nuvanil
and
capsavanil.
Particularly preferably, the medicament according to the invention is suitable
for the
treatment and/or prophylaxis of one or more diseases selected from the group
consisting of pain, preferably of pain selected from the group consisting of
acute
pain, chronic pain, neuropathic pain and visceral pain; migraine; depression;
neurodegenerative diseases, preferably selected from the group consisting of
multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's
disease; cognitive dysfunctions, preferably cognitive deficiencies,
particularly
preferably paramnesia; urinary incontinence; OAB (overactive bladder);
medication
dependency; medication abuse; withdrawal symptoms in medication dependency;
development of tolerance to medication, preferably development of tolerance to
natural or synthetic opioids; drug addiction; drug abuse; withdrawal symptoms
in drug
addiction; alcohol addiction; alcohol abuse and withdrawal symptoms in alcohol
addiction.
Most particularly Preferably, the medicament according to the invention is
suitable for
the treatment and/or prophylaxis of pain, preferably of pain selected from the
group

CA 02608319 2007-11-13
GRA3304/A-PCT
consisting of acute pain, chronic pain, neuropathic pain and visceral pain,
and/or
urinary incontinence.
The present invention further relates to the use of at least one substituted
spiro
compound according to the invention, including the compounds excluded
hereinbefore, and optionally of one or more pharmaceutically compatible
adjuvants
for producing a medicament for vanilloid receptor 1 (VR1/TRPV1) regulation,
preferably for vanilloid receptor 1 (VR1/TRPV1) inhibition and/or for
vanilloid receptor
1 (VR1fTRPV1) stimulation.
Preferred is the use of at least one substituted spiro compound according to
the
invention, including the compounds excluded hereinbefore, and optionally of
one or
more pharmaceutically compatible adjuvants for producing a medicament for the
prophylaxis and/or treatment of disturbances or diseases transmitted, at least
in
some cases, by vanilloid receptors 1.
Particularly preferred is the use of at least one substituted spiro compound
according
to the invention, including the compounds excluded hereinbefore, and
optionally of
one or more pharmaceutically compatible adjuvants for producing a medicament
for
the treatment and/or prophylaxis of one or more diseases selected from the
group
consisting of pain, preferably of pain selected from the group consisting of
acute
pain, chronic pain, neuropathic pain and visceral pain; arthralgia; migraine;
depression; neuropathy; nerve injuries; neurodegenerative diseases, preferably
selected from the group consisting of multiple sclerosis, Alzheimer's disease,
Parkinson's disease and Huntington's disease; cognitive dysfunctions,
preferably
cognitive deficiencies, particularly preferably paramnesia; epilepsy; urinary
incontinence; OAB (overactive bladder); stomach ulcers; irritable bowel
syndrome;
strokes; diarrhoea; pruritus; eating disorders, preferably selected from the
group
consisting of bulimia, cachexia, anorexia and obesity; medication dependency;
medication abuse; withdrawal symptoms in medication dependency; development of
tolerance to medication, preferably to natural or synthetic opioids; drug
addiction;
drug abuse; withdrawal symptoms in drug addiction; alcohol addiction; alcohol
abuse
and withdrawal symptoms in alcohol addiction; for diuresis; for
antinatriuresis; for
influencing the cardiovascular system; for increasing vigilance; for
increasing libido;
56

CA 02608319 2007-11-13
GRA3304/A-PCT
for modulating motor activity; for anxiolysis; for local anaesthetics and/or
for inhibiting
undesirable side effects, preferably selected from the group consisting of
hyperthermia, hypertension and bronchoconstriction, triggered by the
administration
of vanilloid receptor 1 (VR1/TRPV1 receptor) agonists, preferably selected
from the
group consisting of capsaicin, resiniferatoxin, olvanil, arvanil, SDZ-249665,
SDZ-
249482, nuvanil and capsavanil.
Also particularly preferred is the use of at least one substituted spiro
compound
according to the invention and optionally of one or more pharmaceutically
compatible
adjuvants for producing a medicament for the treatment and/or prophylaxis of
one or
more diseases selected from the group consisting of respiratory diseases,
preferably
selected from the group consisting of asthma and pneumonia; coughing;
irritations of
the eyes; irritations of the skin; neurotic skin diseases; and inflammatory
diseases,
preferably intestinal inflammations.
Most particularly preferred is the use of at least one substituted spiro
compound
according to the invention, including the compounds excluded hereinbefore, and
optionally of one or more pharmaceutically compatible adjuvants for producing
a
medicament for the treatment and/or prophylaxis of one or more diseases
selected
from the group consisting of pain, preferably of pain selected from the group
consisting of acute pain, chronic pain, neuropathic pain and visceral pain;
migraine;
depression; neurodegenerative diseases, preferably selected from the group
consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease and
Huntington's disease; cognitive dysfunctions, preferably cognitive
deficiencies,
particularly preferably paramnesia; urinary incontinence; OAB (overactive
bladder);
medication dependency; medication abuse; withdrawal symptoms in medication
dependency; development of tolerance to medication, preferably development of
tolerance to natural or synthetic opioids; drug addiction; drug abuse;
withdrawal
symptoms in drug addiction; alcohol addiction; alcohol abuse and withdrawal
symptoms in alcohol addiction.
Still more preferred is the use of at least one substituted spiro compound
according
to the invention, including the compounds excluded hereinbefore, and
optionally of
one or more pharmaceutically compatible adjuvants for producing a medicament
for
57

CA 02608319 2007-11-13
GRA3304/A-PCT
the treatment and/or prophylaxis of pain, preferably selected from the group
consisting of acute pain, chronic pain, neuropathic pain and visceral pain,
and/or
urinary incontinence.
The medicament according to the invention is suitable for administration to
adults and
children, including toddlers and babies.
The medicament according to the invention can be provided as a liquid,
semisolid or
solid pharmaceutical dosage form, for example in the form of injection
solutions,
drops, juices, syrups, sprays, suspensions, tablets, patches, capsules,
plasters,
suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in
multiparticulate form, for example in the form of pellets or granules,
optionally
compressed to form tablets, introduced into capsules or suspended in a liquid,
and
also be administered as such.
In addition to at least one substituted spiro compound of the above-indicated
general
formula I, optionally in the form of one of its pure stereoisomers, in
particular
enantiomers or diastereomers, its racemate or in the form of mixtures of
stereoisomers, in particular of enantiomers or diastereomers, in any desired
mixing
ratio, or optionally in the form of a corresponding salt or respectively in
the form of a
corresponding solvate, the medicament according to the invention
conventionally
comprises further physiologically compatible pharmaceutical adjuvants which
can be
selected, for example, from the group consisting of excipients, fillers,
solvents,
diluting agents, surface-active substances, dyes, preservatives,
disintegrants, slip
additives, lubricants, aroma substances and binding agents.
The selection of the physiologically compatible adjuvants and the amounts
thereof to
be used are dependent on whether the medicament is to be administered orally,
subcutaneously, parenterally, intravenously, intraperitoneally, intradermally,
intramuscularly, intranasally, buccally, rectally or locally, for example to
infections on
the skin which mucous membranes and on the eyes. Preferably suitable for oral
administration are preparations in the form of tablets, dragees, capsules,
granules,
pellets, drops, juices and syrups, for parenteral, solutions to be
administered topically
and by inhalation, suspensions, easily reconstitutable dry preparations and
sprays.
58

CA 02608319 2013-03-21
=
29732-50
The substituted Spiro compounds according to the invention used in the
medicament
according to the invention in a repository in dissolved form or in a plaster,
optionally
with the addition of means promoting skin penetration, are suitable
percutaneous
administration preparations. Preparation forms to be administered orally or
percutaneously can also release the respective substituted Spiro compound
according to the invention in a delayed manner.
The medicaments according to the invention are prepared using conventional
means,
devices, methods and processes known in the art such as are described, for
example, in õRemington's Pharmaceutical Sciences", A.R. Gennaro (Editor), 17th
edition, Mack Publishing Company, Easton, Pa, 1985, in particular in Part 8,
Chapters 76 to 93.
The amount to be administered to the
patient of the respective substituted spiro compounds according to the
invention of
the above-indicated general formula I may vary and is, for example, dependent
on
the patient's weight or age and on the type of administration, indication and
the
severity of the disease. Conventionally, 0.001 to 100 mg/kg, preferably 0.05
to 75
mg/kg, particularly preferably 0.05 to 50 mg/kg of the patient's body weight
of at least
one compound of this type according to the invention are administered.
59

CA 02608319 2007-11-13
GRA3304/A-PCT
Pharmacological methods:
I. Functional testing carried out on the vanilloid receptor 1 (VRI/TRPV1
receptor)
The agonistic or antagonistic effect of the substances to be tested can be
determined on the rat-species vanilloid receptor 1 (VR1/TRPV1) using the
following
assay. According to this assay, the Ca2+ inflow is quantified through the
receptor
channel using a Ca2+-sensitive dye (type Fluo-4, Molecular Probes Europe By,
Leiden, Netherlands) in a fluorescent imaging plate reader (FLIPR, Molecular
Devices, Sunnyvale, USA).
Method:
Complete medium: 50 mL HAMS F12 nutrient mixture (Gibco Invitrogen GmbH,
Karlsruhe, Germany) with
% by volume of FCS (foetal calf serum, Gibco Invitrogen GmbH, Karlsruhe,
Germany, heat-activated);
2mM L-glutamine (Sigma, Munich, Germany);
1 % by weight of AA solution (antibiotic/antimyotic solution, PAA, Pasching,
Austria)
and 25 ng/ml NGF medium (2.5 S, Gibco Invitrogen GmbH, Karlsruhe, Germany)
Cell culture plate: Poly-D-lysine-coated, black 96 well plates having a clear
base (96
well black/clear plate, BD Biosciences, Heidelberg, Germany) were additionally
coated with laminin (Gibco Invitrogen GmbH, Karlsruhe, Germany), the laminin
being
diluted with PBS (Ca-Mg-free PBS, Gibco Invitrogen GmbH, Karlsruhe, Germany)
to
a concentration of 100 pg/mL. Aliquots having a laminin concentration of 100
pg/mL
were removed and stored at -20 C. The aliquots were diluted with PBS in a
ratio of
1:10 to 10 pg/mL laminin and in each case 50 pL of the solution were pipetted
into a
recess in the cell culture plate. The cell culture plates were incubated for
at least two
hours at 37 C, the excess solution was removed by suction-filtration and the
recesses were each washed twice with PBS. The coated cell culture plates were
stored with excess PBS which was not removed until just before the feeding of
the
cells.

CA 02608319 2007-11-13
GRA3304/A-PCT
Preparation of the cells:
The vertebral column was removed from decapitated rats and placed immediately
into cold HBSS buffer (Hank's buffered saline solution, Gibco Invitrogen GmbH,
Karlsruhe, Germany), i.e. buffer located in an ice bath, mixed with 1 % by
volume
(per cent by volume) of an AA solution (antibiotic/antimyotic solution, PAA,
Pasching,
Austria). The vertebral column was cut longitudinally and removed together
with
fasciae from the vertebral canal. Subsequently, the dorsal root ganglia (DRG)
were
removed and again stored in cold HBSS buffer mixed with 1 A) by volume of an
AA
solution. The DRG, from which all blood remnants and spinal nerves had been
removed, were transferred in each case to 500 pL of cold type 2 collagenase
(PAA,
Pasching, Austria) and incubated for 35 minutes at 37 C. After the addition
of 2.5 %
by volume of trypsin (PAA, Pasching, Austria), incubation was continued for 10
minutes at 37 C. After complete incubation, the enzyme solution was carefully
pipetted off and 500 pL of complete medium were added to each of the remaining
DRG. The DRG were in each case suspended several times, drawn through
cannulae No. 1, No. 12 and No. 16 using a syringe and transferred to a 50 mL
Falcon
tube which was filled up to 15 mL with complete medium. The contents of each
Falcon tube was in each case filtered through a 70 pm Falcon filter element
and
centrifuged for 10 minutes at 1,200 rpm and room temperature. The resulting
pellet
was in each case taken up in 250 pL of complete medium and the number of cells
determined.
The number of cells in the suspension was set to 3 x 105 per mL and 150 pL of
this
suspension were in each case introduced into a recess in the cell culture
plates
coated as described hereinbefore. In the incubator the plates were left for
two to
three days at 37 C, 5 A) by volume of CO2 and 95 A) relative humidity.
Subsequently, the cells were loaded with 2 pM of Fluo-4 and 0.01 % by volume
of
Pluronic F127 (Molecular Probes Europe By, Leiden, Netherlands) in HBSS buffer
(Hank's buffered saline solution, Gibco Invitrogen GmbH, Karlsruhe, Germany)
for
30 min at 37 C, washed 3 times with HBSS buffer and after further incubation
for 15
minutes at room temperature used for Ca2+ measurement in a FLIPR assay. The
Ca2+-dependent fluorescence was measured before and after the addition of
61

CA 02608319 2007-11-13
GRA3304/A-PCT
substances (?ex = 488 nm, Xem = 540 nm). Quantification was carried out by
measuring the highest fluorescence intensity (FC, Fluorescence Counts) over
time.
FLIPR assay:
The FLIPR protocol consists of 2 substance additions. First the compounds to
be
tested (10 pM) were pipetted onto the cells and the Ca2+ inflow was compared
with
the control (capsaicin 10 pM). This provides the result in % activation based
on the
Ca24. signal after the addition of 10 pM capsaicin (OF). After 5 minutes'
incubation,
100 nM of capsaicin were administered and the Ca2+inflow was also determined.
Desensitising agonists and antagonists led to suppression of the Ca2+ inflow.
The %
inhibition was calculated compared to the maximum achievable inhibition with
10 pM
of capsaicin.
Triple analyses (n=3) were carried out and repeated in at least 3 independent
experiments (N=4).
II. Functional testing carried out on the vanilloid receptor (VR1)
The agonistic or antagonistic effect of the substances to be tested can also
be
determined on the vanilloid receptor (VR1) using the following assay.
According to
this assay, the Ca2+ inflow is quantified through the channel using a Ca2+-
sensitive
dye (type Fluo-4, Molecular Probes Europe By, Leiden, Netherlands) in a
fluorescent
imaging plate reader (FLIPR, Molecular Devices, Sunnyvale, USA).
62

CA 02608319 2007-11-13
GRA3304/A-PCT
Method:
Chinese hamster ovary cells (CHO K1 cells, European Collection of Cell
Cultures
(ECACC) United Kingdom) were stably transfected with the VR1 gene. For
functional
testing, these cells were plated out on poly-D-lysine-coated black 96 well
plates
having a clear base (BD Biosciences, Heidelberg, Germany) at a density of
25,000
cells/well. The cells were incubated overnight at 37 C and 5 % CO2 in a
culture
medium (Ham's F12 nutrient mixture, 10% by volume of FCS (foetal calf serum),
18
pg/ml L-proline). The next day the cells were incubated with Fluo-4 (Fluo-4 2
pM,
0.01 % by volume of Pluronic F127, Molecular Probes in HBSS (Hank's buffered
saline solution), Gibco lnvitrogen GmbH, Karlsruhe, Germany) for 30 minutes at
37
C. Subsequently, the plates were washed three times with HBSS buffer and after
further incubation for 15 minutes at room temperature used for Ca2+
measurement in
a FLIPR assay. The Ca2+-dependent fluorescence was measured before and after
the addition of the substances to be tested (?ex wavelength = 488 nm, kern =
540
nm). Quantification was carried out by measuring the highest fluorescence
intensity
(FC, Fluorescence Counts) over time.
FLIPR assay:
The FLIPR protocol consists of 2 substance additions. First the compounds to
be
tested (10 pM) were pipetted onto the cells and the Ca2+ inflow was compared
with
the control (capsaicin 10 pM) (c1/0 activation based on the Ca2+ signal after
the
addition of 10 pM capsaicin). After 5 minutes' incubation, 100 nM of capsaicin
were
administered and the Ca2+inflow was also determined.
Desensitising agonists and antagonists led to suppression of the Ca2+ inflow.
The %
inhibition was calculated compared to the maximum achievable inhibition with
10 pM
of capsaicin.
63

CA 02608319 2013-03-21
= 29732-50
Ill. Formalin test carried out on mice
In the formalin test, the testing to determine the antinociceptive effect of
the
compounds according to the invention was carried out on male mice (NMRI, 20 to
30
g body weight, Iffa, Credo, Belgium).
In the formalin test as described by D. Dubuisson et al., Pain 1977, 4, 161-
174, a
distinction is drawn between the first (early) phase (0 to 15 minutes after
the injection
of formalin) and the second (late) phase (15 to 60 minutes after the injection
of
formalin). The early phase, as an immediate reaction to the injection of
formalin, is a
model of acute pain, whereas the late phase is regarded as a model of
persistent
(chronic) pain (T.J. Coderre et al., Pain 1993, 52, 259-285).
The compounds according to the invention were tested in the second phase of
the
formalin test to obtain information about the effects of substances on
chronic/inflammatory pain.
The moment at which the compounds according to the invention were administered
before the injection of formalin was selected as a function of the type of
administration. 10 mg of the test substances/kg of body weight were
administered
intravenously 5 minutes before the injection of formalin which was carried out
by a
single subcutaneous injection of formalin (20 pL, 1 % aqueous solution) into
the
dorsal side of the right hind paw, thus inducing in free moving test animals a
nociceptive reaction which manifests itself in marked licking and biting of
the
respective paw.
Subsequently, the nociceptive behaviour was continuously detected by observing
the
animals over a test period of three minutes in the second (late) phase of the
formalin
test (21 to 24 minutes after the injection of formalin). The pain behaviour
was
quantified by adding up the seconds over which the animals displayed licking
and
biting of the respective paw during the test period.
64

CA 02608319 2013-03-21
29732-50
The comparison was carried out in each case with control animals which were
given
vehicles (0.9 % aqueous sodium chloride solution) instead of the compounds
according to the invention before the administration of formalin. Based on the
quantification of the pain behaviour, the effect of the substance was
determined in
the formalin test as a percentage change relative to the corresponding
control.
After the injection of substances having an antinociceptive effect in the
formalin test,
the described behaviour of the animals, i.e. licking and biting, was reduced
or
eliminated.
IV. Testing of analgesic efficacy in the writhing test
The testing of analgesic efficacy in the compounds according to the invention
of
general formula I was carried out by phenylquinone-induced writhing in mice
(modified in accordance with I.C. Hendershot and J. Forsaith (1959), J.
Pharmacol.
Exp. Ther. 125, 237-240).
Male NMR1 mice weighing from 25 to 30 g were used for this purpose. 10 minutes
after intravenous administration of the compounds to be tested, groups of 10
animals
per compound dose received 0.3 ml/mouse of a 0.02 % aqueous solution of
phenylquinone (phenylbenzoquinone, Sigma, Deisenhofen, Germany; solution
prepared by adding 5 % by weight of ethanol and stored in a water bath at 45
C)
administered intraperitoneally. The animals were placed individually into
observation
cages. A pushbutton counter was used to record the number of pain-induced
stretching movements (what are known as writhing reactions = straightening of
the
torso with stretching of the rear extremities) for 5 to 20 minutes after
phenylquinone
administration. The control was provided by animals which had received only
physiological saline solution. All of the compounds were tested at the
standard
dosage of 10 mg/kg.
The invention will be described hereinafter with reference to a few examples.
This
description is intended merely by way of example and does not limit the
general idea
of the invention.

CA 02608319 2007-11-13
GRA3304/A-PCT
Examples:
The yields of the compounds prepared are not optimised.
All temperatures are uncorrected.
Abbreviations:
abs. absolute
aq. aqueous
eq. equivalent amount of substance
CDI N,N'-carbonyldiimidazole
DCM dichloromethane
DMF dimethylformamide
Et0Ac ethyl acetate
Et0H ethanol
sat. saturated
Me0H methanol
RT room temperature
THF tetrahydrofuran
The chemicals and solvents used were purchased from the conventional suppliers
(Acros, Avocado, Aldrich, Bachem, Fluka, Lancaster, Maybridge, Merck, Sigma,
TCI,
etc.) or synthesised using the methods known to a person skilled in the art.
The stationary phase used for the column chromatography was silica gel 60
(0.040 -
0.063 mm) from E. Merck, Darmstadt.
The thin-layer chromatographic tests were carried out using HPTLC precoated
plates, silica gel 60 F 254, from E. Merck, Darmstadt.
The mixing ratios of solvents, mobile solvents or for chromatographic tests
are in
each case specified in volume/volume.
The analysis was carried out by mass spectroscopy and NMR.
66

CA 02608319 2007-11-13
GRA3304/A-PCT
1.a. Synthesis of 1-tert-buty1-4-methylenecyclohexane
Methyltriphenylphosphonium bromide (17.4 g, 48.6 mmol) was placed in abs.
diethyl
ether (106 ml) under a nitrogen atmosphere. Potassium tert-butylate (5.0 g,
45.4
mmol) was slowly added at 0 C. After 30 min, 4-tert-butylcyclohexanone (5.0
g, 32.4
mmol) as a solution in diethyl ether (10 ml) was slowly added dropwise, again
at 0
C. The reaction mixture was stirred overnight at RT. For working up, the
reaction
mixture was cooled in an ice bath and mixed with sat. aq. NH4C1 solution. The
phases were separated and the aqueous phase was shaken out several times with
diethyl ether. The combined organic phases were dried over magnesium sulphate
and the solvent was removed under vacuum. After column chromatography (silica
gel, hexane/Et0Ac 2:1), the desired compound 1-tert-butyl-4-
methylenecyclohexane
was obtained as a colourless liquid (3.93 g, 80 % of the theoretical amount).
1.b. Synthesis of 1-(1,1-dimethylpropyI)-4-methylenecyclohexane
A solution of potassium tert-butylate (4.2 g, 37.6 mmol) in abs. THF (40 ml)
was
added dropwise to a suspension of methyltriphenylphosphonium bromide (15 g, 42
mmol) in abs. THF (40 ml) at 0 C under argon within 30 min. There formed a
yellow
mixture which was stirred for 30 min at 0 C. Within 20 min, the ketone 4-(1,1-
dimethylpropyl)cyclohexanone (5.04 g, 30 mmol), dissolved in abs. THF (20 ml)
was
subsequently added at 0 C. The mixture was stirred for 30 min while being
cooled
with ice, the ice bath removed and the mixture stirred for 1.5 h at RT. For
working up
the mixture, the solvent was removed under vacuum and the remaining yellow
crystal
mass taken up in a mixture of sat. aq. NH4C1 solution (150 ml) and Et0Ac (180
ml).
The phases were separated and the aqueous phase was extracted with Et0Ac (2 x
150 ml). The combined organic phases were dried and concentrated. The residue
was washed with cyclohexane (3 x 60 ml) and the undissolved triphenylphosphin
oxides were separated off by filtration. After concentration of the filtrate,
the crude
product remained as a colourless oil. After chromatographic purification of
the crude
67

= CA 02608319 2007-11-13
GRA3304/A-PCT
product [silica gel 60(100 g); cyclohexane (10], the olefin 1-(1,1-
dimethylpropyI)-4-
methylenecyclohexane was isolated as a colourless oil in a yield of 99 A)
(4.9 g).
1.c. Synthesis of 4-methylenebicyclohexyl
A solution of potassium tert-butylate (3.45 g, 31 mmol) in abs. THF (40 ml)
was
added dropwise to a suspension of methyltriphenylphosphonium bromide (12.0 g,
34
mmol) in abs. THF (70 ml) at 0 C under argon within 30 min. There formed a
yellow
mixture which was stirred for 30 min at 0 C. 4-Cyclohexylcyclohexanone (4.32
g, 24
mmol), dissolved in abs. THF (30 ml) was subsequently added within 20 min at 0
C.
The mixture was stirred for 30 min while being cooled with ice and for 1.5 h
at RT.
For working up the mixture, the solvent was removed under vacuum and the
remaining yellow crystal mass taken up in a mixture of sat. aq. NH4CI solution
(50 ml)
and Et0Ac (60 ml). Between the phases there remained undissolved a portion of
the
triphenylphosphin oxide formed which was separated off by filtration. The
phases
were separated from the filtrate and the aqueous phase was extracted with
Et0Ac (2
x 60 ml). The combined organic phases were dried and concentrated. The residue
was washed with cyclohexane (3 x 80 ml) and the undissolved triphenylphosphin
oxide separated off by filtration. After concentration of the filtrate, the
crude product of
the olefin 4-methylenebicyclohexyl remained as a colourless oil. After
chromatographic purification of the crude product [silica gel 60 (70 g);
cyclohexane
(400 ml)], the olefin 4-methylenebicyclohexyl was isolated as a colourless oil
in a
yield of 92 % (3.94 g).
68

CA 02608319 2007-11-13
= GRA3304/A-PCT
2.a. Synthesis of 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic
acid
ethyl ester
0
CI
0
,OH
= --IN
0
0
A solution of 2-chloro-2-hydroxyiminoacetic acid ethyl ester (2.2 g, 14.6
mmol) in
DCM (20 ml) was slowly added dropwise at 0 C to a solution of 1-tert-butyl-4-
methylenecyclohexane (740 mg, 4.86 mmol) in DCM (20 ml). Subsequently, a
solution of triethylamine (1.5 ml) in DCM (10 ml) was slowly added dropwise at
0 C
and the resulting mixture was stirred overnight at RT. The reaction mixture
was
diluted with water. The aqueous phase was extracted several times with DMC.
The
combined organic phases were dried and the solvent was removed under vacuum.
After purification of the residue (silica gel, hexane/ether 2:1) by column
chromatography, the desired product 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-
ene-3-
carboxylic acid ethyl ester was obtained as a yellowish liquid (1.21 g, 93 %
of the
theoretical amount).
2.b. 8-(1,1-dimethylpropyI)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
ethyl ester
A solution of the olefin 1-(1,1-dimethylpropyI)-4-methylenecyclohexane (4.9 g,
30
mmol) in abs. DCM (140 ml) was mixed with 2-chloro-2-hydroxyiminoacetic acid
ethyl
ester (22.74 g, 150 mmol) under argon and while being cooled with ice. The
solution
was subsequently cooled down to - 5 C. Within 1 h, a solution of
triethylamine (20.9
ml, 15.2 g, 150 mmol) in abs. DCM (70 ml) was added dropwise in such a way
that
the internal temperature did not exceed 0 C. Subsequently, the mixture was
stirred
for 3 d at RT. Triethylamine hydrochloride was gradually precipitated. For
working up,
the reaction mixture was washed with 10 % aq. citric acid solution (3 x 70 ml)
and
with sat. aq. NaHCO3 solution (70 ml). The organic phase was dried and
69

CA 02608319 2007-11-13
=
GRA3304/A-PCT
concentrated. There was obtained a yellow oil (19.9 g) which was separated by
column chromatography [silica gel 60 (300 g); Et0Ac/cyclohexane (1:7, 2.5 I)].
The
ester 8-(1,1-dimethylpropyI)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
ethyl
ester was isolated as a colourless solid in a yield of 36 % (3.0 g) having a
melting
point of 82-87 C.
2c. Synthesis of 8-cyclohexy1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
ethyl ester
A solution of the olefin 4-methylenebicyclohexyl (3.9 g, 21.9 mmol) in abs.
DCM (100
ml) was mixed with 2-chloro-2-hydroxyiminoacetic acid ethyl ester (16.52 g,
109
mmol) under argon and while being cooled with ice. The solution was
subsequently
cooled down to - 5 C. Within 1 h, a solution of triethylamine (15.2 ml, 109
mmol) in
abs. DCM (45 ml) was added dropwise in such a way that the internal
temperature
did not exceed 0 C. Subsequently, the mixture was stirred for 20 h at RT.
Triethylamine hydrochloride gradually precipitated. For working up, the
reaction
mixture was washed with 10 A aq. citric acid solution (3 x 100 ml) and with
sat. aq.
NaCI solution (70 m1). The organic phase was dried and concentrated. There was
obtained a yellow oil (17.8 g) which was separated by column chromatography
[silica
gel 60 (200 g); cyclohexane/Et0Ac/7:1 (1 I)]. The ester 8-cyclohexy1-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxylic acid ethyl ester was isolated as a
colourless
solid in a yield of 39 % (2.5 g) having a melting point of 64-71 C.
3.a. Synthesis of 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic
acid
HO
0
=
0
0 --N
0
=
0
A mixture of 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
ethyl ester
(2.4 g, 9 mmol) in Me0H (50 ml) and lithium hydroxide monohydrate (1 g, 13.5
mmol)
in H20 (8 ml) was stirred overnight at RT. After removal of the solvent under
vacuum,

CA 02608319 2007-11-13
GRA3304/A-PCT
the residue was taken up in 10 A) aq. citric acid solution and Et0Ac and the
phases
were separated. The aqueous phase was extracted several times with Et0Ac,
dried
over magnesium sulphate and desolventised under vacuum. 2.17 g (100% of the
theoretical amount) of the free acid 8-tert-buty1-1-oxa-2-azaspiro[4.5]clec-2-
ene-3-
carboxylic acid was obtained in the form of a colourless solid.
3.b. Synthesis of 8-(1,1-dimethylpropyI)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-
carboxylic acid
The ester 8-(1,1-dimethylpropy1)-1-oxa-2-azaspiro[4.5]clec-2-ene-3-carboxylic
acid
ethyl ester (2.8 g, 10 mmol) was dissolved in Me0H (50 ml), mixed with lithium
hydroxide (357 mg, 15 mmol) in water (8 ml) and stirred for 23 h at RT. For
working
up the mixture, Me0H was removed under vacuum and water (25 ml) added. After
the addition of 10 % aq. citric acid solution (20 ml), there formed at a pH of
4 the acid
8-(1,1-dimethylpropy1)-1-oxa-2-azaspiro[4.5]clec-2-ene-3-carboxylic acid. The
mixture
was stirred for a further 1 h at RT, removed by suction-filtration and washed
with
water (3 x 25 ml). The acid was isolated as a colourless solid in a yield of
99 % (2.55
g).
3.c. Synthesis of 8-cyclohexy1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic
acid
The ester 8-cyclohexy1-1-oxa-2-azaspiro[4.5]clec-2-ene-3-carboxylic acid ethyl
ester
(2.5 g, 8.5 mmol) was dissolved in Me0H (80 ml) while being heated, mixed with
lithium hydroxide (306 mg, 13 mmol) in water (8 ml) and stirred for 60 h at
RT. For
working up the mixture, Me0H was removed under vacuum and water (25 ml) added.
After the addition of 10 % aq. citric acid solution (20 ml), there formed at a
pH of 4 the
acid 8-cyclohexy1-1-oxa-2-azaspiro[4.5]clec-2-ene-3-carboxylic acid. The
mixture was
stirred for a further 1 h at RT, removed by suction-filtration and washed with
water (3
x 25 ml). The acid 8-cyclohexy1-1-oxa-2-azaspiro[4.5]clec-2-ene-3-carboxylic
acid
was isolated as a colourless solid in a yield of 82 % (1.84 g) having a
melting point of
139-142 C.
4. General directions for reacting 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-
3-
carboxylic acid or 3',4',4a',5',6',7',8',8a'-octahydro-1 'H,4H-spiro[isoxazol-
5,2%
71

CA 02608319 2007-11-13
GRA3304/A-PCT
naphthalene]-3-carboxylic acid with amines of general formula HNR13R14
The cornpound 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid or
3',4',4a',51,6',7',8',8a'-octahydro-111-1,4H-spiro[isoxazol-5,2'-naphthalene]-
3-carboxylic
acid (in each case 1 eq.), the amine of general formula HNR13R14 (1 eq.), 4-
methylmorpholine (3 eq.) and 0-(benzotriazol-1-y1)-N,N,N`,N`-
tetramethyluronium
hexafluorophosphate (3 eq.) (HBTU) were dissolved in DMF and stirred overnight
under a nitrogen atmosphere at RT. The solvent was removed under vacuum, the
residue taken up in Et0Ac and sat. aq. NaHCO3 solution and the phases were
separated. The aqueous phase was extracted several times with Et0Ac and the
combined organic phases were dried over magnesium sulphate and the solvent was
removed under vacuum. After purification by column chromatography, the desired
product was obtained as a diastereomer mixture.
4a. Synthesis of exemplary compound 54:
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(4-tert-
butylphenyl)amide
HO
=
0 101 NH
--N
0 I 0
= 0--IN
The compound 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(220
mg, 0.91 mmol), 4-tert-butylaniline (137 mg, 0.91 mmol), 4-methylmorpholine
(279
mg, 2.76 mmol) and 0-(benzotriazol-1-y1)-N,N,M,N'-tetramethyluronium
hexafluorophosphate (528 mg, 1.20 mmol) (HBTU) were dissolved in DMF (10 ml)
and stirred overnight under a nitrogen atmosphere at RT. The solvent was
removed
under vacuum, the residue taken up in Et0Ac and sat. aq. NaHCO3 solution and
the
phases were separated. The aqueous phase was extracted several times with
Et0Ac
and the combined organic phases were dried over magnesium sulphate and the
solvent was removed under vacuum. After purification by column chromatography
(silica gel, ether/hexane 2:1), the desired product 8-tert-butyl-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxylic acid-(4-tert-butylphenyl)amide was
obtained as a
72

CA 02608319 2007-11-13
GRA3304/A-PCT
diastereomer mixture in a yield of 80 mg (24 % of the theoretical amount).
4b. Synthesis of exemplary compounds 7 and 25:
cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-fluoro-4-
methanesulphonylaminobenzylamide and trans-8-tert-butyl-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-fluoro-4-
methanesulphonylaminobenzylamide
HN-S-
0 F
HO (21
HN
0 0
= II
HN-S -
II
OF
0
=
The compound 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(120
mg, 0.51 mmol), N-(4-aminomethy1-2-fluorophenyl)methanesulphonamide (110 mg,
0.51 mmol), 4-methylmorpholine (101 mg, 1.02 mmol) and 0-(benzotriazol-1-y1)-
N,N,N`,N`-tetramethyluronium hexafluorophosphate (288 mg, 0.65 mmol) (HBTU)
were dissolved in DMF (10 ml) and stirred overnight under a nitrogen
atmosphere at
RT. The solvent was removed under vacuum, the residue taken up in Et0Ac and
sat.
aq. NaHCO3 solution and the phases were separated. The aqueous phase was
extracted several times with Et0Ac and the combined organic phases were dried
over magnesium sulphate and the solvent was removed under vacuum. After
purification by column chromatography (silica gel, hexane/Et0Ac 2:1), the
desired
product 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(4-tert-
butylphenyl)amide was obtained as a trans isomer (30 mg, 13 % of the
theoretical
amount) and cis isomer (100 mg, 45 % of the theoretical amount).
4c. Synthesis of exemplary compounds 5 and 6:
73

CA 02608319 2007-11-13
. ,
GRA3304/A-PCT
trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-thiazol-2-
ylpiperazin-1-
yl)methanone and cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-
thiazol-2-ylpiperazin-1-yl)methanone
HO 0
¨
=
N N
0 o
N
--N
N\.,)
N
The compound 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(120
mg, 0.51 mmol), 1-thiazol-2-ylpiperazine (110 mg, 0.51 mmol), 4-
methylmorpholine
(101 mg, 1.02 mmol) and 0-(benzotriazol-1-y1)-N,N,N`N-tetramethyluronium
hexafluorophosphate (288 mg, 0.65 mmol) (HBTU) were dissolved in DMF (10 ml)
and stirred overnight under a nitrogen atmosphere at RT. The solvent was
removed
under vacuum, the residue taken up in Et0Ac and sat. aq. NaHCO3 solution and
the
phases were separated. The aqueous phase was extracted several times with
Et0Ac
and the combined organic phases were washed with sat. aq. NaCI solution, dried
over magnesium sulphate and the solvent was removed under vacuum. After
purification by column chromatography (silica gel, hexane/Et0Ac 3:1), the
desired
product (8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-yI)-(4-thiazol-2-
ylpiperazin-1-
yl)methanone was obtained as a trans isomer (50 mg, 26 % of the theoretical
amount) and as a cis isomer (100 mg, 51 % of the theoretical amount).
4d. Synthesis of exemplary compounds 28 and 29:
trans-(8-tert-butyl-1-oxa-2-za-spiro[4.5]dec-2-en-3-y1)44-(3-chloropyridin-2-
yl)piperazin-1-yl]methanone and cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-
en-
3-y1)44-(3-chloropyridin-2-Apiperazin-1-yl]methanone
74

CA 02608319 2007-11-13
GRA3304/A-PCT
0
0
HO
6, 0,
N¨\
0
ojN
cI
The compound 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(150
mg, 0.63 mmol), 1-(3-chloropyridin-2-yl)piperazine (361 mg, 0.82 mmol), 4-
methylmorpholine (190 mg, 1.88 mmol) and 0-(benzotriazol-1-y1)-N,N,NI,N`-
tetramethyluronium hexafluorophosphate (361 mg, 0.81 mmol) (HBTU) were
dissolved in DMF (10 ml) and stirred overnight under a nitrogen atmosphere at
RT.
The solvent was removed under vacuum, the residue taken up in Et0Ac and sat.
aq.
NaHCO3 solution and the phases were separated. The aqueous phase was extracted
several times with Et0Ac and the combined organic phases were washed with sat.
aq. NaC1 solution, dried over magnesium sulphate and the solvent was removed
under vacuum. After purification by column chromatography (silica gel,
ether/hexane
2:1), the desired product (8-tert-buty1-1-oxa-2-za-spiro[4.5]dec-2-en-3-y1)44-
(3-
chloropyridin-2-yl)piperazin-1-yl]methanone was obtained as a cis isomer (100
mg,
38 % of the theoretical amount) and as a trans isomer (90 mg, 34 % of the
theoretical
amount).
4e. Synthesis of exemplary compound 90:
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(3-fluoro-4-
methanesulphonylaminophenyl)amide
The acid 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (359
mg, 1.5
mmol) was dissolved in THF (15 m1). N,N'-carbonyldiimidazole (243.5 mg, 1.5
mmol)
was added while stirring. For activation, the mixture was stirred for 1 h at
RT. The N-
(4-amino-2-fluorophenyl)methanesulphonamide (326.8 mg, 1.60 mmol) was then
added as a solid. The course of the reaction was controlled by DC. After 3 d
only
small amounts of starting products could still be seen in the DC. For working
up, THF
was removed by distillation. The residue was dissolved in 0.5 N aq. HCI (10
ml) and

CA 02608319 2007-11-13
GRA3304/A-PCT
Et0Ac (40 ml). The phases were separated. The organic phase was washed
successively with 0.5 N aq. HC1 (2 x 8 ml), with water (1 x 10 ml), with 1.1 M
aq.
NaHCO3 solution (3 x 7 ml) and water (3 x 10 m1). The organic phase was dried
with
Na2SO4. The solvent was removed by distillation. The light brown residue was
stirred
out with diethyl ether (3 x 2 ml). The solvent was in each case removed by
suction-
filtration. The light pink residue was the mixture of the diastereoisomers of
8-tert-
buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(3-fluoro-4-
methanesulphonylaminophenyl)amide (353 mg, mp 104-107 C and 228-232 C, 55
0/0).
4f. Synthesis of exemplary compound 91:
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid43-fluoro-4-
(bismethanesulphonyl)aminophenyllamide
The acid 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (292.8
mg,
1.22 mmol) was dissolved in THF (12 ml). N,N'-carbonyldiimidazole (198 mg,
1.22
mmol) was added while stirring. For activation, the mixture was stirred for 1
h at RT.
The amine N-(4-amino-2-fluorophenyl)bismethanesulphonamide (380 mg, 1.34
mmol) was then added as a solid. The course of the reaction was controlled by
DC.
After 4 d, a plurality of new products could be seen in the DC in addition to
the
starting products. For working up, THF was removed by distillation. The
residue was
dissolved in 0.5 N aq. HCI (7 ml) and Et0Ac (30 ml). The phases were
separated.
The organic phase was washed successively with 0.5 N aq. HC1 (2 x 7 ml), with
water (1 x 10 ml), with 1.1 M aq. NaHCO3 solution (3 x 5 ml) and water (1 x 5
m1).
The organic phase was dried with Na2SO4. The solvent was removed by
distillation.
The beige residue (502 mg) was very difficult to dissolve in cyclohexane/Et0Ac
(2:1).
The insoluble content was removed by suction-filtration. The clear filtrate
was highly
concentrated. The product mixture was purified by flash chromatography [silica
gel
60(30 g); eluent: cyclohexane/Et0Ac (4:1; 500 ml), cyclohexane/Et0Ac (3:1; 400
ml)
and cyclohexane/Et0Ac (1:1; 300 ml)]. The mixture of the diastereoisomers 8-
tert-
buty1-1-oxa-2-azaspiro[4.51dec-2-ene-3-carboxylic acid-[3-fluoro-4-
(bismethanesulphonyl)aminophenyl]amide
(89 mg, mp 98-104 C and 124-126 C, 14 %) was thus isolated as a beige solid.
76

CA 02608319 2007-11-13
GRA3304/A-PCT
4g. Synthesis of exemplary compound 89:
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(4-fluoro-3-
methanesulphonylaminophenyl)amide
The acid 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (359
mg, 1.5
mmol) was dissolved in THF (15 ml). N,A1"-carbonyldiimidazole (243.5 mg, 1.5
mmol)
was added while stirring. For activation, the mixture was stirred for 1 h at
RT. The
amine N-(5-amino-2-fluorophenyl)methanesulphonamide (337 mg, 1.65 mmol) was
then added as a solid. The course of the reaction was controlled by DC. After
3 d
only small amounts of starting products could still be seen in the DC. For
working up,
THF was removed by distillation. The viscous residue was dissolved in 0.5 N
aq. HCI
(10 ml) and Et0Ac (10 ml). The phases were separated. The organic phase was
washed successively with 0.5 N aq. HCI (2 x 5 ml), with 1.1 M aq. NaHCO3 (3 x
5 ml)
and water (2 x 5 ml). The organic phase was dried with Na2SO4. The solvent was
removed by distillation. The beige residue was the mixture of the
diastereoisomers of
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(4-fluoro-3-
methanesulphonylanninophenyl)amide (381.5 mg, mp 180-183 C and 200-204 C,
73 /0).
4h. Synthesis of exemplary compound 87:
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(2-fluoro-5-
methanesulphonylaminophenyl)amide
The acid 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (240
mg, 1
mmol) dissolved was in THF (5 m1). N,Ar-carbonyldiimidazole (163 mg, 1 mmol)
was
added while stirring. For activation, the mixture was stirred for 1 h at RT.
The amine
N-(3-amino-4-fluorophenyl)methanesulphonamide (306 mg, 1.5 mmol), dissolved in
THF (5 ml), was then added dropwise. The course of the reaction was controlled
by
DC. Even after 5 d, starting products could still be seen in the DC. The
reaction
mixture was dark brown in colour and contained little precipitate. For working
up, THF
was removed by distillation. The residue was dissolved in 0.5 N aq. HCI (7
ml), water
(5 ml) and Et0Ac (35 ml). The phases were separated. The organic phase was
washed successively with 0.5 N aq. HCI (2 x 7 ml), with 1.1 M aq. NaHCO3
solution
77

CA 02608319 2007-11-13
GRA3304/A-PCT
(3 x 10 ml) and water (2 x 5 ml). The organic phase was dried with Na2SO4. The
solvent was removed by distillation. The residue was purified by flash
chromatography [silica gel 60 (30 g); eluent: cyclohexane/Et0Ac (3:1; 300 ml),
cyclohexane/Et0Ac (1:1; 700 ml)]. The mixture of the diastereoisomers of 8-
tert-
buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(2-fluoro-5-
methanesulphonylaminophenyl)amide (46 mg, mp 155-165 C, 11 %) was a beige
solid.
41. Synthesis of exemplary compound 88:
8-fert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid42-fluoro-5-(bis-
methanesulphonyl)aminophenyl]amide
The acid 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (240
mg, 1
mmol) was dissolved in THF (10 m1). NX-carbonyldiimidazole (163 mg, 1 mmol)
was added while stirring. For activation, the mixture was stirred for 1 h at
RT. The
amine N-(3-aminofluorophenyl)bismethanesulphonamide (310 mg, 1.1 mmol) was
then added as a solid. The course of the reaction was controlled by DC. After
24 h, a
product spot was still clearly visible in the DC. The reaction mixture was a
suspension. For working up, THF was removed by distillation. The residue was
mixed
with 0.5 N aq. HCI (7 ml), water (15 ml) and Et0Ac (40 ml). The organic phase
contained a solid. The solid was removed by suction-filtration, washed, dried
and
analysed (74 mg, light yellow, no product). The phases were separated. The
organic
phase was washed with 1.1 M aq. NaHCO3 solution (1 x 15 ml) and water (2 x 20
ml). The organic phase was dried with Na2SO4. The solvent was removed by
distillation. The residue was purified by flash chromatography [silica gel 60
(30 g);
eluent: cyclohexane/Et0Ac (4:1; 200 ml), cyclohexane/Et0Ac (3:1; 300 ml)]. The
mixture of the diastereoisomers 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-
carboxylic acid-[2-fluoro-5-(bismethanesulphonyl)aminophenyl]amide (54 mg, mp
94-
97 C, 11 %) was a light beige solid.
4j. Synthesis of exemplary compound 4:
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid isoquinolin-5-
ylamide
78

CA 02608319 2007-11-13
GRA3304/A-PCT
Pyridine (5 drops) and oxalyl chloride (0.151 ml, 1.75 mmol) were added to a
solution
of the acid 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (300
mg,
1.25 mmol) in dry toluene (40 ml). The mixture was stirred for 45 min at RT.
Subsequently, the reaction mixture was stirred for 30 min at 30-40 C and then
for 1
h at RT. The solvent and excess oxalyl chloride were removed under vacuum. The
acid chloride formed was used for further reaction immediately and without
purification.
5-Aminoisoquinoline (0.36 g, 2.5 mmol) was placed in abs. toluene (20 m1).
Subsequently, the acid chloride, dissolved in abs. toluene (20 ml), was slowly
added
dropwise to this solution. The mixture was stirred for 1 h at RT. For working
up the
mixture, the toluene was removed under vacuum and the residue mixed with DCM
(70 ml). The organic solution was washed with water (2 x 50 ml), 2 N aq.
HC1(30 ml),
sat. aq. NaHCO3 solution (50 ml) and sat. aq. NaCl solution (50 ml), dried
over
NaSat and concentrated. The crude product thus obtained (oil, 680 mg) was
purified
by means of column chromatography [silica gel 60(50 g); Et0Ac/Et0H (15:1; 500
ml)]. The amide 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
isoquinolin-5-ylamide was isolated as a light yellow solid having a melting
point of 99-
119 C as a diastereoisomer mixture in a yield of 57 % (266 mg).
4k. Synthesis of exemplary compound 83:
8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(7-
hydroxynaphthalen-1-yl)amide
Oxalyl chloride (0.13 ml, 1.5 mmol) was added to a solution of the acid 8-tert-
buty1-1-
oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (239 mg, 1 mmol) in dry toluene
(20
ml) at RT. The mixture was stirred for 18 h at RT. To remove the excess oxalyl
chloride, the solvent was concentrated under vacuum to approx. 10 ml. The
solution
formed of the acid chloride was used for further reaction immediately and
without
purification. 8-Amino-2-naphthol (159 mg, 1 mmol) was placed in abs. methylene
chloride (40 ml), mixed with triethylamine (0.4 ml, 2.9 mmol) and stirred for
10 min at
RT. Subsequently, the solution of the acid chloride was added dropwise within
10
min. Although hardly any amines were left after stirring for 1 h (DC,
cyclohexane/Et0Ac 1:1), the mixture was stirred for a further 20 h at RT. For
working
79

CA 02608319 2007-11-13
GRA3304/A-PCT
up, the mixture was mixed with 1 N aq. HCI (20 ml). The organic phase was
separated off, the aqueous phase was extracted with DCM (2 x 20 ml). The
combined organic phases were washed with water (2 x 10 ml), dried over Na2SO4
and subsequently concentrated. The residue obtained was purified by column
chromatography [mobile solvent: cyclohexane/Et0Ac (7:3)]. The residue obtained
was recrystallised from cyclohexane (30 ml). There was obtained a reddish
solid (60
mg, 15 % yield, mp: 168-191 C) which consisted of the diastereomers of 8-tert-
butyl-
1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(7-hydroxynaphthalen-1-
yl)amide.
41. Synthesis of exemplary compound 79:
8-tert-buty1-1-oxa-2-azaspiro[4.5]clec-2-ene-3-carboxylic acid-(2,3-
dihydrobenzo[1,4]dioxin-5-yl)amide
Pyridine (2 drops) and oxalyl chloride (0.151 ml, 1.75 mmol) were added to a
solution
of the acid 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (300
mg,
1.25 mmol) in dry toluene (40 ml). The mixture was stirred for 45 min at RT.
Subsequently, the reaction mixture was stirred for 30 min at 30-40 C and then
1 h at
RT. The solvent and excess oxalyl chloride were drawn off under vacuum. The
acid
chloride formed was used for further reaction immediately and without
purification. 5-
Amino-1,4-benzodioxane (0.37 g, 2.5 mmol) was placed in abs. toluene (20 m1).
Subsequently, the acid chloride, dissolved in abs. toluene (20 ml), was added
dropwise to this solution within 20 min. The mixture was stirred for 1 h at
RT. For
working up the mixture, the toluene was removed under vacuum and the residue
taken up in DCM (70 m1). Subsequently, the organic phase was washed with water
(2
x 50 ml), 2 N aq. HCI (30 ml), sat. aq. NaHCO3 solution (50 ml) and sat. aq.
NaC1
solution (50 ml), dried over Na2SO4 and concentrated. The amide 8-tert-buty1-1-
oxa-
2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(2,3-dihydrobenzo[1,4]dioxin-5-
yl)amide
was thus isolated as a light yellow solid having a melting point of 120-126 C
as a
diastereoisomer mixture in a yield of 98 A (500 mg).

CA 02608319 2007-11-13
=
= ,
GRA3304/A-PCT
4m. Synthesis of exemplary compound 86:
8-fert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(5-
hydroxynaphthalen-1-yl)amide
N,Af-carbonyldiimidazole (765 mg, 4.72 mmol) was added to a solution of the
acid 8-
tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (1.03 g, 4.29
mmol) in
abs. THE (50 m1). The mixture was stirred for 3 h at RT. After the addition of
the
amine 5-aminonaphthalen-1-ol (683 mg, 4.29 mmol) in abs. THF (20 ml), the
solution
was stirred for 3 days at RT. For working up, THE was removed by distillation.
The
brown oily residue was mixed with water (20 ml) and Et0Ac (40 ml) and brought
to
pH 3 using 1 N aq. NCI. The phases were separated. The organic phase was
washed
with sat. aq. NaHCO3 solution (2 x 20 ml) and sat. aq. NaCI solution (2 x 20
ml). After
drying, the solvent was removed by distillation. Recrystallisation of the
residue
[cyclohexane (10 ml)] yielded a solid (melting point from 188 C, yield 245
mg, 15 %)
which is the diastereoisomer mixture of 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-
2-ene-
3-carboxylic acid-(5-hydroxynaphthalen-1-yl)amide.
4n. Synthesis of exemplary compound 80:
N-(3-fluoro-4-(methylsulphonamido)benzy1)-8-tert-penty1-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxamide
81

CA 02608319 2007-11-13
GRA3304/A-PCT
A solution of the acid 8-(1,1-dimethylpropyI)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-
carboxylic acid (253 mg, 1 mmol) in dry THF (15 ml) was mixed with CD (178 mg,
1.1 mmol) and stirred for 1.5 h at RT. A solution consisting of the amine N-(4-
aminomethy1-2-fluorophenyl)methanesulphonamide (240 mg, 1.1 mmol) and THF (10
ml) was then added. The mixture was stirred for 20 h at RT. The colourless
clear
solution was concentrated. The oily residue was stirred with Et0Ac (40 ml) and
10 %
aq. citric acid solution (20 ml) for 10 min. The phases were then separated
and the
organic phase was washed with sat. aq. NaHCO3 solution (2 x 15 ml) and with
sat.
aq. NaC1 solution (1 x 15 ml). The organic phase was dried and concentrated.
The
residue was purified by column chromatography [silica gel 60 (70 g);
cyclohexane/Et0Ac (5:1; 500 ml); Et0Ac (500 ml)]. The compound N-(3-fluoro-4-
(methylsulphonamido)benzy1)-8-tert-penty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-
carboxamide was obtained as a colourless oil in a yield of 25 % (112 mg).
4.o. Synthesis of exemplary compound 82:
8-cyclohexy1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-fluoro-4-
methanesulphonylaminobenzylamide
A solution of the acid 8-cyclohexy1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-
carboxylic acid
(531 mg, 2 mmol) in dry THF (30 ml) was mixed with CDI (357 mg, 2.2 mmol) and
stirred for 1.5 h at RT. A solution consisting of the amine N-(4-aminomethy1-2-
fluorophenyl)methanesulphonannide (480 mg, 2.2 mmol) and THF (10 ml) was then
added. The mixture was stirred for 20 h at RT. The colourless clear solution
was
concentrated. The oily residue was stirred with Et0Ac (50 ml) and 10 (1/0 aq.
citric acid
solution (25 ml) for 10 min. The phases were then separated and the organic
phase
was washed with sat. aq. NaHCO3 solution (2 x 20 ml) and with sat. aq. NaCI
solution (1 x 20 ml). The organic phase was dried and concentrated to approx.
5 ml,
wherein a colourless solid formed. The mixture was stored for 18 h in a
refrigerator
and the solid removed by suction-filtration. The compound 8-cyclohexy1-1-oxa-2-
azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-fluoro-4-
methanesulphonylaminobenzylamide was obtained as a colourless solid (99 mg, 7
%) having a melting point of 225-228 C.
82

CA 02608319 2007-11-13
GRA3304/A-PCT
4.p. Synthesis of exemplary compound 81:
8-(1,1-dimethylpropy1)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-(2,3-
dihydrobenzo[1,4]clioxin-5-yl)amide
Oxalyl chloride (0.13 ml, 1.5 mmol) was added to a solution of the acid 841,1-
dimethylpropy1)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (253 mg, 1
mmol)
in dry toluene (20 ml) at RT. The mixture was stirred for 18 h at RT. To
remove the
excess oxalyl chloride, the solvent was concentrated under vacuum to approx.
10 ml.
The solution formed of the acid chloride was used for further reaction
immediately
and without purification. 2,3-Dihydrobenzo[1,4]dioxin-5-ylamine (151 mg, 1
mmol)
was placed in abs. toluene (20 ml) and mixed with triethylamine (0.2 ml, 1.45
mmol).
Subsequently, the solution of the acid chloride was added dropwise within 20
min at
RT. Although hardly any amines were left after stirring for 1 h [DC,
cyclohexane/Et0Ac 3:1)], the mixture was stirred for a further 14 h at RT. For
working
up the mixture, the mixture was mixed with IN aq. NaOH solution (10 ml) and
shaken
out. The organic phase was separated off, the aqueous phase was washed with
Et0Ac (3 x 20 ml). The combined organic phases were washed with 1 N aq. HCI
(10
ml), dried over Na2SO4 and concentrated under vacuum. The residue obtained was
purified by chromatography [mobile solvent: cyclohexane/Et0Ac (9:1)]. The
desired
amide 8-(1,1-dimethylpropy1)-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-
(2,3-
dihydrobenzo[1,4]dioxin-5-yl)amide was thus obtained in a yield of 223 mg (58
%,
glass-like solid, mp from 45 C) as an isomer mixture.
The exemplary compounds 58 ((5R,8R)-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-
3-
y1)(4-(3-chloropyridin-2-y1)-2,6-dimethylpiperazin-1-yOmethanone and 59
((5S,8S)-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)(4-(3-chloropyridin-2-
y1)-2,6-
dimethylpiperazin-1-yl)methanone were synthesised as described hereinbefore
and
have the following structures:
83

CA 02608319 2007-11-13
GRA3304/A-PCT
=
Beispielverbindung 58: Beispielverbindung 59:
s.
0
s
H"..01\11
N N
Beispielverbindung = Exemplary compound
The following substituted spiro compounds according to the invention were
prepared
as described under 4.
84

GRA3304/A-PCT
Name
[M+H]
1 8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
aminobenzylamide 344.5
2 trans-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
methanesulphonylaminobenzylamide 422.6
3 cis-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
methanesulphonylaminobenzylamide 422.6
trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-thiazol-2-
ylpiperazin-1-yl)methanone 391.5
6 cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-thiazol-2-
ylpiperazin-1-yl)methanone 391.5
7 cis-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-
fluoro-4-m ethanesulphonylam i nobenzylam id e 440.5
8 trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-
trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone 453.5
9 cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-
trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone 453.5
trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(4-
hydroxyphenyl)piperazin-1-Amethanone 400.5
11 cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(4-
hydroxyphenyl)piperazin-1-yl]methanone 400.5
12 (8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(6,7-dihydroxy-3,4-
dihydro-1H-isoquinolin-2-yl)rnethanone 387.5
0
13 cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(6-methylpyridazin-
3-yl)piperazin-1-ylimethanone 400.5
14 trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(6-
methylpyridazin-3-yl)piperazin-1-yl]methanone 400.5 0
CO
UJ
cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-pyrimidin-2-
ylpiperazin-1-yl)methanone 386.5
16 trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(4-pyrimidin-2-
ylpiperazin-1-yl)methanone 386.5
0
17 cis-(8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(4-chloro-[I
,2,5]thiadiazol-3-yl)piperazin-1-yl]methanone 427.0 0
18 trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(6,7-dimethoxy-3,4-
dihydro-1H-isoquinolin-2-yl)methanone 415.5
19 cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)-(6,7-dimethoxy-3, 4-
di hydro-1H-isoquinolin-2-yl)methanone 415.5
UJ
trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(4-chloro-
[1,2,5]thiadiazol-3-y1)piperazin-1-Amethanone 427.0
21 trans-(8-tert-butyl-1 -oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-chloropyridin-
2-y1)[1,4]diazepan-1-yl]methanone 434.0
22 cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-chloropyridin-2-
y1)41 ,4]diazepan-1-yl]methanone 434.0
23 trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid
(pyridin-4-ylmethyl)amide 330.4
24 cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid (pyridin-
4-ylmethyl)amide 330.4
trans-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-3-fluoro-4-
methanesulphonylaminobenzylamide 440.5
26 trans-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
hydroxy-3-methoxybenzylamide 375.5
27 cis-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-hydroxy-
3-methoxybenzylamide 375.5
28 trans-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-chloropyridin-
2-yl)piperazin-1-ylimethanone 420.0
29 cis-(8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)44-(3-chloropyridin-2-
yl)piperazin-1-Amethanone 420.0
3',4',4a', 5',6', 7',8', 8a'-octahydro-1 'H,4H-spiro[isoxazol-5,2'-
naphthalene]-3-carboxylic acid-(4-tert-butyl phenyl )amide 369.5

GRA3304/A-PCT
31 3',4',4a',5',6',7',8',8a'-octahydro-l'H,4H-spiro[isoxazol-5,2'-naphthalene]-
3-carboxylic acid-(4-tert-butylbenzyl)amide 383.5_
32 3',4',4a',5',6',7',8',8a'-octahydro-l'H,4H-spiro[isoxazol-5,2'-naphthalene]-
3-carboxylic acid- 3-fluoro-4- 438.5
methanesulphonylaminobenzylamide
92 8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-ene-3-carboxylic acid-4-
pentafluorosulphanylbenzylamide
55 3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-trans-(4-tert-
butylphenyl)amide
56 8-tert-butyl-N-(4-(methylsulphonamido)benzyI)-1-oxa-2-azaspiro[4.5]dec-2-
ene-3-carboxamide
60 ((5R,8R)-8-tert-buty1-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)(4-(3-
chloropyridin-2-y1)-2-methylpiperazin-1-yl)methanone
61 ((5S,8S)-8-tert-butyl-1-oxa-2-azaspiro[4.5]dec-2-en-3-y1)(4-(3-
chloropyridin-2-y1)-2-methylpiperazin-1-yl)methanone
84 N-(4-tert-butylpheny1)-3-(4-(3-chloropyridin-2-yl)piperazin-1-carbony1)-1-
oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
85 N-(4-tert-butylbenzy1)-3-(4-(3-chloropyridin-2-yl)piperazin-1-carbony1)-1-
oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
0
c7,
0
CO
UJ
0
0
UJ
86

CA 02608319 2007-11-13
GRA3304/A-PCT
5. Synthesis of 4-methylenecyclohexanecarboxylic acid ethyl ester
0 0
0 0
Methyltriphenylphosphonium bromide (34.1 g, 95.5 mmol) was placed in abs.
diethyl
ether (420 ml) under a nitrogen atmosphere. At 0 C, potassium tert-butylate
(13.1 g,
113.1 mmol) was slowly added. After 30 min, again at 0 C, ethy1-4-
oxocyclohexanecarboxylate (10.7 g, 62.9 mmol) was slowly added dropwise as a
solution in diethyl ether (80 m1). The reaction mixture was stirred overnight
at RT. For
working up, the reaction mixture was cooled in an ice bath and mixed with sat.
aq.
NR4C1 solution (250 ml). The phases were separated and the aqueous phase was
shaken out several times with Et0Ac (3 x 200 m1). The combined organic phases
were dried over magnesium sulphate and the solvent was removed under vacuum.
The precipitate thus formed was removed by suction-filtration and dried
overnight
using a pump. The mother liquor was placed onto a glass frit filled with
silica gel and
flushed with ether/hexane (400 ml). The filtrate was concentrated and the
residue not
dried any further. 7.1 g (66 % of the theoretical amount) of the desired
product 4-
methylenecyclohexane carboxylic acid ethyl ester were obtained.
6.a. Synthesis of 1-chloro-1-hydroxyiminomethylbenzene
,OH
CII
N ¨ H
+ 0 N 0
c,
N-chlorosuccinimide (4.63 g, 34. 7 mmol) was added to a solution of
benzaldehyde
oxime (3.5 g, 28.9 mmol) in DMF (30 ml) at RT, causing the temperature to rise
briefly to 50 C. The reaction mixture was cooled in an ice bath, stirred for
3 h at RT,
mixed with water (100 ml) while being cooled with ice and extracted with ether
(3 x
100 ml). The combined organic phases were washed with water (150 ml) and sat.
aq.
87

CA 02608319 2007-11-13
GRA3304/A-PCT
NaCI solution (150 ml), dried and the solvent was removed under vacuum. The
desired product 1-chloro-1-hydroxyiminomethylbenzene was obtained as a
yellowish
solid (4.28 g).
6.b. Synthesis of 1-chloro-1-hydroxyiminomethyl-3-methoxybenzene
OH
Cl
aot N¨ OH
+ 0Nr0
CI
0
0\
N-chlorosuccinimide (32.2 g, 241 mmol) was added to a solution of 3-
methoxybenzaldehyde oxime (30.4 g, 201 mmol) in DMF (200 ml) at RT, causing
the
temperature to rise briefly to 50 C. The reaction mixture was cooled in an
ice bath,
stirred overnight at RT, mixed with water (250 ml) while being cooled with ice
and the
precipitate formed was removed by suction-filtration. The filtrate was
extracted with
ether (3 x 400 ml) and the combined organic phases were washed with water (300
ml) and sat. aq. NaCI solution (300 ml), dried and the solvent was removed
under
vacuum. The desired product 1-chloro-1-hydroxyiminomethy1-3-methoxybenzene was
obtained as a yellowish solid (32.86 g).
6.c. Synthesis of 1-chloro-1-hydroxyiminoethane
Cl OH
N¨OH
+ 0Nr0
1
Cl
N-chlorosuccinimide (20.3 g, 152 mmol) was added to a solution of acetaldehyde
oxime (8 g, 127 mmol) in DMF (100 ml) at RT, causing the temperature to rise
briefly
to 50 C. The reaction mixture was cooled in an ice bath, stirred overnight at
RT and
mixed with water (250 ml) while being cooled with ice. The mixture was
extracted
with ether (200 ml) and the combined organic phases were washed with water
(100
88

CA 02608319 2007-11-13
= = GRA3304/A-PCT
ml) and sat. aq. NaCI solution (100 ml), dried and the solvent was removed
under
vacuum. The desired product 1-chloro-1-hydroxyiminoethane was obtained as a
colourless oil (10.84 g).
7.a. Synthesis of 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid
ethyl ester
OH
401
0 4.
0
= 0
0\
A solution of 1-chloro-1-hydroxyiminomethylbenzene (1.26 g, 8.1 mmol) in DCM
(20
ml) was slowly added dropwise to a solution of 4-
methylenecyclohexanecarboxylic
acid ethyl ester (454 mg, 2.70 mmol) in DCM (15 ml) at 0 C. Subsequently, a
solution of triethylamine (656 pl) in DCM (15 ml) was slowly added dropwise at
0 C
and the resulting mixture was stirred overnight at RT.
The reaction mixture was diluted with DCM and with water. The combined organic
phases were washed with 10 %. aq. citric acid solution and sat. aq. NaCI
solution,
dried over sodium sulphate and the solvent was removed under vacuum. After
purification of the residue (silica gel, hexane/ether 5:1) by column
chromatography
and crystallisation from ether and hexane, the desired product 3-phenyl-1-oxa-
2-
azaspiro[4.5]dec-2-ene-8-carboxylic acid ethyl ester was obtained as a white
solid
(190 mg, 25 % of the theoretical amount).
7.b. Synthesis of 3-(3-methoxypheny1)-1-oxa-2-azaspiro[4.5]clec-2-ene-8-
carboxylic acid ethyl ester
/0H
0 4.
0 0
0 CI = --N
0
0
89

CA 02608319 2007-11-13
GRA3304/A-PCT
A solution of 1-chloro-1-hydroxyiminomethy1-3-methoxybenzene (31 g, 167 mmol)
in
DCM (50 ml) was slowly added dropwise to a solution of 4-
methylenecyclohexanecarboxylic acid ethyl ester (28 g, 167 mmol) in DCM (950
ml)
at 0 C. Subsequently, a solution of triethylamine (50 ml) in DCM (50 ml) was
slowly
added dropwise at 0 C and the resulting mixture was stirred overnight at RT.
The reaction mixture was diluted with water (500 m1). The combined organic
phases
were washed with 10 % aq. citric acid solution (800 ml) and sat. aq. NaCl
solution
(500 ml), dried over sodium sulphate and the solvent was removed under vacuum.
The desired product 3-(3-methoxyphenyI)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxylic acid ethyl ester (51 g) was reacted without further purification.
7.c. Synthesis of 3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid
ethyl ester
N OH 0
0\
= --N
CI 0 0
A solution of 1-chloro-1-hydroxyiminoethane (1.5 g, 16 mmol) in DCM (10 ml)
was
slowly added dropwise to a solution of 4-methylenecyclohexanecarboxylic acid
ethyl
ester (1.68 g, 10 mmol) in DCM (10 ml) at 0 C. Subsequently, a solution of
triethylamine (3 ml) in DCM (10 ml) was slowly added dropwise at 0 C and the
resulting mixture was stirred overnight at RT.
The reaction mixture was diluted with water (50 ml) and DCM. The combined
organic
phases were washed with 10 % aq. citric acid solution (80 ml) and sat. aq. Naa
solution (50 ml), dried over sodium sulphate and the solvent was removed under
vacuum. The desired product 3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxylic
acid ethyl ester (2 g) was obtained after purification by column
chromatography
(Si02, hexane/Et0Ac 1:1).
8.a. Synthesis of 3-phenyl-1-oxa-2-azaspiro[4.51dec-2-ene-8-carboxylic acid

= CA 02608319 2007-11-13
= = GRA3304/A-PCT
0 AL 1010
0
0,N
0 IMF I
,N
HO 0
A mixture of 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid ethyl
ester
(190 mg, 0.67 mmol) in Me0H (5 ml) and lithium hydroxide monohydrate (74 mg,
1.0
mmol) in H20 (1 ml) was stirred overnight at RT. After removal of the solvent
under
vacuum, the residue was taken up in 10 % aq. citric acid solution and Et0Ac
and the
phases were separated. The aqueous phase was extracted several times with
Et0Ac, dried over magnesium sulphate and desolventised under vacuum. 150 g (87
% of the theoretical amount) of the free acid 3-pheny1-1-oxa-2-
azaspiro[4.5]dec-2-
ene-8-carboxylic acid was obtained in the form of a colourless solid.
8.b. Synthesis of 3-methoxypheny1-1-oxa-2-azaspiro[4.51dec-2-ene-8-carboxylic
acid
=0 0
0 0
0\
0.--N
=
HO 0
A mixture of 3-(3-methoxyphenyI)-1-oxa-2-azaspiro[4.5jdec-2-ene-8-carboxylic
acid
ethyl ester (51 g, 161 mmol) in Me0H (1000 ml) and lithium hydroxide
monohydrate
(18 g, 241 mmol) in H20 (145 ml) was stirred overnight at RT.
The precipitate was removed by suction-filtration and washed with a small
amount of
ether. The mother liquor was concentrated, taken up in water (200 ml) and the
mixture was extracted with Et0Ac (3 x 300 ml). The combined organic phases
were
adjusted to pH 1 using aq. HCI (25 %) and reextracted with Et0Ac (3 x 300 ml).
The
combined organic phases were washed with activated carbon and dried over
magnesium sulphate.
91

CA 02608319 2007-11-13
= GRA3304/A-PCT
After removal of the solvent under vacuum, 24 g of the free acid 3-
methoxypheny1-1-
oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid were obtained in the form of a
viscous oil.
8.c. Synthesis of 3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid
o 0 HO"-/VN
A mixture of 3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid ethyl
ester
(570 mg, 2.5 mmol) in Me0H (15 ml) and lithium hydroxide monohydrate (284 mg,
3.8 mmol) in H20 (3 ml) was stirred overnight at RT.
After removal of the solvent under vacuum, the residue was taken up in 10 %
aq.
citric acid solution and Et0Ac and the phases were separated. The aqueous
phase
was extracted several times with Et0Ac, dried over magnesium sulphate and
desolventised under vacuum. After removal of the solvent under vacuum, the
free
acid 3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid was obtained.
9. General directions for reacting 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxylic acid with amines of general formula HNR11R12
3-Phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid (1 eq.) was slowly
added
to a solution of N-ethyldiisopropylamine (3 eq.), 1-hydroxybenzotriazole
hydrate (1
eq.), 0-(benzotriazol-1-y1)-N,N,N`,Nr-tetramethyluronium tetrafluoroborate (1
eq.) and
an amine of general formula HNRII iR 2 (1 eel.) in abs. THF. The reaction
mixture was
stirred overnight and the solvent removed under vacuum. The residue was taken
up
in Et0Ac. The organic phase was washed successively with sat. aq. NaCl
solution,
sat. aq. NaHCO3 solution, sat. aq. ammonium sulphate solution and sat. aq.
NaCI
solution, dried over magnesium sulphate and the solvent removed under vacuum.
The desired product was obtained as a diastereomer mixture.
92

CA 02608319 2007-11-13
GRA3304/A-PCT
9a. Synthesis of exemplary compound 50:
3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4-tert-
butylphenyl)amide
0 411
1
0
--N = HN 0--N
HO 0
I.
3-Phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid (400 mg, 1.5 mmol)
was
slowly added to a solution of N-ethyldiisopropylamine (662 mg, 4.6 mmol), 1-
hydroxybenzotriazole hydrate (206 mg, 1.5 mmol), 0-(benzotriazol-1-y1)-
N,N,N`,N'-
tetramethyluronium tetrafluoroborate (496 mg, 1.5 mmol) and 4-tert-
butylaniline (230
mg, 1.5 mmol) in abs. THF (11 ml). The reaction mixture was stirred overnight
and
the solvent removed under vacuum. The residue was taken up in Et0Ac (75 ml).
The
organic phase was washed successively with sat. aq. NaCl solution, sat. aq.
NaHCO3
solution, sat. aq. ammonium sulphate solution and sat. aq. NaCl solution,
dried over
magnesium sulphate and the solvent removed under vacuum. The desired product 3-
pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4-tert-
butylphenyl)amide
was obtained as a diastereomer mixture in a yield of 220 mg (37 A, of the
theoretical
amount).
9b. Synthesis of exemplary compounds 48 and 49:
cis-(4-(3-chloropyridin-2-yppiperazin-1-y1]-(3-phenyl-1-oxa-2-azaspiro[4.5]dec-
2-
en-8-yl)methanone and trans44-(3-chloropyridin-2-yl)piperazin-1-y1]-(3-phenyl-
1-oxa-2-azaspiro[4.5]dec-2-en-8-yOmethanone
93

CA 02608319 2007-11-13
GRA3304/A-PCT
0 ak
w
( N
Diq
/CI
0
= /IN
HO 0
0
. I
ciN b¨ N
/ CI
3-Pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid (750 mg, 2.9 mmol)
was
slowly added to a solution of N-ethyldiisopropylamine (1.02 g, 7.1 mmol), 1-
hydroxybenzotriazole hydrate (320 mg, 2.4 mmol), 0-(benzotriazol-1-y1)-
N,N,N`,N`-
tetramethyluronium tetrafluoroborate (758 mg, 2.4 mmol) and 1-(3-chloropyridin-
2-
yl)piperazine (467 mg, 2.4 mmol) in abs. THF (17 ml). The reaction mixture was
stirred overnight and the solvent removed under vacuum. The residue was taken
up
in Et0Ac (100 m1). The precipitate formed was removed by suction-filtration.
The
organic phase was washed successively with sat. aq. NaC1 solution, sat. aq.
NaHCO3
solution, sat. aq. ammonium sulphate solution and sat. aq. NaCI solution,
dried over
magnesium sulphate and the solvent removed under vacuum. The precipitate and
the residue were purified by column chromatography (silica gel, hexane/Et0Ac
1:1).
The desired product [4-(3-chloropyridin-2-yl)piperazin-1-y1]-(3-pheny1-1-oxa-2-
azaspiro[4.5]dec-2-en-8-yl)methanone was obtained as a cis isomer (294 mg, 24
%
of the theoretical amount) and trans isomer (192 mg, 15 % of the theoretical
amount).
9c. Synthesis of exemplary compounds 52 and 53:
94

CA 02608319 2007-11-13
GRA3304/A-PCT
3-phenyl-1-oxa-2-azaspiro[4.51dec-2-ene-8-carboxylic acid-cis-3-fluoro-4-
methanesulphonylaminobenzylamide and 3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-
ene-8-carboxylic acid-trans-3-fluoro-4-methanesulphonylaminobenzylamide
0
HN = 0--IN =
0 =
HN F
\
\
HO CrN
0 411
--N
HN 0
HN F
\
\
3-Pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid (400 mg, 1.54 mmol)
was
slowly added to a solution of N-ethyldiisopropylamine (662 g, 4.6 mmol), 1-
hydroxybenzotriazole hydrate (206 mg, 1.54 mmol), 0-(benzotriazol-1-y1)-N,N,N
tetramethyluronium tetrafluoroborate (496 mg, 1.54 mmol) and N-(4-aminomethy1-
2-
fluorophenyl)methanesulphonamide (336 mg, 1.54 mmol) in abs. THF (11 ml). The
reaction mixture was stirred overnight and the solvent removed under vacuum.
The
residue was taken up in Et0Ac (75 ml). The precipitate formed was removed by
suction-filtration, washed with a small amount of ether and dried. The desired
product
3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-3-fluoro-4-
methanesulphonylaminobenzylamide was obtained as a cis isomer (89 mg, 13 % of
the theoretical amount). The organic phase was washed successively with sat.
aq.
NaCI solution, sat. aq. NaHCO3 solution, sat. aq. ammonium sulphate solution
and
sat. aq. NaCI solution, dried over magnesium sulphate and the solvent removed
under vacuum. The residue was boiled up in Et0Ac (2.5 ml) and DCM (1 m1). The
precipitate formed was removed by suction-filtration and washed with a small
amount
of ether. The desired product 3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxylic

CA 02608319 2007-11-13
GRA3304/A-PCT
acid-3-fluoro-4-methanesulphonylaminobenzylamide was obtained as a trans
isomer
(138 mg, 19 % of the theoretical amount).
9d. Synthesis of exemplary compound 57:
N-(4-tert-butylphenyI)-3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
0
HN
= 1111 .--IN
HO 0
=
N,N'-diisopropylcarbodiimide (96 mg, 0.76 mmol) was added to a solution of 3-
methy1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid (150 mg, 0.76 mmol) in
DCM (40 ml). The reaction mixture was mixed after 30 minutes with 1-
hydroxybenzotriazole hydrate (HOBt, 101 mg, 0.76 mmol) and tert-butylaniline
(113
mg, 0.76 mmol), stirred overnight and the solvent removed under vacuum. The
residue was taken up in Et0Ac. The organic phase was washed successively with
diluted aq. citric acid solution and sat. aq. NaCl solution, dried over
magnesium
sulphate and the solvent removed under vacuum. The desired product N-(4-tert-
butylpheny1)-3-methy1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide was
obtained
after purification by column chromatography (Si02, hexane/Et0Ac 1:1) as a
diastereomer mixture in a yield of 66 mg.
The following substituted Spiro compounds according to the invention were
prepared
as described under 4.
Name [M+H]
33 3-methyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4- 365.9
tert-butylphenyl)amide
46 cis-[3-(4-tert-butylpheny1)-1-oxa-2-azaspiro[4.5]dec-2-en-8-y1]-[4-
496.1
(3-chloropyridin-2-yOpiperazin-1-yl]methanone
47 trans-[3-(4-tert-butylpheny1)-1-oxa-2-azaspiro[4.5]dec-2-en-8-y1]-
496.1
[4-(3-chloropyridin-2-yl)piperazin-1-yl]methanone
48 cis44-(3-chloropyridin-2-yOpiperazin-1-y1]-(3-pheny1-1-oxa-2- 440.0
azaspiro[4.5]dec-2-en-8-yl)methanone
49 trans44-(3-chloropyridin-2-yl)piperazin-1-y1]-(3-pheny1-1-oxa-2-
440.0
azaspiro[4.5]dec-2-en-8-yl)methanone
96

CA 02608319 2007-11-13
GRA3304/A-PCT
50 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid-(4- 391.5
tert-butylphenyl)amide
51 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid cis-
391.5
(4-tert-butylphenyl)amide
52 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid cis-3-
460.5
fluoro-4-methanesulphonylaminobenzylamide
53 3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid trans- 460.5
3-fluoro-4-methanesulphonylaminobenzylamide
93 3-(3-methoxyphenyI)-1-oxa-2-azaspiro[4. 5]d ec-2-ene-8-
carboxylic acid-(4-pentafluorosulphanylphenyl)amide
62 (4-(3-chloropyridin-2-yl)piperazin-1-y1)(3-(3-methoxypheny1)-1-oxa-2-
azaspiro[4.5]dec-2-en-8-y1)methanone
63 3-(3-methoxypheny1)-N-(4-(trifluormethoxy)benzy1)-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
64 N-(1H-indo1-5-y1)-3-(3-methoxypheny1)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-
carboxamide
65 N-(3-fluoro-4-(methylsulphonamido)benzyI)-3-(3-methoxypheny1)-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
66 N-(4-tert-butylpheny1)-3-(3-methoxypheny1)-1-oxa-2-azaspiro[4.5]dec-2-
ene-8-carboxamide
67 N-(2,3-dihydrobenzo[b][1,4]dioxin-6-y1)-3-(3-methoxypheny1)-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
68 N-(4-tert-butylpheny1)-3-(4-fluoropheny1)-1-oxa-2-azaspiro[4.5]dec-2-
ene-8-
carboxamide
69 (5R,8R)-3-phenyl-N4(2-(piperidin-1-y1)-6-(trifluormethyppyridin-3-
y1)methyl)-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
70 (5R,8R)-N4(2-(4-methylpiperidin-1-y1)-6-(trifluormethyppyridin-3-
y1)methyly
3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
71 (5S,8S)-N-((2-(3-chloro-4-fluoropheny1)-6-(trifluormethyl)pyridin-3-
yl)methyl)-3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
72 (5S,8S)-N4(2-(4-methylpiperidin-1-y1)-6-(trifluormethyppyridin-3-
y1)methyl)-
3-phenyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
73 (5S,8S)-3-phenyl-N-((2-(piperidin-1-y1)-6-(trifluormethyppyridin-3-
y1)methyly
1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide
74 (5R,8R)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-y1)-3-pheny1-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
75 (5S,8S)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-y1)-3-pheny1-1-oxa-2-
azaspiro[4.5]dec-2-ene-8-carboxamide
97

CA 02608319 2007-11-13
GRA3304/A-PCT
10. Synthesis of 2-methylenedecahydronaphthalene
2
Q 111.
0
Methyltriphenylphosphonium bromide (89.2 g, 249 mmol) was placed in abs.
diethyl
ether (800 ml) under a nitrogen atmosphere. At 0 C potassium tert-butylate
(34 g,
295 mmol) was slowly added. After 30 min octahydronaphthalen-2-one (25 g, 164
mmol) as a solution in diethyl ether (500 ml) was slowly added dropwise, again
at 0
C. The reaction mixture was stirred overnight at RT. For working up, the
reaction
mixture was cooled in an ice bath and mixed with sat. aq. NH4Clsolution. The
phases were separated and the aqueous phase was shaken out several times with
Et0Ac. The combined organic phases were dried over magnesium sulphate and the
solvent was removed under vacuum. The residue was taken up in hexane/ether
1:1,
removed by suction-filtration and the residue washed with hexane/ether 1:1.
The
filtrate was concentrated and the residue also removed by suction-filtration.
The
desired compound 2-rnethylenedecahydronaphthalene was obtained as a solid
(16.3
g, 66 % of the theoretical amount).
11. Synthesis of 4-tert-butylbenzaidehyde oxime
NOH
0
Hydroxylamine hydrochloride (4.65 g, 67.4 mmol) was slowly added to a solution
of
4-tert-butylbenzaldehyde (109, 61.6 mmol) in water (34 ml) and Et0H (7 ml). An
aqueous solution of sodium hydroxide (3.6 g, 153 mmol) was slowly added
dropwise,
so the temperature of the reaction mixture did not exceed 25 C. The reaction
mixture was stirred overnight at RT and mixed with diethyl ether. The aqueous
phase
was neutralised with 0.5 M aq. hydrochloric acid solution and extracted
several times
98

CA 02608319 2007-11-13
GRA3304/A-PCT
with ether. The combined organic phases were dried over magnesium sulphate and
the solvent was removed under vacuum. The desired product 4-tert-
butylbenzaldehyde oxime was obtained in a yield of 84 % of the theoretical
amount
(9.1 g).
12. Synthesis of 1-chloro-1-hydroxyiminomethy1-4-tert-butylbenzene
,OH
1:110 Cl
õOH
N-chlorosuccinimide (8.1 g, 61 mmol) was added to a solution of 4-tert-
butylbenzaldehyde oxime (9 g, 50.1 mmol) in DMF (50 ml) at RT, causing the
temperature to rise briefly to 50 C. The reaction mixture was cooled in an
ice bath,
stirred for 3 h at RT, mixed with water (100 ml) while being cooled with ice
and
extracted with ether (3 x 100 ml). The combined organic phases were washed
with
water (150 ml) and sat. aq. NaC1 solution (150 ml), dried and the solvent was
removed under vacuum. The desired product 1-chloro-1-hydroxyiminomethy1-4-tert-
butylbenzene was obtained as a yellowish solid (10.7 g).
13. Synthesis of exemplary compound 40:
4-tert-buty1-3-pheny1-3",4",4a",5",6",7",8",8a"-octahydro-1"H,4H-
spiro[isoxazol-
5,2"-naphthalene]
CZR+ CI O-N =
N
A solution of 1-chloro-1-hydroxyiminomethy1-4-tert-butylbenzene (272 mg, 1.3
mmol)
in DCM (5 ml) was slowly added dropwise to a solution of 2-
methylenedecahydronaphthalene (150 mg, 1 mmol) in DCM (5m1) at 0 C.
Subsequently, a solution of triethylamine (312 mg) in DCM (5 ml) was slowly
added
dropwise at 0 C and the resulting mixture was stirred overnight at RT.
99

CA 02608319 2007-11-13
GRA3304/A-PCT
The reaction mixture was diluted with DCM and with water. The combined organic
phases were washed with 10 % aq. citric acid solution and sat. aq. NaCI
solution,
dried over sodium sulphate and the solvent was removed under vacuum. The
desired
product 4-tert-buty1-3-pheny1-3",4",4a",5',6",7",8",8a"-octahydro-1"H,4H-
spiro[isoxazol-5,2"-naphthalene] was obtained in an amount of 212 mg.
Examples 34 to 39 and 41 to 45 were synthesised similarly to the synthesis of
Example 40, as is described under 10. to 13.
Name [M 1-1]
34 3-phenyl-3 ',4 ',4a",5,6",7",8,8a "-octahydro-1"1-1,4H-spiro[isoxazol-
270.4
5,2"-naphthalene]
35 3,8-dipheny1-1-oxa-2-azaspiro[4.5]dec-2-ene 292.4
36 8 pheny1-3-p-toly1-1-oxa-2-azaspiro[4.5]dec-2-ene 306.4
37 8 pheny1-3-(4-trifluormethylpheny1)-1-oxa-2-azaspiro[4.5]dec-2-ene
360.4
38 7,7,9,9-tetramethy1-3-pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene 272.4
39 3-(4-tert-butylphenyI)-8 pheny1-1-oxa-2-azaspiro[4.5]dec-2-ene
348.5
40 4-tert-buty1-3-pheny1-3",4",4a",5",6",7",8",8a"-octahydro-1"1-1,4H-
326.5
spiro[isoxazol-5,2"-naphthalene]
41 3-(4-tert-butylpheny1)-7,7,9,9-tetramethy1-1-oxa-2- 328.5
azaspiro[4.5]dec-2-ene
42 8 phenyl-3-pyridin-2-y1-1-oxa-2-azaspiro[4.5]dec-2-ene 293.4
43 8-(1 ,1-dimethylpropy1)-3-pyridin-2-y1-1-oxa-2-azaspiro[4.5]dec-2-
287.4
ene
44 3-(4-tert-butylphenyI)-8-(1,1-dimethylpropy1)-1-oxa-2- 342.5
azaspiro[4.5]dec-2-ene
45 3-(4-tert-butylpheny1)-8-ethy1-1-oxa-2-azaspiro[4.5]dec-2-ene 300.5
100

CA 02608319 2007-11-13
,
, GRA3304/A-PCT
Pharmacological data
The affinity of the Spiro compounds according to the invention for the
vanilloid
receptor 1 (VR1/TRPV1 receptor) was determined as described hereinbefore.
Compound VR1 (human) VR1 (human) VR1 (rat) VR1
(rat)
according to ( /0 stimulation (% inhibition (% stimulation ( /0
inhibition
the example compared to 10 compared to 10 compared to 10 compared to 10
pM CP) pM CP) pM CP) pM
CP)
1 20.67 23.56 44.72 71.32
2 -0.32 58.09 , -15.97 100.87
3 -1.29 80.10 0.10 102.62
4 -0.33 76.33 -0.54 73.69 _
7 -0.05 92.79 0.23 105.33
8 0.22 20.73 0.57 97.15 _
9 0.41 61.74 1.05 91.46 _
10 2.84 17.54 8.77 22.95
_
11 -0.05 28.56 -0.37 62.42
-
12 100.98 79.89 112.30 94.31 _
17 -0.05 14.95 0.33 58.92 _
18 24.24 22.05 84.04 97.62
19 13.41 22.55 70.81 95.49
21 -0.05 6.75 0.37 52.32
22 0.13 0.14 -0.37 16.63
23 23.79 54.21 55.21 69.46
_ 24 91.72 83.01 87.96
97.79
25 0.16 56.47 1.04 98.31
50 15 64 60 97
51 17 25 73 91
58 27 67 46 107
66 53 54 87 101 _
80 35 42 48 103
84 33 31 61 103
90 36 34 43 100
Compound K CAP rat [pM] K CAP human
IC50 CAP rat IC50 CAP human
according to [PM] [PM] [PM]
the example
7 0.0797 1.989 0.126 1.24
9 0.894 , 4.861 1.55 3.34
50 0.0637 0.545
80 0.341 2.05 1.22 2.87
101